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Cardiac sudden death (CSD) is the leading cause of death in the United States. Although the 
causes of CSD are not understood completely, cardiac arrhythmias have been indicated as the 
major contribution to CSD. The main purpose of this thesis is to investigate the mechanisms 
underlying cardiac arrhythmias, therefore providing scientific basis for clinical applications in 
the future to lower the rate of CSD.   
 
My thesis contains four chapters. Chapter 1 aims to examine a novel role of tyrosine 
phosphorylation in the arrhythmogenesis. To achieve this goal, a rat arrhythmia model was 
established without structural remodeling, and the Src tyrosine kinase and protein tyrosine 
phosphatase were evaluated in the induction of cardiac arrhythmias by using electrocardiography 
(ECG) technique (two manuscripts are in preparation). 
 
In chapter 2, we elucidate the mechanism tyrosine phosphorylation used to modulate the cardiac 
pacemaker channels that directly contribute to the regulation of heart rate and their potential new 
role in cardiac arrhythmias (J Biol Chem 284: 30433-30440, 2009). 
 
In chapter 3, we explore a novel role of Hyperpolarization-activated, cyclic nucleotide-gated 
(HCN) channels serving as a regulatory protein to regulate the Ca2+ influx via inactivation of L-
type calcium channel (LTCC) (Am J Physiol Cell Physiol 298(5): C1029-37, 2010). 
 
In chapter 4, the results that have not been published are summarized. These results represented 
my efforts to explore previously unrecognized mechanisms that underlie the genesis and 
development of cardiac arrhythmias that predispose the heart to CSD, claiming more than 
300,000 lives each year in the US. 
 
Collectively, our results indicate that tyrosine phosphorylation plays a critical role in the 
regulation of cardiac rhythm, possibly via modulation the activities of HCN pacemaker channels. 
Furthermore, we also found that HCN channels can limit the Ca2+ influx via induction of fast 
inactivation of LTCC. These results not only help us to better understand the mechanisms of 
cardiac arrhythmias, but can also be applied to the future drug development for the prevention of 
CSD caused by cardiac arrhythmias. 
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Cardiac sudden death (CSD) affects approximately 300,000 people in the United Stated 
every year, and is estimated to account for nearly 50 percent of all death from 
cardiovascular causes (Myerburg et al., 1997). Major cardiac diseases such as ischemia, 
heart failure, and cardiac hypertrophy have been reported to cause CSD via ion channel 
remodeling and changes in ion influx or efflux (Heman et al., 1996; Hynes et al., 2002; 
Mammarella et al., 2000; Wolfe et al., 1991). However, there are also cases where 
people, especially young adults, died of sudden CSD in the absence of defective heart 
structure including hypertrophy (Heman et al., 1996; Hynes et al., 2002; Mammarella et 
al., 2000; Wolfe et al., 1991). This indicates that our knowledge of CSD is not a complete 
picture. From a pathological point of view, it is commonly accepted that the underlying 
cause of CSD is tachycardia-induced arrhythmias (Kannel et al., 1987; Willich et al., 
1987). Therefore, to obtain a comprehensive understanding of arrhythmias is the key to 
understand the causes of CSD. However, the underlying mechanisms of cardiac 
arrhythmias still remain obscure due to lack of a good animal model system with 
inducible and controlled real-time ventricular arrhythmias, which the first part of my 
thesis is focused on.  
  
To provide an ionic basis of cardiac arrhythmias that I observed in the new arrhythmic 
animal model described in the first part, the second part of this thesis concentrates on two 
ion channels: Hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels 
and L-type calcium channels (LTCCs). Ion channels can directly cause diseases. The 




channels (Robert et al., 2005). Mutations in the channel proteins or abnormal regulation 
of the channel contribute to the channelopathy (Hunter et al., 1994; Zhou et al., 2009). In 
the past decade, numerous mutations in ion channels have been identified in patients and 
directly linked to a variety of arrhythmias (Dai et al., 2005; Peter et al., 2007). Therefore, 
my study aims to provide the molecular and cellular basis of how regulation of ion 
channels of interest (HCN channels and LTCCs) can serve as good strategies for the 
therapeutic purposes of cardiac arrhythmias. 
 
1. Mechanisms of cardiac arrhythmias: 
Ion channels are major players to regulate the flow of ions across biological membranes 
and to maintain cellular homeostasis in the physiological condition. They provide a 
molecular basis of action potential propagation during the cell excitation. In the resting 
state, the more negative charges intracellularly make the resting membrane potential 
around -70mV in neurons and -90mV in myocytes. Once the action potential arrives, the 
cells are depolarized by making the intracellular cell membrane more positive via the 
flow of ions across the channels (Hodgkin et al., 1952; Noble et al., 1960). In heart, the 
action potential is generated in the “primary pacemaker” sinoatrial node (SA node) in the 
right atrium and then conducts along atria, the atrial-ventricular node (AV node), Bundles 
of His, Purkinje fibers, and ventricles. Regulation of SA node rate is critical in 
understanding of mechanisms, leading to better management of cardiac arrhythmias such 









1.1 Abnormal impulse initiation 
Cardiac arrhythmias are defined as abnormal cardiac electrical properties attributed to 
two factors: the abnormality in impulse initiation and impulse conduction. Normal 
impulse initiation is associated with automatic foci determined by the slope of phase 4 
depolarization, which establishes the time required to reach threshold potential and 
generate a spontaneous action potential. The sinus node is the primary pacemaker to 
initiate and coordinate the electrical impulse which then conducts to the atrium and 
ventricle. If the sinus node firing rate is slower than atrial cells, the electrical impulse can 
be initiated and coordinated by atrial cells instead of the sinus node and ectopic activities 
occurred. The function of If currents (mediated by HCN channels) contributed to the 
phase 4 of sinus node or atrial or Purkinje action potential and make the “U” turn of the 
maximal diastolic potential. However, when the slope of phase 4 is accelerated by the 
increase of HCN channel expressions, the ectopic impulse or the tachycardia induced 
arrhythmias will be generated (Hoffman et al., 1981). Cardiac remodeling caused by 
atrial tachycardia or heart failure (failing ventricles) has been demonstrated to be 
associated with the enhancement of HCN channel expressions (Nattel S et al., 2007).  
 
Different from the mechanism in phase 4, delayed after depolarizations (DADs) and early 
after depolarizations (EADs) are caused by abnormalities in cellular Ca2+ handling. 
DADs are represented by spontaneous hump-shaped depolarizations after repolarization, 
which will increase more Ca2+ load and trigger sustained tachycardia (Chen et al., 2001; 
Coutu et al., 2006; Stambler et al., 2003). EADs occur when action potentials become 




depolarization at plateau phases, which are characterized in Purkinje fibers and long-QT 
syndrome (Burashnikov et al., 2003; Nattel et al., 1988; Satoh et al., 1998).  
 
1.2 Abnormal impulse conduction 
Abnormal impulse conduction causes reentrant excitation. Reentry occurred when an 
ectopic impulse was blocked by refractory tissues while propagating in one direction and 
will then propagate in the other direction where the tissues have faster recovering from 
refractory periods. For the maintaining of reentry, the time of conducting has to be longer 
than the refractory period in the circuit (to make sure the impulse can re-excite all points 
of the entire circuit). The time of conduction is determined by conduction velocity and 
circuit path length. Slower conduction velocity and longer circuit path length create the 
environment in which reentry can be maintained. Refractory period of action potential is 
also a critical determinant for reentry. Short refractory period increases the opportunity 
that tissues are available to be reactivated by the reentering pulse (Hoffman et al., 1981). 
Previous studies have demonstrated that atrial remodeling caused by ischemia or heart 
failure increases the risk of reentrant excitation by increase of circuit path spaces and 
decrease of refractory periods (For example, decrease inward calcium currents via 
LTCCs), which potentially results in atrial fibrillation (Cha et al., 2006; Yue et al., 1997). 
 
2. HCN channels 
2.1 Properties of HCN channels 
Hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channels are the major 




Irisawa et al., 1978). Exploring the new mechanisms that control the HCN channel 
properties by tyrosine phosphorylation constitutes the majority of my thesis work. 
HCN channels form tetramers on the cell membrane and each subunit consists of six 
transmembrane domains including the voltage sensor S4 domain, P loop with the GYG 
motif for the selectivity of the K+ ion flow, and the cyclic nucleotide-binding domain 
(CNBD) on the C-terminus (Fig 1). There are four isoforms (HCN1-4) of HCN channels. 
Despite their similarity in structure, different HCN isoforms do not express uniformly in 
the heart. HCN4 is the dominant isoform in SA node whereas HCN2 is mainly expressed 
in ventricles. HCN1 transcripts are expressed at low levels in SA node, and cannot be 
detected in ventricles (Shi et al., 1999).  
 Unlike most other voltage-gated ion channels that are activated by membrane 
depolarization, the Na+/K+ 
permeable HCN channels can 
only be activated by membrane 
hyperpolarization, generating a 
voltage- and time- dependent 
inward current, called If in heart 
and Ih in neurons. If contributes 
to the termination of the repolarization and generation of the diastolic depolarization to 
the threshold for firing an action potential  (Brown et al., 1982; DiFrancesco, 1993; 
Irisawa et al., 1978).  
 
HCN channels are regulated by autonomic nervous system. The activation of β-




increase of intracellular cAMP. In a phosphorylation-independent regulation manner, 
cAMP can interact with HCN channels at the cyclic nucleotide-binding domain (CNBD) 
on their C-terminal tail. This triggers conformational change of HCN channels, resulting 
in the net positive charge influx, to generate voltage and time dependent inward currents. 
As a result, the activation curve will shift to more positive voltages (increase of the 
channel sensitivity in response to the voltage stimulation), contributing to an increase in 
the heart rate (Accili et al., 1997; Altomare et al., 2001; DiFrancesco et al., 1999). 
 
On the contrary, the activation of muscarinic acetylcholine receptors (type II) by 
acetylcholine can cause the decrease of cAMP and make activation curve shift to more 
negative voltages (decrease of the channel sensitivity in response to the voltage 
stimulation), leading to an decrease in the heart rate for physiological effect (Accili et al., 
1997; Altomare et al., 2001; DiFrancesco et al., 1999).  
 
2.2 Tyrosine Phosphorylation of HCN channels in the heart 
One of the important regulations of HCN channels is via tyrosine phosphorylation. In 
2000, the If has been found to be reduced by approximately 30% after applying genistein, 
a tyrosine kinase inhibitor, with epidermal growth factor (EGF) when compared with 
EGF alone in rabbit sinus node myocytes. In accordance with the results in rat ventricular 
myocytes, not only was If enhanced, but its activation threshold was also positively shift 
by nearly +20mv after washout of genistein, demonstrating that tyrosine phosphorylation 
is critical in the regulation of HCN channels function (Wu et al., 2000).  
 
To further investigate the phosphorylation-related regulation of the different subtypes of 




or HCN4. It has been demonstrated that the conductance of HCN2 and HCN4 were both 
reduced; whereas V1/2 (the voltage where the 50% channels can be activated) of HCN2 
but not HCN4 was shifted to more negative charge after applying genistein. However, 
neither the conductance nor V1/2 was affected by genistein for HCN1 channels, 
suggesting that different subtypes of HCNs respond differently to tyrosine 
phosphorylation. These results strongly indicate that HCN channels, especially HCN2 
and HCN4, can be tightly regulated by tyrosine phosphorylation (Yu et al., 2004).  
 
To search for the intracellular tyrosine kinases that can provide tyrosine phosphorylation 
regulation of HCN channels, tyrosine kinase Src was studied. The Src family is 
composed of nine members, three of which are ubiquitously expressed in heart- Src, Yes, 
and Fyn. Structurally, these proteins are highly homologous and consist of an amino-
terminal site, SH domains, and a carboxyl-terminal regulatory region. Functionally, they 
can phosphorylate the proteins in the signal transduction cascade (Thomas et al., 1997). 
Interestingly, previous study indicated that Src529, a constitutively active Src tyrosine 
kinase, was capable of enhancing current densities and positively shifting the V1/2 and 
activation threshold after co-expression with HCN4 channels in HEK 293 cells. In 
contrast, Src296, a dominant negative Src tyrosine kinase, caused the reduction of current 
densities and decreased the gating properties of HCN4 channels. This suggests that the 
regulation of HCN is probably via Src-mediated tyrosine phosphorylation (Arinsburg et 
al., 2006).    
 
In 2008, by using a specific Src kinase inhibitor, PP2 (4-amino-5-(4-chlorophenyl)-7-(t-




channels was significantly decreased and the activation threshold was also negatively 
shifted due to the reduction of tyrosine phosphorylation. Immunoprecipitation results 
demonstrate the possible association between the kinase Src and HCN4 channels. By 
employing PP2 and whole-cell patch clamp technique, our lab also found that Y531 is the 
main residue for the Src-mediated tyrosine phosphorylation (Li et al., 2008).  
 
Recently, a tyrosine phosphatase inhibitor, phenylarsine oxide (PAO), has also been 
demonstrated to enhance the If density of HCN4 channels and positively shift the 
threshold of activation about +40mV in adult ventricular myocytes.  To further identify 
the specific tyrosine phosphatase that contributed to the PAO effects on If, we 
investigated the potential modulation of receptor protein tyrosine phosphates (RPTP). 
Receptor Protein Tyrosine Phosphatase α (RPTPα), a member of receptor-type tyrosine 
phosphatase, was cotransfected with HCN2 or HCN4 channels in HEK 293 cells. 
Interestingly, HCN2 or HCN4 currents were totally eliminated by RPTPα two days after 
transient co-transfection HCN2 or HCN4 with RPTPα. Biochemical approach further 
indicates that tyrosine dephosphorylation by RPTPα impairs membrane trafficking of 
HCN2 channels, possibly due to an association between RPTPα and HCN2 channels. 
This may explain why the If density was significantly reduced in rat ventricle by applying 
a tyrosine phosphatase inhibitor PAO (Huang et al., 2008).   
 
2.3 HCN4 mutants in Human Cardiac Arrhythmias 
HCN4 channels are closely related to the initiation of cardiac pacemaker activity. Defects 
in the HCN4 channels including gene knockout have caused death in embryo, and severe 




Several gene mutations of HCN4 channels have been reported to be implicated to the 
cardiac arrhythmia and to impair the cardiac function such as HCN4-573X, S672R, 
G480R, and D553N mutations.        
 
HCN4-573X is a single base pair mutation, which leads to a premature stop codon 
resulting in the protein truncation of C-terminal including the CNBD domain of the 
channels. This leads to loss of interaction with cAMP and alteration of deactivation 
kinetics in channels (Schulze et al., 2003).  
 
S672R missense mutation is located in the β roll of the CNBD domain. This mutant 
channel causes a shift of the activation threshold towards the more hyperpolarizing 
direction (which reduces If in sinoatrial node at a given hyperpolarized voltage), therefore 
slows down the heart rate. This mutant also decreases the sensitivity of the channels in 
response to the membrane hyperpolarization. However, the cAMP modulation is not 
changed in this single base mutation (Milanesi et al., 2006).  
 
G480R is located in the pore region of HCN4 channels and has been reported to be 
associated with reduction of pacemaker currents and HR. Previous studies by using 
Xenopus oocytes and HEK293 cells revealed that reduction of current expression is 
attributed to a more negative voltage dependence of channel activation as well as 
decrease of membrane expression of this mutant (Nof et al., 2007).   
 
The relevant one to my own study is the D553N missense mutation in the C-linker of 
HCN4 channels. This mutant was found in a patient who suffers from a severe cardiac 




QT syndrome, and ventricular tachycardia polymorphisms indicated by 
electrocardiogram (ECG) (Ueda et al., 2004). By employing the electrophysiology and 
imaging, further investigation also implicated that this mutant is a dominant negative 
mutant and causes the membrane trafficking defect of the channels. Not only the current 
densities are significantly reduced, this mutant can also alter the kinetics of activation and 
deactivation of the channel. As the trafficking defect of this mutant results in cardiac 
arrhythmia, my main goal is to test the hypothesis that the Src kinases-mediated tyrosine 
phosphorylation can rescue the defective trafficking of this mutant. 
 
3. L-type calcium channels (LTCCs): 
3.1 Properties of LTCCs: 
LTCCs are pivotal to control the extracellular calcium influx into the cell and in turn to 
regulate the calcium-dependent physiological functions of the cell. LTCCs consist of the 
pore-forming α1 subunit with several accessory subunits such as α2δ, β, and γ subunits 
surrounding this pore subunit (Arikkath et al., 2003; McCleskey et al., 1994; Tsien et al., 
1995; Yasuda et al., 2004). The pore-forming α1 subunit has four repeats and each one 
has six transmembrane domains, which is capable of mediating the biophysical and 
pharmacological properties of the channels, while its accessory subunits are critical to 
regulate the gating and trafficking of the channels (Arikkath et al., 2003; Yasuda et al., 
2004). It is generally accepted that LTCCs require association of the pore-forming α1 
subunit with its accessory β and α2δ subunits to generate the functional calcium currents 





In the heart, cardiac contractions of the atrium and ventricle occur via activation of 
LTCCs. In a resting condition, the intracellular calcium concentration is maintained at 
approximately 0.1µM, which is nearly 1/10000 of the extracellular free calcium 
concentration (1mM) (Bers, 2002). During action potential, in cardiomyocytes calcium 
enters the cell through depolarization-activated calcium channels as inward calcium 
current, which can trigger calcium release from the sarcoplasmic reticulum (calcium 
induced calcium release), and then switches on the contractile machinery (Bers, 2000). 
Therefore, the physiological function of the heart is controlled by this excitation-
contraction coupling (EC-coupling) (Bers, 2002).  
 
Abnormal pacemaking or conduction can lead to cardiac arrhythmia, such as long QT 
syndromes (LQTS), a precursor of sudden cardiac arrest. On the other hand, once the EC 
coupling is impaired by disruptive Ca2+ homeostasis, the ventricular pacing will not be 
controlled by sinus node rate, making the ventricle prone to arrhythmias (Splawski et al., 
2004; 2005). 
 
Long QT syndrome is caused by either an increase in inward currents (causing the 
prolonged plateau phase of ventricular action potential) or a decrease of outward currents 
(causing the delayed repolarization of plateau phase of ventricular action potential) 
(Morita et al., 2008). As L-type calcium current is one of the main inward currents 
(Splawski et al., 2004; 2005), it is commonly believed that by modulating the inactivation 







3.2 Role of LTCC inactivation in calcium homeostasis 
Calcium influx regulation is critical for the normal function of cardiac cells. The amount 
of Ca2+ ions can be delicately regulated by the activation and inactivation of calcium 
channels. The inactivation process of LTCCs has been extensively studies in Xenopus 
oocytes or HEK 293 cells (Kim et al., 2004; Zuhlke et al., 1998). The C-terminus of α1 
subunit locates intracellularly and contains motifs including the IQ motif and EF hand. 
Although the potential inactivation mechanisms for LTCCs are controversial, it is 
generally believed that the IQ motif and the EF hand upstream the IQ motif on the α1 
subunit C-terminal region are where calmodulin (CaM) is pre-associated with; and these 
domains combined with I-II loop are responsible for mediating the calcium-dependent 
fast inactivation (CDI) (using Ca2+ as the charge carrier) as well as the voltage-dependent 
slow inactivation (VDI) (using Ba2+ as the charge carrier) of the calcium channels (Cens 
et al., 2006; Kim et al., 2004; Pitt et al., 2001; Zuhlke et al., 1998).  
 
Calcium influx is a pivotal second messenger for intracellular signal transduction to 
maintain cell physiological function such as cell contraction, neurotransmitter release, 
and cardiac cell excitability (Adams et al., 1986; Dewaard et al., 1998; Forder et al., 
1985). On the other hand, high intracellular calcium concentration is also toxic and 
causes cell damage, which has been demonstrated in myocardial ischemia (Fleckenstein 
et al., 1974) and muscle dystrophy (Wrogemann et al., 1976). Moreover, the abnormal 
calcium influx is directly linked to cardiac arrhythmias (Novotny et al., 1986; Williams et 
al., 1984). In my thesis work, I identified a novel role of HCN channel to control 





General materials and methods 
 
Whole animal preparation and drugs administration 
2% isoflurane mixed with oxygen at the flow rate of 2 liter/min inhaled by adult Sprague-
Dawley (SD) rats was used for anesthetization in accordance with Animal Care and Use 
Committee guidelines for implantation of catheters.  
 
The catheter (polyurethane, 1 French size) was inserted into the jugular vein for different 
doses of drug administration. ECG was measured by using two leads vector. The arterial 
catheter was connected to a heparin filled pressure transducer for at least 20 minutes 
before measurements are made.  
 
In part I of chapter 1, different doses of Na3VO4 were applied for the induction of 
ventricular arrhythmias. At the beginning, 3.8 mg/kg of Na3VO4 was administrated via 
the catheter injection which catheter has been placed in jugular vein to induce 
arrhythmias. For more severe arrhythmias induction, a relatively higher dose of Na3VO4 
(5.5 mg/kg) was applied. 
 
In part II of chapter 1, different doses of PP2, ZD7288, PP3, and isoproterenol were 
applied via jugular vein to see effects on HRV. High dose of PP2 (0.3 mg/kg) or ZD7288 
(0.7 mg/kg) as well as low dose of PP2 or ZD7288 (0.2 mg/kg) were applied whereas the 
dose of 0.2 mg/kg was applied in PP3 (negative control of PP2). For isoproterenol, 0.4 





The data were recorded and analyzed using cardiovascular continuous monitoring 
software (PowerLab/4SP, ADInstruments, Colorado Springs, CO). Values for 
hemodynamic measures are derived by 1KHz sampling rate. All the results are repeated 
by at least 10~12 times (n=10~12). 
 
cDNA plasmid preparation  
For HCN4 and HCN4-D553N cDNA plasmids, the human version of HCN4-pcDNA1.1 
was kindly provided by Dr. U. B. Kaupp and subcloned into pcDNA3.1 vector. HCN4-
D553N-pcDNA3 was made by substituting aspartic acid with asparagine using PCR. 
HCN4-D553N-DsRed was made by subcloning HCN4-D553N into the DsRed vector. 
RPTPα was a generous gift from Dr. Jan Sap (University of Copenhagen, Copenhagen, 
Denmark). The constitutively active form of Fyn, FynY531F, in pcDNA3.1 vector, was 
kindly provided by Dr. Shigeru Kanda (Nagasaki University, Nagasaki, Japan). The 
constitutively active form of Yes (YesY537F) was kindly provided by Dr. Arkadiusz 
Welman (Edinburgh Cancer Research Center), and we subcloned it into the pcDNA3.1 
vector. Src529 (SrcY529F) was purchased from Upstate Biotechnology (Millipore). For 
simplicity, we also use Src, Fyn, and Yes and Src529, Fyn531, and Yes537 in the text for 
interchangeable use with the constitutively active form of each kinase: SrcY529F, 
FynY531F, and YesY537F.  
For HCN2 DNA plasmids, mouse HCN2 cDNA in an oocyte expression vector, pGH, 
was initially obtained from Drs. Bina Santoro/Steve Siegelbaum (Columbia University). 




(Invitrogen) for functional expression in mammalian cells. RPRPα inserted in pRK5 
vector was kindly provided by Dr. Jan Sap (University of Copenhagen, Denmark).  
Cell culture and plasmids transfection 
For the study of HCN currents, HEK293 cells were grown in Dulbecco's modified Eagle's 
medium (Invitrogen), supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 
and 100 g/liter streptomycin. Cells with 50–70% confluence in 6-well plates were used 
for plasmid transfection (2-5 μg for each plasmid transfection) using Lipofectamine2000 
(Invitrogen). For the study of LTCC inactivation, an HEK293 cell line stably expressing 
α2δ/β1 was kindly provided by Dr. Richard Tsien (Stanford University). Culture of these 
cells was similar to that described above except for addition of antibiotics, G418 (0.5 
mM/ml) and 5 mM L-glutamine, to the DMEM. Primary embryonic day 18 rat 
hippocampus neurons were used for studying the interaction between α1C and HCN2. 
Neuron culture and plasmid transfection were completed following the instruction manual 
(Invitrogen).   
 
Whole-cell patch technique  
For recording IHCN4, day 1 (24–30 h) up to day 4 (90–98 h) post-transfection HEK293 
cells with green fluorescence were selected for patch clamp studies. The HEK293 cells 
were placed in a Lucite bath in which the temperature was maintained at 25 ± 1 °C by a 
temperature controller (Cell MicroControls). IHCN4 currents were recorded using the 
whole cell patch clamp technique with an Axopatch-200B amplifier. The current 
amplitude of HCN4 or D553N current is defined as the amplitude of the onset time-




jump at the beginning of the pulse. The current density is the current amplitude divided 
by the cell capacitance measured in each cell studied. The pipettes had a resistance of 2–4 
MΩ when filled with internal solution: 6 mM NaCl, 130 mM potassium aspartate, 2 mM 
MgCl2, 5 mM CaCl2, 11 mM EGTA, and 10 mM HEPES; pH was adjusted to 7.2 by 
KOH. The external solution contained 120 mM NaCl, 1 mM MgCl2, 5 mM HEPES, 30 
mM KCl, 1.8 mM CaCl2; pH was adjusted to 7.4 by NaOH. The Ito blocker, 4-
aminopyridine (2 mM), was added to the external solution to inhibit the endogenous 
transient potassium current, which can overlap with and obscure IHCN4 tail currents 
recorded at +20 mV. The data were acquired by CLAMPEX and analyzed by 
CLAMPFIT (pClamp 8; Axon).  
For IHCN4 analysis, the data are shown as the means ± S.E. The threshold activation of 
IHCN4 is defined as the first hyperpolarizing voltage at which the first time-dependent 
inward current can be observed. Student's t test was used for statistical analysis with p < 
0.05 being considered statistically significant. Time constants were obtained by using 
Boltzmann best fit with one exponential function on current traces that reach steady state. 
HCN4 activates slowly, and the cells would not tolerate pulses sufficiently long to reach 
the steady state. We therefore used the following approach to obtain an accurate estimate 
of the steady state activation (Arinsburg et al., 2006). The onset current traces were fitted 
with a single exponential function to 30–40 s to allow estimates of steady state current 
levels. The fitted current amplitudes were then divided by the driving force (the 
difference between test pulses and the reversal potential that was measured in each cell) 




normalizing the conductance to its maximal value in response to the most negative test 
pulse. 
For recording IHCN2, day 1 (24–30 h) up to day 4 (90–98 h) post-transfection, HEK293 
cells with green fluorescence were selected for patch clamp studies. The HEK293 cells 
were placed in a Lucite bath in which the temperature was maintained at 25 ± 1 °C by a 
temperature controller (Cell MicroControls, Virginia Beach, VA).  
IHCN2 were recorded using the whole-cell patch clamp technique with an Axopatch-200B 
amplifier. The pipettes had a resistance of 2–4 megohms when filled with internal 
solution (mM) as follows: NaCl 6, potassium aspartate 130, MgCl2 2, CaCl2 5, EGTA 11, 
and HEPES 10; pH adjusted to 7.2 by KOH. The external solution contained (mM) the 
following: NaCl 120, MgCl2 1, HEPES 5, KCl 30, CaCl2 1.8, and pH was adjusted to 7.4 
by NaOH. The Ito blocker, 4-aminopyridine (2 mM), was added to the external solution to 
inhibit the endogenous transient potassium current, which can overlap with and obscure 
IHCN2 tail currents recorded at 20 mV. Data were acquired by CLAMPEX and analyzed 
by CLAMPFIT (pClamp 8, Axon Instruments).  
For IHCN2 analysis, data are shown as mean ± S.E. The threshold activation of If is defined 
as the first hyperpolarizing voltage at which the time-dependent inward current can be 
observed. Student's t test was used for statistical analysis with p < 0.05 being considered 
as statistically significant. Time constants were obtained by using Boltzmann best fit with 





For the study of LTCC inactivation, patch-clamp recordings are the same as previously 
reported (Huang et al., 2008). The pipettes had a resistance of 2–5 M  when filled (in 
mM): 108 CsCl, 4 MgCl2, 9 EGTA, and 9 HEPES. The bath solution contained (in mM) 
2 BaCl2, 1 MgCl2, 10 HEPES, 40 tetraethylammonium, 10 glucoses, and 65 CsCl. Both 
solutions were adjusted with CsOH to pH 7.2. Unless specifically mentioned in the text, 
the Ba2+ currents (IBa) were recorded at +10 mV from a holding potential of –90 mV. IBa 
current inactivation was sometimes normalized for better comparison of kinetics in 
different combinations of plasmids coexpressed in different HEK-293 cells. 
Normalization is indicated without vertical scales; where vertical scales are present, P/4 
protocols were used to remove the leak currents. The capacitive currents were minimized 
with 75–85% series resistance compensation. 
 
Confocal fluorescent imaging  
HEK293 cells transfected with HCN4-DsRed or HCN4-DsRed-D553N or ER marker 
KKXX or stained by FMI34 (cell membrane dye) were incubated on coverslips and fixed 
in 4% paraformaldehyde/PBS for 15 min and then washed with PBS (10 mM phosphate 
buffer, 150 mM NaCl, pH 7.4) for 5 min for three times, followed by blocking in 1% 
bovine serum albumin/PBS, pH 7.4, for 60 min. After washing six times in PBS, the 
coverslips were mounted on slide glasses using Fluoromount G (Southern 
Biotechnology). The cells were imaged by a LSM510 confocal microscopy using a Plan-
Neofluar 40×/0.75 objective or a Plan-Apochromat 63×/1.4 Oil differential interference 
contrast M27 objective. For DsRed imaging, a 1.2-milliwatt 543-nm HeNe laser was used 




For hippocampal neurons, live-cell images of hippocampal neurons were visualized using 
an inverted Nikon TE2000S epifluorescent microscope with Prior filter wheels and a 
Photometrics Coolsnap HQ charge-coupled device camera. 
 
Fluorescence recovery after photobleaching (FRAP) 
HEK 293 cells transfected with different combinations of plasmids were placed under 
LSM510 microscope and stimulated by the laser beam. 480nm was used for GFP. 
Briefly, FRAP parameters in Capture Preferences was set followed by searching a region 
to be FRAPed using Focus Window (Eric et al., 2001; Brian et al., 2005). The region of 
interests was then photobleached by Laser beam. The data were then analyzed by Igor 














Establishment of a Rat Arrhythmia Model without Structural 
Remodeling for Studying Ventricular Arrhythmias 
The goal of the work presented in this chapter is to explore the potential role of tyrosine 
phosphorylation in cardiac arrhythmias. Two parts are included. Part I summarizes the 
role of tyrosine phosphorylation in ventricular arrhythmias. Part II summarizes the role of 





















Using a small molecule, sodium orthovanadate (Na3VO4) to inhibit the cellular tyrosine 
phosphatase activity, we have reproducibly detected several major ventricular 
arrhythmias. At the dose of 3.8 mg/kg, frequent premature ventricular contractions 
(PVCs) can be induced leading to ventricular tachycardia (VT). Fragmented QRS, a 
strong marker of abnormal conduction in the ventricle, also appeared. At the higher dose 
(5.5 mg/kg), the most severe ventricular arrhythmia, ventricular fibrillation, occurred.  
 
Our goal is to develop a rat model with controllable occurrence of ventricular 
arrhythmias without cardiac structural remodeling, providing a reliable small animal 
model to study the novel mechanisms of ventricular arrhythmias and to develop new 















Major heart diseases (ischemia, hypertrophy, heart failure) are associated with ventricular 
arrhythmias leading to sudden cardiac death (Hernan et al., 1996; Hynes et al., 2002; 
Mammarella et al., 2000; Wolfe et al., 1991). Ventricular arrhythmias also cause cardiac 
death without cardiac structural remodeling. The underlying mechanisms are unknown, 
and are hard to study due to lack of a good animal model with inducible and controlled 
ventricular arrhythmias. 
 
Previous animal models for studying arrhythmias frequently used (Hynes et al., 2002) 
aorta bandage to create ischemic condition (Billman, 2002; 2005), (2) fast pacing to 
induce heart failure (Shinbane et al., 1997; Moe et al., 1998; Kashem et al., 2003; Timek 
et al., 2003), (3) genetic ablation (Benkusky et al., 2007). Significant progress has been 
made regarding the underlying mechanisms of a variety of cardiac arrhythmias. All these 
studies have led to the ion channel remodeling under each condition. These studies 
created either a structural change in heart (ischemia, heart failure) or an altered 
expression level of a specific protein. However, it remains as a puzzle as to how heart 
stop beating without structural changes and unaltered expression levels of relevant 
proteins. In fact, an ion channel protein has multiple functions. For example, the 
selectivity of a channel is controlled by the amino acids lining in the pore regions 
between S5 and S6 domains. The activation, inactivation and deactivation of a channel 
can be controlled by amino acids in the N- or C-terminal regions (Staes et al., 2001; 
Gustina et al., 2011; Takahiro et al., 2007). In addition, the gating kinetics of a channel 




These biophysical studies have led to the recent discoveries of many single amino acid 
mutations of channels identified in patients with arrhythmias such as long QT (Moss et 
al., 2005; Hedley et al., 2009).      
 
To explore new mechanisms independent of cardiac structural changes, seen in ischemia 
and heart failure, or mutations in ion channels, we established an inducible rat arrhythmia 
model to investigate how altered state of tyrosine phosphorylation might be relevant to 
the arrhythmogenesis. 
 
Tyrosine phosphorylation has recently been demonstrated to be involved in the regulation 
of gating properties and surface expressions of pacemaker channels, which may in turn 
result in the alteration of cardiac tune (Huang et al., 2008; Lin et al., 2009). Inhibition of 
tyrosine phosphatases may associate with the enhancement of tyrosine kinase-mediated 
tyrosine phosphorylation and thus change the ventricular activity.  
 
Our results showed that sodium orthovanadate, a tyrosine phosphatase inhibitor (Gordon, 
1991), can reliably induce several types of ventricular arrhythmias at relatively low 
doses. These results indicated our initial success in the establishment of a valid in vivo rat 
model for studying the novel mechanisms (such as tyrosine phosphorylation) of 











In this study, two different doses of sodium orthovanadate were administrated via jugular 
vein injection. In order to investigate whether ventricular arrhythmias can be induced, I 
applied the dose of sodium orthovanadate at 3.8 mg/kg. PVC, fragmented QRS (Fig 2), 
and ventricular tachycardia (VT) (Fig 3) can be induced by this dose in comparison with 
the basal (Fig 1). It is worth to notice here that Torsades de pointes, a rapid, polymorphic 
ventricular tachycardia, followed by frequent VT can also be recorded at the dose of 3.8 
mg/kg (Fig 3).  
 
For the more serious ventricular arrhythmias induction, an increasing dose up to 5.5 
mg/kg sodium orthovanadate was applied. The reliable induction of ventricular 
fibrillation can be recorded by this dose (Fig 4). 
 
These results suggested that different types of ventricular arrhythmias can be reliably 
induced depending upon different doses of sodium orthovanadate administration. Thus, 
this established animal model can be served as a good model to study ventricular 
































Fig 1. Normal ECG in anesthetized SD rats.  
Upper panel indicates the overview of the measurement of ECG. Lower panel indicates 
the enlarged scope from the upper panel. X-axis represents the time scale (sec), Y-axis 































                                      
Fig 2. PVC and fragmented QRS were induced by Na3VO4 at the dose of 3.8 mg/kg. 
Upper panel represents multiple PVCs (black arrow) whereas lower panel indicates 









Fig 3. Ventricular tachycardia (VT) was induced by Na3VO4 at the dose of 3.8 
mg/kg.  
Torsades de pointes, a rapid, polymorphic ventricular tachycardia, followed by frequent 
VT (black arrow in upper panel) can also be recorded by applying Na3VO4 at the dose of 















Fig 4. Ventricular Fibrillation (VF) was induced by Na3VO4 at the dose of 5.5 
mg/kg. Upper panel indicates the overview of VF (black arrow) whereas red line 

































Several cardiac diseases such as ischemia, hypertrophy, and cardiac sudden death are 
associated with ventricular arrhythmias. However, the underlying mechanism of how 
ventricular arrhythmias occur is still obscure due to lack of a feasible animal model with 
the controlled ventricular arrhythmias. By using sodium orthovanadate, a tyrosine 
phosphatase inhibitor, we established a valid small-molecule inducible rat model to study 
the mechanisms of ventricular arrhythmias without cardiac structural remodeling. 
 
Sodium orthovanadate is a small molecule which can rapidly enter the cell to inhibit 
cellular tyrosine phosphatase activity. Our previous studies demonstrated that tyrosine 
phosphorylation was involved in the regulation of surface expression and gating 
properties of HCN channels, which may consequently lead to the alteration of ventricular 
activities (Huang et al., 2008; Lin et al., 2009). Thus, reduced tyrosine phosphatase 
activity may be involved in tyrosine kinase activity increasing and tachycardia-mediated 
ventricular arrhythmias. Surprisingly, by using two different doses of sodium 
orthovanadate, our results demonstrated that different dose-based types of ventricular 
arrhythmias can be reliably induced, possibly through increasing HCN channel activities 
(either increase surface expressions or gating properties) mediated by increased tyrosine 
phosphorylation.  
 
This model will help us understand how tyrosine phosphorylation contributes to 
ventricular arrhythmogenesis and is useful in effort to test small molecules to delay and 





Part II: Inhibition of Src kinase activity reduces heart rate without 




Heart rate variability (HRV) is the cardiac index representing the oscillation of the 
intervals between consecutive heartbeats (RR intervals in the ECG). It reflects the 
influences of the autonomic nervous system (ANS) on the sinus node. In order to 
investigate the involvement of tyrosine phosphorylation in cardiac function of the whole 
rat system and its effect on HRV, we employed a potent selective inhibitor of Src family 
kinases, PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyramidine), to 
inhibit the activity of Src kinases that include Src, Fyn, and Yes.  
 
Heart rate was decreased 20% by PP2 at the dose of 0.2 mg/kg. PP3, a negative control 
compound of PP2, which does not inhibit the activity of Src kinases decreased heart rate 
by 8% (when at the identical dose of 0.2 mg/kg) when compared with the basal. 
Interestingly, HRV was not significantly altered at a relatively low dose of PP2 (0.2 
mg/kg) when compared with that of PP3 or the basal. Unlike that of PP2, HRV was 
significantly decreased after application of 0.4 μg/kg isoproterenol. Similar to that of 
PP2, ZD7288, a specific inhibitor of HCN channels, when at the low dose of 0.2 mg/kg, 






Furthermore, atrial ventricular block (AV block) can be induced at the higher dose of PP2 
(0.3 mg/kg) whereas in ZD7288, higher dose application (0.7 mg/kg) can elicit both 
premature ventricular contraction (PVC) and AV block. 
 
Although PP2 and ZD7288 slightly increased the short-term (SD1) and the long-term 
(SD2) HRV, larger degree of increase in SD1 or SD2 was observed in isoproterenol. The 
fractal scaling exponent alpha 1 (α1) in basal level was 0.640, which was comparable to 
that of PP3 (0.605), but slightly decreased in PP2 (0.328) and ZD7288 (0.144) at the low 
dose of 0.2 mg/kg.  
 
Overall, PP2, like ZD7288, can serve as a potential candidate in the treatment of 


















Sudden cardiac death caused by cardiac arrhythmias has affected nearly 300,000 people 
in the United States every year and contributes to approximately 50% of all death of 
cardiovascular causes (Myerburgh et al., 1997). Tachycardia, represented fast heart beat, 
has been demonstrated to be the common reason to cause cardiac arrhythmias (Kannel et 
al., 1987; Willich et al., 1987). However, the underlying mechanism of cardiac 
arrhythmias is still obscure. In the previous study by using tyrosine phosphatase inhibitor 
sodium orthovanadate in a whole animal rat model, we demonstrate that different degree 
of ventricular arrhythmias can be reliably induced by decreasing endogenous tyrosine 
phosphastase activity. Here we demonstrated that reduction of Src-mediated tyrosine 
phosphorylation by its specific inhibitor PP2 decreased the heart rate to nearly 20% at 
low dose of 0.2 mg/kg in comparison to the basal.  
 
HRV is the cardiac index representing oscillation of RR interval of ECG, reflecting the 
effect of autonomic system on the sinus node. Accumulating evidence indicates that there 
is a strong association between the compromised autonomic nervous system and sudden 
cardiac death (Jouven et al., 2005; Schwartz et al., 1992; 1998). HRV has been widely 
used to measure alterations in the autonomic nervous system, which in turn influences the 
rhythm of heart. Several studies have shown that decreased HRV can serve as a powerful 
predictor for sudden cardiac death than established clinical predictors such as left 
ventricular ejection fraction (Bauer et al., 2006; Makikallio et al., 2005; Scmiddt et al., 
1999). Decreased HRV has also been shown to be directly link to the risk of long-term 




treatment of sudden cardiac death by strategically decrease tachycardia-induced 
arrhythmias with little change of HRV is especially important for the sudden cardiac 
death.  
 
Here, we found that the inhibition of Src-mediated tyrosine phosphorylation by its 
specific inhibitor PP2 can significantly decrease heart rate at a relatively low dose 
without a significant alteration of HRV (in comparison with the effect of isoproterenol on 
HRV). Thus, PP2, like ZD7288, may serve as a potential candidate in the treatment of 
tachycardia-induced arrhythmias via inhibition of Src-mediated tyrosine phosphorylation 



















Representative traces of ECG in the administration of different drugs 
In Fig 1, high dose of PP2 (0.3 mg/kg) or ZD7288 (0.7 mg/kg) (lower panel) as well as 
low dose of PP2 or ZD7288 (0.2 mg/kg) (upper panel) were applied and exhibit the 
waveforms of ECG. At the high dose of PP2, multiple AV block can be induced. PVC 
(dash arrow) or AV block (black line) can also be elicited at high dose of ZD 7288 (lower 
panel). The identical low dose (0.2 mg/kg) of PP3 was applied as a negative control of 
PP2. The dose of 0.4 μg/kg isoproterenol was used as the positive control of PP2 and 
ZD7288 effects on heart rate and HRV. 
 
The effects of different drugs on HRV 
In Fig 2, the distribution pattern of HRV reveals bell shape distribution in the basal (the 
first left and middle panel). HRV was slightly decreased by PP2 (the fourth panel) in 
comparison to isoproterenol which significantly decreased HRV (the second panel). PP3 
or ZD7288 reduces HRV very slightly in comparison to the basal. We also compared the 
distribution pattern of heart rate and HRV. Interestingly, the distribution pattern of heart 
rate in each drug is comparable (right panels) to that of HRV.  
 
HRV analysis in Poincare Plot 
 
Poincare plot is a geometric method normally used for dynamic analysis of HRV in 
which the correlation between each RR interval and the preceding RR interval can be 
plotted, indicating the degree of RR interval complexity. As indicated in Fig 3, Poincare 
plot analysis includes the parameters of short-term HRV (SD1) and long-term HRV 




SD2=5.9), but significantly increased in isoproterenol (SD1=30.9, SD2=30.3) in 
comparison to the basal (SD1=1.1, SD2=1.2). The values of SD1 and SD2 in PP3 
(SD1=1.8, SD2=1.6) were more comparable to those in the basal, indicating that PP3 has 
the similar beat-to-beat variability with the basal. 
 
The fractal scaling exponent alpha 1 (α1) is the slope of the plot between logarithm of the 
RR interval fluctuation and the logarithm of the size of time scale indicating self-
similarity of heart rate dynamics, representing how random of heart rate dynamics is. In 
PP3, the value of α1 was 0.605, which is comparable to that of basal level (0.640). The 
values of α1 were slightly decreased in PP2 (0.328) and ZD7288 (0.144) at a relative low 
dose of 0.2 mg/kg in comparison to the basal and isoproterenol (α1 slightly increase 
(0.742)).  
 
HRV results in the presence of different drugs administration 
Table 1 is the summary of the representative values of different parameters for each drug. 
We applied 0.2 mg/kg in PP2, PP3, and ZD 7288, and 0.4 μg/kg in isoproterenol. Each 
experiment was repeated at least ten times (n=10-12). From this table, heart rate 
significantly decreased 20% in PP2 and 35% in ZD7288 when compared with the basal. 
PP3 can also decrease heart rate by 8%. The percentage decrease of heart rate is identical 
to the percentage increase of mean RR. The longer the RR interval is, the slower the heart 
rate will be. Standard deviation of R-R interval (STD RR) revealed slight increasing in 
PP2 (8.7) and ZD7288 (5.7) whereas significantly increase in isoproterenol (30.6) in 
comparison with PP3 (1.8) and the basal (1.1). SD1, SD2, and α1 have been analyzed in 




Overall, our data strongly demonstrate that PP2 is able to reduce heart rate without a 
















Fig 1. ECG in PP2, ZD7288, and controls. 
Representative waveforms of ECG can be recorded in the presence of different drugs. 
High dose of PP2 (0.3 mg/kg) or ZD7288 (0.7 mg/kg) as well as low dose of PP2 or 
ZD7288 (0.2 mg/kg) were applied and the waveforms of ECG were exhibited. In PP2, the 
upper panel represents the ECG in low dose application whereas in high dose application 
in the lower panel. Multiple AV (black arrow) block can be induced at high dose 
application of PP2. In ZD7288, high dose application (lower panel) can also elicit PVC 
(dash arrow) or AV block (black arrow). PP3, a negative control of PP2, was applied at 
the dose of 0.2 mg/kg for the comparison with low dose of PP2. 0.4 μg/kg isoproterenol 
was applied for the positive control of PP2 and ZD7288. The ECG of the basal was also 






















Fig 2. HRV in PP2, ZD7288, and controls. 
HRV reveals bell shape distribution pattern in the basal (the first left and middle panel). 
Isoproterenol (the second panel) reveals significant whereas PP2 (the fourth panel) 
indicates slight reduction of HRV. PP3 or ZD7288 reduces very slightly in HRV in 
comparison with the basal. The distribution pattern of HR in each drug is in an inverse 
trend (right panels) with that of HRV since HR is inversely proportional to HRV. The 

















Fig 3. HRV analysis in Poincare Plot. 
Poincare plot analysis also revealed that both of short-term HRV (SD1) and long-term 
HRV (SD2) were slightly increased in PP2 and ZD7288, but significantly increased in 
isoproterenol in comparison with the basal. The fractal scaling exponent alpha 1 (α1) in 
basal level is 0.640, which is comparable with that of PP3 (0.605), but decrease in PP2 



















Mean RR (ms) STD RR (ms)Mean HR (bmp) SD1 (ms) SD2 (ms) α1
320 187.2 1.1 1.1 1.2 0.640
380 161.2 30.6 30.9 30.3 0.742
294 203.6 1.8 1.6 2.0 0.605
259 231.3 8.7 10.0 7.1 0.328




Table 1. HRV results with drugs. 
The representative values of different parameters for each drug were calculated from the 
kubios software. The applied dose of PP2, PP3 and ZD7288 was at 0.2 mg/kg whereas 
isoproterenol was at 0.4 μg/kg. Each experiment was repeated at least ten times (n=10-
























Heart rate variability includes time domain and frequency domain which is normally used 
to depict the effects of autonomic nervous system on the sinus node. Time domain 
includes the parameters of RR interval, standard deviation of RR interval (STD RR). 
Frequency domain includes the parameters of short-term HRV (SD1) and long-term HRV 
(SD2) in Poincare plot as well as the fractal scaling exponent alpha 1 (α1) (Goldberger et 
al., 2002; Peng et al., 1995; Pumprla et al., 2002; RajendraAcharya et at., 2006; 
Thuraisingham et al., 2006). 
 
Poincare plot is a geometric method normally used for dynamic analysis of HRV in 
which the correlation between each RR interval and the preceding RR interval is plotted. 
It represents the degree of RR interval complexity. There are two parameters used for 
Poincare plot analysis: short-term HRV (SD1) and long-term HRV (SD2). SD1 
represents the points vertical to the line of identity and reflects beat-to-beat variability. 
SD2 represents the dispersion of the RR interval points along the line of identity and 
reflects the long-term records of HRV (Brunetto et al., 2005; Smith et al., 2007). Our data 
reveal slight increase of SD1 and SD2 in PP2 and ZD7288 indicating PP2 and ZD7288 
will not significantly change the RR interval.    
 
α1 is the slope of the plot between logarithm of the RR interval fluctuation and the 
logarithm of the size of time scale, representing self-similarity of HR dynamics: how 
random of the relationship between logarithm of the RR interval fluctuation and the 
logarithm of the size of time scale. When compared with the control, the higher or lower 




pattern) (Peng et al., 1993; Weibel et al., 1991). The slight decrease of α1 in PP2 and 
ZD7288 when compared with PP3 and the basal represented that these two drugs will not 
significantly cause the loss of fractal correlation properties of HR dynamics toward more 
random HR dynamics.     
 
ZD7288, a selective blocker of HCN channel, has become a potent drug clinically used 
for the treatment of tachycardia in Europe. Here, we test the effect of ZD7288 on HRV as 
the comparison with PP2. Our results indicate that at the low dose (0.2 mg/kg) of 
ZD7288 and PP2, heart rate was significantly reduced nearly 35% and 20%, respectively, 
when compared with the basal (which inversely corresponds to the percentage change of 
mean RR interval) with slight change of HRV. However, PP3, a negative control 
compound of PP2, which does not inhibit the activity of Src kinases, can decrease heart 
rate by 8%. Whether PP3 involves in signal cascades that contribute to the regulation of 
heart rate is still unknown and need to be investigated. A β adrenergic receptor agonist, 
isoproterenol, is also applied here as a positive control showing the increase of the heart 
rate. Especially, the distribution pattern of the RR interval in ZD7288 and PP2 has a 
slight change in comparison to that of the basal or PP3.  
 
Our previous studies demonstrated that Src-mediated tyrosine phosphorylation plays a 
pivotal role in the regulation of activities of HCN channels in HEK 293 cells. Reduced 
Src-mediated tyrosine phosphorylation results in deceased activities of HCN channels 
including reduction of surface expression and gating properties of the channels. PP2, a 
specific Src kinase inhibitor, can reduce surface expression and gating properties of HCN 




to see whether PP2 can affect the heart rate through decrease of HCN channel activities, 
we employ a whole animal rat in this study to investigate the potential role on the heart 
rate regulation. Indeed, we found that the heart rate was significantly reduced after 
applying PP2 within the time scale of minutes at a relative low dose.          
 
The different percentage decrease of heart rate in ZD7288 and PP2 may be due to 
intrinsically mechanistic difference. ZD7288 inhibits HCN channels by penetrating into 
the cells and directly blocks the pore region of the channels. As HCN channels are the 
pacemaker channels associated with the heart rate, inhibition of the channels by ZD7288 
results in more efficient reduction of the heart rate than PP2. Src-mediated tyrosine 
phosphorylation regulates gating properties of other ion channels and exchangers, which 
can contribute to an increase in heart rate.   
 
The association between Src and adrenergic receptors has been reported in the previous 
study (Huang et al., 2004; Naohiro et al., 2007). The slight effect of PP2 on HRV may be 
attributed to disruption of this association where the inhibition of Src kinases by PP2 may 
somehow cause the change of adrenergic receptor-mediated signal cascades and slightly 
influence HRV. Further studies are needed for the confirmation.   
       
Atenolol (used to substitute the non-specific propranolol) and Metoprolol are the β1-
specific inhibitors used for the treatment of cardiac arrhythmias. However, side effects 
caused by them implicate the potential problems. Through significant reduction of heart 
rate by decreased Src-mediated tyrosine phosphorylation, our studies strongly indicate 
that PP2 may serve as a potential candidate for the treatment of tachycardia-induced 






Elucidate cellular mechanisms of tyrosine phosphorylation in 
the regulation of heart rate and cardiac arrhythmias 
The goal of this chapter is to elucidate the cellular mechanism of tyrosine 
phosphorylation in the regulation of cardiac pacemaker channels that directly contribute 
to the regulation of heart rate and their potential new role in cardiac arrhythmias. Two 
parts are included. Part I summarizes the role of tyrosine phosphorylation in rescuing a 
trafficking defective pacemaker channel mutant. Part II summarizes the role of tyrosine 
phosphorylation in the modulation of pacemaker channels. The results in this chapter 





















Part I: Rescue of a Trafficking Defective Human Pacemaker 






Therapeutic strategies such as using channel blockers and reducing culture temperature 
have been used to rescue some long QT-associated voltage-gated potassium Kv 
trafficking defective mutant channels. A hyperpolarization-activated cyclic nucleotide-
gated HCN4 pacemaker channel mutant (D553N) has been recently found in a patient 
associated with cardiac arrhythmias including long QT. D553N showed the defective 
trafficking to the cell surface, leading to little ionic current expression (loss-of-function). 
We show in this report that enhanced tyrosine phosphorylation mediated by Src, Fyn, and 
Yes kinases was able to restore the surface expression of D553N for normal current 
expression. Src or Yes, but not Fyn, significantly increased the current density and 
surface expression of D553N. Fyn accelerated the activation kinetics of the rescued 
D553N. Co-expression of D553N with Yes exhibited the slowest activation kinetics of 
D553N. A combination of Src, Fyn, and Yes rescued the current expression and the 
gating of D553N comparable with those of wild-type HCN4. In conclusion, we 
demonstrate a novel mechanism using three endogenous Src kinases to rescue a 
trafficking defective HCN4 mutant channel (D553N) by enhancing the tyrosine 








Defective trafficking leading to the reduced surface expression of ion channels is one of 
the mechanisms responsible for a loss-of-function of the ion channel on the plasma 
membrane (Delisle et al., 2004). Several methods have been developed to rescue the 
voltage-gated potassium Kv trafficking defective channels: reducing the culture 
temperature, applying the channel blockers, altering the molar ratio of glycerol, and using 
the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin (Delisle et 
al., 2003; Furutani et al., 1999; Paulussen et al., 2002; Zhou et al., 1998; 1999;).  
Hyperpolarizing-activated cyclic nucleotide-gated (HCN) pacemaker channels generate 
time- and voltage-dependent inward currents, named Ih in neurons or If in the heart 
(Robinson et al., 2003). They are important in various cell functions including 
excitability, synapse transmission, and rhythmic activity (Robinson et al., 2003). The 
most well studied regulation of If is its response to autonomic stimulation. β-Adrenergic 
receptor activation increases and acetylcholine receptor activation decreases the 
intracellular cAMP levels, which in turn increases/decreases If by binding to the cyclic 
nucleotide-binding domain of the HCN channels, respectively (Robinson et al., 2003). 
Other important mechanisms for the modulation of If/HCN channels have recently been 
found including β-subunit (Yu et al., 2001), lipids (Fogle et al., 2007; Pian et al., 2006), 
and p38 mitogen-activated protein kinase (Poolos et al., 2006).  
Accumulating evidence has revealed tyrosine phosphorylation as an important 
mechanism for modulation of HCN channel properties (Arinsburg et al., 2006; Li et al., 




phosphorylation of If or HCN channels increases the channel activity, including an 
increase in the current amplitude, a positive shift of the voltage-dependent activation, an 
acceleration of activation kinetics, and an increase in whole cell conductance (Arinsburg 
et al., 2006; Li et al., 2008; Wu et al., 2000; Yu et al., 2006). Recently, we discovered 
that the cell surface expression of HCN2 channels can be remarkably inhibited by 
tyrosine dephosphorylation mediated by receptor-like protein tyrosine phosphatase α 
(RPTPα) and increased by tyrosine phosphorylation via Src kinase after long term 
treatment (Huang et al., 2008).  
D553N, a missense HCN4 mutant, was recently identified in a patient with cardiac 
arrhythmia associated with depressed HCN gating properties (Ueda et al., 2004). 
Functional and structural assays revealed that D553N expresses little ionic currents, 
which is possibly due to the defective channel trafficking so that the channels cannot 
reach the plasma membrane for normal functions (Ueda et al., 2004).  
The Src kinase family has nine members (Thomas et al., 1997). They are closely related 
and share the same regulatory function. Three of them, Src, Fyn, and Yes, are 
ubiquitously expressed in a variety of tissues including neurons and myocytes (Kalia et 
al., 2004; Thomas et al., 1997). Without stimulation, they are inactive. However, 
mutation of key tyrosine residue results in the constitutively active form of the kinase, 
SrcY529F, FynY531F, and YesY537F, respectively (Barraclough et al., 2007; Kanda et 
al., 2005). Using these Src kinases, we show in this report a novel approach that can 








Inhibition of HCN4 Current Expression by RPTPα 
We have recently demonstrated that RPTPα can inhibit the surface expression of HCN2 
channels via tyrosine dephosphorylation (Huang et al., 2008). Given the high structural 
homology between HCN2 and HCN4 (>80%) (Robinson et al., 2003), it was expected 
that RPTPα may also inhibit the surface expression of HCN4. Fig. 1 shows a typical 
current expression of HCN4 expressed in HEK293 cells (Fig. 1A). The expression was 
dramatically suppressed across the test voltages (−65 to −135 mV) when HCN4 was co-
expressed with RPTPα after 1 day of transfection (Fig. 1B). The reduction in current 
expression was associated with a negative shift in threshold activation (Figs. 1, A and B, 
arrows). After 2 days of transfection, RPTPα almost eliminated the current expression of 
HCN4 (Fig. 1C). The effect of RPTPα on HCN4 current expression is similar to that on 
HCN2 current expression (Huang et al., 2008). As a control, the empty vector, pRK5 
(used to subclone RPTPα), did not affect the current expression of HCN4 (Fig. 1D). Each 
of these results was confirmed in additional 5–7 cells.  
 
Inhibited Surface Expression of HCN4 by RPTPα 
To further seek supporting evidence that reduced ionic current expression of HCN4 is 
caused by the suppressed surface expression of HCN4 channels, we tagged HCN4 with a 
fluorescent protein, DsRed, and examined the distribution of HCN4 using fluorescent 
confocal microscopy. Fig. 2A shows a typical fluorescent image of HCN4 expressed 
alone in a HEK293 cell (left panel). When co-expressed with RPTPα, most HCN4 




significantly enhanced the cell surface expression of HCN4 (Fig. 2A, right panel). As a 
control, Fig. 2B shows the fluorescence (left panel) and bright field (right panel) images 
of the empty DsRed vector expressed in HEK293 cells. 
 
Rescuing D553N Current Expression by Src, Fyn, and Yes 
D553N has been recently identified in a patient suffering from sinus node dysfunction, 
long QT, ventricular tachycardia, and torsade de pointes (Ueda et al., 2004). In vitro 
studies of the mutant channel revealed defective surface expression on plasma membrane, 
leading to the loss of current expression (Ueda et al., 2004). Given the facts that the 
HCN4 channel activity including the channel surface expression can be significantly 
enhanced by Src-mediated tyrosine phosphorylation and the ubiquitous expression of 
three Src kinase family members (Src, Fyn, and Yes), we set forth to test the hypothesis 
that the current expression of the defective trafficking D553N can be restored by 
constitutively active forms of Src kinases (Src529, Fyn531, and Yes537).  
Fig. 3 provides a typical set of current recordings under different conditions. The current 
expression of wild-type HCN4 is shown in Fig. 3A, as compared with the loss of current 
expression for D553N (Fig. 3B). Fig. 3 (C–E) shows the effects of individual Src, Fyn, 
and Yes on D553N current expression, respectively. Fig. 3 (F–H) also shows the effects 
of Src+Fyn, Src+Yes, and Fyn+Yes on D553N current expression, respectively. Fig. 4I 





For effective comparison of the actions of Src kinases on D553N to HCN4, we calculated 
the current density and the activation kinetics at −125 mV, which is near the fully 
activated voltage. Current density at the voltage in which all channels are open is directly 
related to our central interest of evaluating whether Src kinases can rescue the surface 
expression of D553N. The current densities under different conditions are shown in Fig. 
4A. 
Src and Yes, but not Fyn, can significantly rescue D553N current expression. Different 
combinations of three kinases all enhanced the current expression of D553N (Fig. 4A, 
asterisk). All three Src kinases expressed together (Fig. 3I) can restore ∼68% current 
expression of D553N as compared with the wild-type HCN4 expression (Fig. 4A, dark 
bars, HCN4: 37.15 ± 3.21 pA/pF, n = 7; D553N+Src/Fyn/Yes: 25.25 ± 2.17 pA/pF, n = 
10) (Fig. 4A).  
The effects of Src/Fyn/Yes kinases on the current activation kinetics are also different 
(Fig. 4B). The time constants for activation kinetics were obtained by fitting the onset 
current with one-exponential function at −125 mV under different conditions. Fyn 
accelerated but Yes slowed the activation kinetics of D553N, whereas Src had no effects 
(p* values). The combinations of Src+Fyn and Fyn+Yes can accelerate D553N activation 
kinetics, whereas the combination of Src+Yes cannot. A combination of all three Src 
kinases can speed D553N activation kinetics at −125 mV (Fig. 4, B and D); the time 
constants are 4.07 ± 0.59 s (n = 3) for D553N and 1.24 ± 0.05 s (n = 9) for 
D553N/Src/Fyn/Yes, respectively (p = 0.01). It is worth pointing out that in 16 D553N 




currents at −125 mV and that were used for calculating current density and activation 
kinetics shown in Fig. 4 (A and B). The other 13 cells expressed no currents at the test 
potentials ranging from −75mV to −135mV. As a comparison, we also showed the 
statistical analysis of comparing Src kinases on D553N to HCN4 indicated by p values in 
Fig. 4B.  
To assess the overall functional rescuing effects of Src/Fyn/Yes on D553N gating, we 
examined the biophysical properties of D553N co-expressed with Src/Fyn/Yes (Fig. 3I) 
in comparison with the wild-type HCN4 (Fig. 3A). The Boltzmann equation best fit from 
the averaged activation curves obtained from tail currents showed a small depolarizing 
shift of D553N+Src/Fyn/Yes compared with HCN4 with no altered slope factors(s). 
However, statistical analysis from the means of two groups yielded no significant 
difference (V0.5_HCN4: −86.1 ± 1.5 mV, n = 7; V0.5_D553N+Src/Fyn/Yes: −81.6 ± 1.4 
mV, n = 9; p = 0.0724, s_HCN4: 8.2 ± 0.2 mV, n = 7; s_D553N+Src/Fyn/Yes: 8.4 ± 0.2 
mV, n = 9, p = 0.577) (Fig. 4C). On the other hand, the effects of Src kinases on D553N 
activation kinetics are complex. Compared with the wild-type HCN4, the averaged 
activation kinetics for D553N+Src/Fyn/Yes were slowed at the beginning of the 
activation curve, accelerated near the middle of the activation curve, but statistically 
indistinguishable at the potentials after the half-activation point (Fig. 4D) (n = 7 for 






Enhanced Membrane Surface Expression of D553N by Src, Fyn, and Yes Tyrosine 
Kinases 
We have previously shown that Src-mediated tyrosine phosphorylation increases the 
HCN2 and HCN4 channel activity via shifting the activation curve to depolarizing 
potentials (short term effect) and enhancing the cell surface expression (long term effect) 
(Arinsburg et al., 2006; Huang et al., 2008; Li et al., 2008; Yu et al., 2004). To seek 
further supporting evidence for rescuing surface expression of D553N by three Src 
kinases, we constructed the D553N-DsRed fusion protein and performed the confocal 
imaging experiments. Fig. 5 shows that most wild-type HCN4 is expressed on the cell 
surface (Fig. 5A). By contrast, most D553N cannot reach the cell surface (Fig. 5B). Co-
expression with either Src (Fig. 5D) or Yes (Fig. 5F) can significantly enhance the 
surface expression of D553N. However, Fyn has been much less significant on D553N 
surface expression, as evidenced by a significant amount of D553N remaining in the 
cytosol (Fig. 5E). DsRed vector itself was uniformly expressed across the cell (Fig. 5C) 
and served as a negative control. These results, combined with the protein biochemistry 
analysis, collectively provide the cellular evidence for the functional rescue of D553N 









Fig 1. RPTPα on HCN4 current expression in HEK293 cells.  
A, HCN4 current expression in response to 15-s hyperpolarizing pulses from −65 to −135 
mV in 10-mV increments. Tail currents were recorded at +20 mV. B, in a cell co-
transfected with RPTPα after 1 day of incubation, HCN4 current expression in response 
to 10-s hyperpolarizing pulses from −65 to −135 mV in 10-mV increments. C, in a cell 
co-transfected with RPTPα after 2 days of incubation, HCN4 current expression in 
response to 10-s hyperpolarizing pulses from −65 to −135 mV in 10-mV increments. D, 














Fig 2. Src/RPTPα on HCN4 cell surface expression in HEK293 cells. 
A, fluorescence imaging of HCN4-DsRed, HCN4-DsRed+RPTPα, and HCN4-
DsRed+Src529. B, fluorescence (left panel) and bright field (right panel) images of cells 


















Fig 3. Src/Fyn/Yes kinases on current expression of D553N at −125 mV.  
Currents elicited by hyperpolarizing pulses in 10-mV increments are presented for HCN4 
(A), D553N (B), D553N+Src529 (C), D553N+Fyn531 (D), D553N+Yes537 (E), 
D553N+Src529+Fyn531 (F), D553N+Src529+Yes537 (G), D553N+Fyn531+Yes537 
(H), and D553N+Src529+Fyn531+Yes537 (I). The test potentials are labeled in the 
figures. The pulse durations were 15 s for A–C, E, and G; 12 s for F, H, and I; and 6 s for 










Fig 4. Src/Fyn/Yes kinases on current density and gating of D553N compared with 
HCN4. A, current density measured at −125 mV under different conditions. An asterisk 
indicates a statistically significant difference in comparison with D553N current density. 
B, time constants of activation kinetics at −125 mV under different conditions. p values 
indicated statistical significance in comparing the effects of the kinases on D553N to 
HCN4 (white bar). p* values indicated statistical significance in comparing the effects of 
the kinases on D553N to D553N alone (gray bar). C, activation curves of HCN4 (WT) 
and D553N+Src/Fyn/Yes. D, activation kinetics of HCN4 (WT) and 
D553N+Src/Fyn/Yes. All of the statistical results were from seven to nine cells for each 





                  
      
 
 
Fig 5. Src/Fyn/Yes kinases on D553N fluorescence imaging.  
Fluorescence images of cells transfected with HCN4 (A), D553N (B), DsRed vector (C), 
D553N+Src529 (D), D553N+Fyn531 (E), and D553N+Yes537 (F). All of the results 


























































Defective trafficking of mutant channels represents an important mechanism for Kv 
channels causing long QT2 (Delisle et al., 2004). Studying long QT related Kv channel 
modulation has led to the findings that lower temperature and channel blockers can 
restore the surface and ionic current expression of the defective trafficking mutant 
channels (Delisle et al., 2004). In this work, we showed for the first time that by 
modulating the Src/Fyn/Yes kinase activity, a human HCN4 trafficking defective mutant 
D553N (also linked to long QT (Ueda et al., 2004)) can be rescued for normal surface 
and current expression. The corrected D553N exhibited the gating properties comparable 
with those of the wild-type HCN4 channels.  
Enhanced tyrosine phosphorylation increased the activity of the cardiac pacemaker 
current, If, in the sinoatrial node cells (Wu et al., 2000). Using genistein, a nonspecific 
tyrosine kinase inhibitor, we found a differential modulation of tyrosine phosphorylation 
for HCN1, HCN2, and HCN4 expressed in Xenopus oocytes; genistein had no effects on 
HCN1 but reduced HCN2 or HCN4 current expression (Yu et al., 2004). In the case of 
HCN2, there was also a negative shift in the voltage dependence of activation that 
accompanied the current reduction. These studies represent the acute effects of altered 
tyrosine phosphorylation of HCN channel proteins on the gating properties of If.  
To investigate the long term effects of specific tyrosine kinases on HCN channels in a 
mammalian background, we studied the effects of Src kinase on HCN4 channel (the main 
isoform in the heart) expressed in HEK293 cells. We focused on the Src kinases for two 




Src homology 3 domain was initially used to clone the first HCN channels (Santoro et al., 
1997). We found that Src associated with and phosphorylated the HCN4 channel 
proteins, leading to the enhanced HCN4 current density near diastolic potentials 
(Arinsburg et al., 2006). This was the first direct evidence showing that 1) HCN4 
channels can be phosphorylated by Src-mediated tyrosine kinases and 2) long term 
effects of tyrosine phosphorylation of HCN4 channels can induce the changes in the 
current density, which directly correlates with the number of functional channels 
expressed at the plasma membrane. Accompanying the increased current density were the 
accelerated activation kinetics and a positive shift in the voltage-dependent activation, 
which has been typically observed in the short term modulation of HCN4 channels. These 
conclusions were confirmed by the subsequent investigation on the major tyrosine 
residues that mediate Src actions (Li et al., 2008). Using PP2, a selective inhibitor of Src 
kinase family, we found that the reduced Src kinase activity can indeed shift the voltage-
dependent activation to hyperpolarizing potentials, an effect mediated by HCN4 Tyr531 
(Li et al., 2008). Another tyrosine residue, HCN4 Tyr554 previously reported by others 
(Zong et al., 2005), also contributed to the slowing of activation kinetics by PP2 (Li et al., 
2008).  
Work on the action of PP2 on HCN4 also resulted in two surprising observations. First, 
the PP2-induced negative shift of HCN4 voltage-dependent activation is not in agreement 
with our previous results with genistein. At least two factors can contribute to this 
discrepancy: mammalian cell (HEK293) versus amphibian (Xenopus oocytes) 
background and general (genistein) versus selective (PP2) inhibition of tyrosine kinases. 




2008). These results implied that even the short term effect of altered tyrosine 
phosphorylation may affect the number of functional channels at the plasma membrane.  
More recently in the investigation of the potential role the tyrosine phosphatase might 
play in the modulation of HCN channel function, we found the dramatic inhibition of 
HCN2 current expression by RPTPα (Huang et al., 2008). The inhibited HCN2 current 
expression was due to the reduced surface expression of HCN2 channels via association 
between RPTPα and the HCN2 channel proteins, resulting in the channel 
dephosphorylation (Huang et al., 2008). The work demonstrated a previously 
unrecognized feature of HCN channel modulation by tyrosine phosphorylation: the 
tyrosine phosphorylation state of HCN channel proteins represents one important 
regulatory mechanism for the cell surface expression of the functional channels, which 
directly determines the current expression of functional HCN channels. This feature may 
be utilized to enhance the surface and ionic current expression of HCN mutant channel 
that cannot reach the plasma membrane for normal function.  
Indeed, the evidence presented in this work showed that the enhanced tyrosine 
phosphorylation mediated by Src kinases can rescue the surface expression of D553N for 
normal channel function. What was unexpected, however, is the finding that three Src 
kinases that were ubiquitously expressed in the heart have different functional effects on 
D553N channel activity. In agreement with the previous studies, the Src kinase-mediated 
tyrosine phosphorylation is associated with the acceleration of channel activation kinetics 
(Arinsburg et al., 2006; Li et al., 2008; Zong et al., 2005). These differential effects by 




The differential phosphorylation of both wild-type HCN4 and D553N channels by three 
Src kinases suggested that different tyrosine residues are involved in mediating each of 
the kinases. These results also suggested a possibility that D553N may undergo a protein 
misfolding that prevents the nearby tyrosine residues from being phosphorylated. 
Association of Src tyrosine kinases appears to partially correct the protein folding that 
leads to the exposure of key tyrosine residues for phosphorylation.  
To understand the mechanism by which tyrosine phosphorylation used to restore the 
surface expression of D553N, we proposed a model utilizing the three-dimensional 
crystal structure of the C-linker region of HCN2 for the following three reasons. First, 
D553N mutation occurred in the C-linker. Second, there is a high homology (91.6%) 
between HCN2 and HCN4 in the C-linker. Third, HCN2 is the only protein in the HCN 
family whose crystal structure of the C-linker has been solved (Zagotta et al., 2003). 
HCN4 Asp553 corresponds to HCN2 Asp475. Among many potential mechanisms 
responsible for the defective trafficking of HCN4-D553N, protein misfolding is an 
attractive one. We hypothesized that there may exist a potential electrostatic interaction 
between Asp475 and Lys472 of the B′ helix. The negatively charged Asp475 is spatially 
close to the positively charged Lys472, similar to the relative spatial locations of Lys472 
and Glu502 of the D′ helix, which have been demonstrated to form a salt bridge critical in 
maintaining the local folding of C-linker (Zagotta et al., 2003). The putative D475N 
(equivalent to D553N in HCN4) mutation can cause the loss of a negative charge, which 
may change the intersubunit interaction between Lys472 and Glu502 to alter local folding 
of the C-linker structure. We noted that Lys472 is changed to Arg550 in HCN4. With a 




interactions with nearby residues having negative side chains. Therefore, in HCN4-
D553N mutant, the potential salt bridge of Asp553 with Arg550 could be disrupted, which 
affected the interaction between Arg550 and Glu580 (Glu502 in HCN2) that is critical in 
intersubunit contacts (Zagotta et al., 2003). Furthermore, the Src kinase-mediated 
tyrosine phosphorylation at Tyr554 residue near Asp553 could introduce a negatively 
charged phosphate group, which could mimic the effect of Asp553 to rebuild the salt 
bridge interaction between Arg550 and Glu580, consistent with the previous studies 
demonstrating the importance of Tyr554 (Li et al., 2008; Zong et al., 2005). For wild-type 
HCN4, the existing negative charge on Asp553 might repel the entry of a phosphate group 
and limit the phosphorylation on certain nearby tyrosine residues.  
While presenting a novel mechanism to correct the surface expression of a trafficking 
defective HCN4 mutant channel, we left at least three questions unanswered. First, what 
are the tyrosine residue(s) in HCN4 channel proteins that mediate the actions of Fyn and 
Yes? The same tyrosine residues (such as Tyr531 and Tyr554) are unlikely to be used by all 
three kinases. Fyn, not Src, accelerated D553N activation kinetics (Fig. 5B). Fyn may 
target the tyrosine residues in or near A′ and B′ helices of the C-linker. On the other hand, 
Yes may phosphorylate different tyrosine residues that are located outside of the C-
linker, which can explain its lack of acceleration in the activation kinetics. Second, what 
is the correlation, if any, among the surface expression and activation kinetics and the 
tyrosine phosphorylation state of HCN4 channels? Fyn showed acceleration of the 
channel activation kinetics but little effect on promoting the channel surface expression. 
Yes slowed the channel activation kinetics, but exhibited the most potency of promoting 




yet to be identified. Third, will an increase in the endogenous Src/Fyn/Yes kinase activity 
in myocytes help promote the surface expression of D553N in vivo? Addressing these 
questions represents our future research endeavors, leading to the discovery of an 
effective endogenous regulatory mechanism to correct cardiac arrhythmias caused by 




























Part II: Novel mechanism for suppression of 
hyperpolarization-activated cyclic nucleotide-gated pacemaker 




Tyrosine phosphorylation plays a pivotal role in the regulation of membrane trafficking 
of HCN channels. Previous reports have demonstrated that both of the If densities and 
gating properties were significantly enhanced by increase of tyrosine phosphorylation 
level in rat myocytes (Wu et al., 2000). Here, we report that a member of receptor-type 
tyrosine phosphatase, RPTPα, can abolish the current expression of HCN2. Our results 
indicated that RPTPα plays the novel role in the regulation of HCN channel function via 
tyrosine dephosphorylation of HCN channel protein. 
 



























Activated by membrane hyperpolarization, the HCN2 channels are important to rhythmic 
activity in neurons and myocytes (Robinson et al., 2003; Santoro et al., 2003). 
Accumulating evidence has also suggested an important role of tyrosine phosphorylation 
in modulating HCN channels (Wu et al., 2000; Yu et al., 2004). We have recently shown 
that increased tyrosine phosphorylation state of HCN4 by activated Src tyrosine kinase 
can enhance the gating of HCN4 channels (Arinsburg et al., 2006). Given that the 
efficacy of tyrosine phosphorylation is determined by the dynamic balance of tyrosine 
kinases and tyrosine phosphatases, reduced tyrosine phosphatase activity is speculated to 
increase HCN channel activity. Receptor-like protein-tyrosine phosphatases (RPTPs) are 
transmembrane phosphatases critical in cell growth and cell adhesion (Stoker, 2005). One 
member of RPTPs, RPTPα, has been proposed to be a positive regulator of Src tyrosine 
kinases (Ponniah et al., 1999; Su et al., 1999). As a protein-tyrosine phosphatase, RPTPα 
should also be able to dephosphorylate phosphotyrosines of channel proteins. This work 
was designed to investigate whether RPTPα can inhibit the HCN channel activity by 















RPTPα Inhibition of HCN2 Currents in HEK293 Cells 
Our recent discovery showed that increased tyrosine phosphorylation of HCN4 channel 
by activated Src tyrosine kinase can enhance the channel gating properties in HEK293 
cells (Arinsburg et al., 2006; Li et al., 2008). We wondered whether increased tyrosine 
dephosphorylation by RPTPα may inhibit the gating properties of HCN channels 
expressed in HEK293 cells.  
Functional expressions of HCN2 after 2 days (44–50 h) of transfection are shown in Fig 
1. HCN2 currents were elicited by hyperpolarizing pulses detailed in the figure legends. 
Typical biophysical properties of the expressed channels such as the threshold activation, 
activation kinetics, and current densities are comparable with those reported previously 
(Arinsburg et al., 2006; Li et al., 2008; Zong et al., 2005). Co-transfection with RPTPα, 
however, resulted in a dramatic inhibition (Fig. 1B) or a surprising loss of HCN2 currents 
(Fig. 1C). Similar results were reproduced in 10 additional cells for each HCN2 channel 
co-expressed with RPTPα. As part of control experiments, the empty pRK5 vector did 
not affect HCN2 expression from 1 to 4 days post-transfection. Fig. 1D shows the HCN2 
recordings in a HEK293 cell co-transfected with HCN2 and pRK5 vector after 2 days. 
Similar results were obtained in an additional five cells.  
Interestingly, we found the degree by which RPTPα inhibited HCN2 current expression 
changed with time. Fig. 2 shows HCN2 current expression recorded in HEK293 cells co-
transfected with RPTPα after 1 day (24–30 h) (A), 2 days (44–50 h) (B), and 4 days (C) 




reduced HCN2 current density (pA/pF) measured at -125 mV by 64% after day 1 (HCN2 
= 38.9 ± 1.7, n = 11; RPTPα = 1.37 ± 0.5, n = 10), by 96% after day 2 (RPTPα = 1.5 ± 
0.5, n = 10), and by 80% after day 4 (RPTPα = 7.7 ± 0.7, n = 10) (Fig. 2D). The time-
dependent inhibition is not only significant as compared with the control, but also 
















Fig 1. RPTPα inhibition of HCN2 current expression. 
HCN2 currents were recorded 2 days after cell transfection. A, HCN2 currents in a 
HEK293 cell expressing HCN2 alone. Hyperpolarizing pulses (4 s) from -65 to -125 mV 
were applied. B, hyperpolarization-activated currents in a HEK293 cell co-transfected 
with HCN2 and RPTPα. Hyperpolarizing pulses (5 s) from -75 to -125 mV were applied. 
C, hyperpolarization-activated currents in a HEK293 cell co-transfected with HCN2 and 
RPTPα. Hyperpolarizing pulses (3 s) from -75 to -125 mV were applied. D, HCN2 
currents in a HEK293 cell co-transfected with HCN2 and the empty pRK5 vector. 
Hyperpolarizing pulses (5 s) from -65 to -125 mV were applied. The tail currents were 
recorded at +20 mV. The holding potential was -10 mV. Arrows in A and D indicate the 







Fig 2. RPTPα induced time-dependent inhibition of HCN2 current expression. 
Hyperpolarizing pulses of 5 s ranging from -75 to -125 mV (A and B) or from 85 to -125 
mV (C) in 10-mV increments were applied to elicit HCN2 currents in HEK293 cells co-
transfected HCN2 with RPTPα after day 1 (A), day 2 (B), and day 4 (C). D, averaged 















In this study, we provided evidence showing dramatic inhibitory effects of tyrosine 
dephosphorylation by RPTPα on HCN2 channels. Two mechanisms are likely involved 
as follows: tyrosine dephosphorylation and membrane trafficking of HCN channels. Both 
are mediated by RPTPα.  
In HEK293 cells co-expressing HCN2 channels with RPTPα for 2 days yielded 
surprising inhibition or even elimination of the current expression. There are two 
plausible explanations as follows: the channels were retained in the cytoplasm leading to 
little or no expression of functional channels on plasma membrane, or gating properties 
of the channels on the plasma membrane were inhibited. In this study, we also performed 
western blot analysis on the membrane fraction of cells and revealed that the 
constitutively active Src, which increases the tyrosine phosphorylation level of the 
channels, increased the surface expression of the channels. On the other hand, RPTPα, 
which decreases the tyrosine phosphorylation level of the channels, retained most 
channels in the cytoplasm. 
It is surprising that the HCN2 channel expression was largely blocked by RPTPα after 2 
days of transfection and reappeared after 4 days of transfection (Fig. 2B). It offers a likely 
explanation to no measurable or much smaller time-dependent inward currents in 
HEK293 cells co-transfected by HCN2 with RPTPα for the same time periods (Fig. 1, B 
and C). It is worth noting that whole-cell patch clamp technique applied to individual 




of cells. Therefore, after transfection for 2 days we were able to detect small current 
expression in some cells, but not in protein expression.  
Protein-tyrosine phosphatases, like protein-tyrosine kinases, play a critical role in the 
regulation of physiological events (Ponniah et al., 1999; Su et al., 1999). RPTPα has a 
short extracellular domain (about 123–150 amino acids long) that contains eight potential 
N-glycosylation sites (Daum et al., 1994; Kaplan et al., 1990). Following a 
transmembrane region, there are two tandem domains having phosphatase catalytic 
activity. RPTPα is expressed in two isoforms differing by nine residues (Kaplan et al., 
1990) that are highly glycosylated, p100 and p130 on SDS-PAGE (Daum et al., 1994). 
The p100 form contains only N-linked glycosylation, whereas p130 contains both N-
linked and O-linked.  
Our data have shown a critical role that RPTPα plays in the tyrosine dephosphorylation 
of HCN2 channels. The short-term likely involves the tyrosine dephosphorylation, is the 
reduced If activity in cardiac myocytes. The long-term effects (days) include the 
inhibition of HCN channel surface expression and possibly channel biosynthesis. 
Recently, HCN4 mutants have been linked to the bradycardia and long-QT arrhythmias 
(Milanesi et al., 2006; Nof et al., 2007; Schulze et al., 2003; Ueda et al., 2004). The 
common cellular mechanism was retaining membrane trafficking caused by the truncated 
HCN4 protein lacking cyclic nucleotide binding domain (Schulze et al., 2003), D553N in 
the C-linker between S6 and cyclic nucleotide binding domain (Ueda et al., 2004), and 
G480R in the channel pore region (Nof et al., 2007). The evidence we presented in this 
work provided a novel mechanism that may be used to enhance the surface expression of 






Inactivation of L-type calcium channel modulated by HCN2 
channel 
The goal of this chapter is to explore a new role of HCN serving as a regulatory protein  
to regulate the Ca2+ influx via the control of L-type calcium channel (LTCC) inactivation. 
The results in this chapter have been published (Am J Physiol Cell Physiol 298(5): 
















Ca2+ entry is delicately controlled by inactivation of L-type calcium channel (LTCC) 
composed of the pore-forming subunit α1C and the auxiliary subunits β1 and α2δ. 
Calmodulin is the key protein that interacts with the COOH-terminal motifs of α1C, 
leading to the fine control of LTCC inactivation. In this study we show evidence that a 
hyperpolarization-activated cyclic nucleotide-gated channel, HCN2, can act as a 
nonchannel regulatory protein to narrow the L-type Ca2+ channel current-voltage curve. In 
the absence of LTCC auxiliary subunits, HCN2 can induce α1C inactivation. Without 
α2δ, HCN2-induced fast inactivation of α1C requires calmodulin. With α2δ, the 
α1C/HCN2/α2δ channel inactivation does not require calmodulin. In contrast, β1-subunit 
plays a relatively minor role in the interaction of α1C with HCN2. The NH2 terminus of 
HCN2 and the IQ motif of α1C subunit are required for α1C/HCN2 channel interaction. 
Ca2+ channel inactivation is significantly slowed in hippocampus neurons (HNs) 
overexpressing HCN2 mutant lacking NH2 terminus and accelerated in HNs 
overexpressing the wild-type HCN2 compared with HN controls. Collectively, these 
results revealed a potentially novel protection mechanism for achieving the LTCC 









L-TYPE CALCIUM CHANNEL (LTCC) current inactivation is dependent on both Ca2+ 
ions and voltage (Cens et al., 2006; Liang et al., 2003). The β- and α2δ-subunits regulate 
the membrane expression and the voltage-dependent inactivation of the α1C-subunit 
(Arikkath et al., 2003). Calmodulin (CaM) plays a central role in both Ca2+-dependent 
inactivation (CDI) and voltage-dependent inactivation (VDI) using Ba2+ as the charge 
carrier (Kim et al., 2004; Liang et al., 2003). CaM is proposed to tether with the IQ motif 
in the COOH terminus of α1C (Peterson et al., 1999; Pitt et al., 2001). Ca2+ influx 
through LTCC activates apoCaM (Ca2+-free CaM)/IQ complex. The activated CaM/IQ 
triggers a conformational change of the inactivation machinery consisting of α1C COOH-
terminal domains such as peptide A, peptide C (or CB), IQ motif, and CaM. As a result, 
the inactivation machinery rapidly blocks the inner surface of the pore, leading to fast 
CDI (Erickson et al., 2003; Pitt et al., 2001). CaM also has been proposed to interact with 
the linker of the transmembrane I and II segments associated with the β1-subunit to 
modulate VDI (Cens et al., 2006; Kim et al., 2004).  
 
Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels are activated by 
membrane hyperpolarization, generating a voltage- and time-dependent inward current 
called Ih or If, which has been traditionally thought to permeate both Na+ and K+ ions 
(DiFrancesco et al., 1993). Recently, we discovered that Ca2+ ions also can permeate 
HCN channels, even in a small percentage of the total current (Yu et al., 2007). 
Furthermore, activation of Ih and If can increase the synapse transmission in dorsal root 




myocytes (Yu et al., 2007), respectively. However, the underlying mechanisms are not 
well understood. In the present work, we focus on a hypothesis that a closed HCN 
channel can interact with LTCC at the plasma membrane, leading to the fast inactivation 


















CDI and VDI of α1C/α2δ/β1 and α1C/α2δ/β1/HCN2 channels in HEK-293 cells 
Figure 1A exemplified a well-established difference between CDI and VDI: faster 
inactivation for ICa (solid line) than for IBa (shaded line), recorded at +10 mV. This 
difference, however, is largely diminished in the presence of HCN2 (Fig. 1B): like ICa, the 
IBa of α1C/α2δ/β1/HCN2 can inactivate almost completely to the closed state. Figure 1C 
summarizes the time constants of inactivation of ICa and IBa for α1C/α2δ/β1 and 
α1C/α2δ/β1/HCN2. They are 25.0 ± 3.2 ms for ICa and 228.5 ± 24.2 ms for IBa of 
α1C/α2δ/β1, and 58.3 ± 3.3 ms for ICa and 72.5 ± 5.6 ms for IBa of α1C/α2δ/β1/HCN2. 
The difference between ICa and IBa of α1C/α2δ/β1/HCN2 inactivation kinetics was 
diminished compared with that between ICa and IBa of α1C/α2δ/β1 inactivation kinetics, 
indicating that HCN2 can help complete the IBa inactivation. 
We also examined whether the current-voltage relationship curves of α1C/α2δ/β1 are 
altered by HCN2. Representative ICa are shown for α1C/α2δ/β1 (Fig. 1D) and 
α1C/α2δ/β1/HCN2 (Fig. 1E). In the presence of HCN2, there was a positive shift in the 
threshold activation of ICaL and more reduced current amplitude at the depolarized end of 
the bell shape near +50 mV (Fig. 1F, shaded line). All results were repeated in an 






Fast inactivation of α1C/HCN2 channels in HEK-293 
To examine a possible hidden interaction between α1C and HCN2, we studied α1C 
inactivation by coexpressing α1C and HCN2 in the absence of auxiliary subunits. With 
the use of Ba2+ as the charge carrier, α1C exhibited little current inactivation when 
expressed alone (Fig. 2A, top). The auxiliary subunit α2δ could limit the Ca2+ influx by 
inducing a slow inactivation of α1C (Fig. 2A, top). Figure 2B, bottom, shows the absence 
of endogenous time-dependent inward currents in HEK-293 cells without cDNA 
transfection under our experimental conditions. These results are in agreement with the 
previous reports (Felix et al., 1997; Yasuda et al., 2004). However, when HCN2 was 
coexpressed with α1C, a fast inactivation of α1C/HCN2 was observed (Fig. 2B, top). This 
new inactivation has a differential sensitivity for Ba2+ and Ca2+ ions, capable of coming 
back to the closed state in the presence of Ca2+ (shaded line) but not Ba2+ (solid line), the 
typical characteristics of the conventional LTCC inactivation (Kim et al., 2004; Zuhlke et 
al., 1998). Adding α2δ did not significantly affect the α1C/HCN2 inactivation (Fig. 2A, 
bottom). With Ba2+ as the charge carrier, time constants for inactivation of α1C/α2δ, 
α1C/HCN2, and α1C/HCN2/α2δ were 156 ± 19, 26 ± 4, and 22 ± 2 ms, respectively (n = 
8). The inactivation for α1C/α2δ channels was significantly slower than that for 
α1C/HCN2 or α1C/HCN2/α2δ (P = 0.002, n = 8). There was no statistical difference 
between α1C/HCN2 and α1C/HCN2/α2δ channel inactivation (P = 0.5, n = 8). To verify 
that the current is via the conventional α1C channel, verapamil (10 µM) was applied to 




To address the concern that the fast inactivation of α1C/HCN2 or α1C/HCN2/α2δ 
channel was probably due to the contamination from the deactivation of HCN2 channels, 
we studied current expression of HCN2 in the external solution normally used for 
characterization of HCN2 and in the external solution used to record IBa inactivation (e.g., 
Fig. 2, A and B). The hyperpolarization-activated HCN2 channels permeate both Na+ and 
K+ ions (DiFrancesco et al., 1993). The channel cannot be activated in the absence of 
external Na+ and K+ ions (DiFrancesco et al., 1993). In the external solution containing 
140 mM Na+ and 30 mM K+, a typical HCN2 current (the time-dependent inward current) 
was recorded in response to a 3-s hyperpolarizing pulse to –125 mV (Fig. 2C), consistent 
with the previous report (Yu et al., 2007). When the Na+ and K+ ions were removed from 
the external solution, no time-dependent inward current was recorded (Fig. 2C).  
HCN2 channels are closed at membrane depolarization that is used to activate LTCC 
(DiFrancesco et al., 1993). In response to a depolarization to +10 mV from the holding 
potential of –90 mV, there was no HCN2 activation current in the solution containing 140 
mM Na+ and 30 mM K+ (Fig. 2D). The inactivation of α1C/HCN2/α2δ channel in the 
Na+- and K+-free solution was used as a comparison (Fig. 2D). These data strongly 
indicate that the closed HCN2 channels can act as the nonfunction channel to induce a 
fast inactivation of α1C.  
Role of Ca2+-free CaM in α1C/HCN2 channel inactivation  
Given the pivotal role CaM plays in the Ca2+ channel inactivation, we tested the idea that 
CaM may be involved in the fast inactivation of α1C/HCN2 channel for two reasons: 




tethered to structural domains in the COOH terminus of α1C subunit (Erickson et al., 
2003; Pitt et al., 2001).  
We first used two structurally different calmodulin inhibitors, W-7 [N-(6-aminohexyl)-5-
chloro-1-naphthalenesulfonamide] (Hidaka et al., 1981) and trifluoperazine (TFP) 
(Reinhart et al., 1980), to study their potential effects on α1C/HCN2 channel inactivation. 
After binding Ca2+ ions, CaM undergoes a conformational change leading to the exposure 
of its hydrophobic activation site for binding to its substrate, CaM-dependent kinase 
(CaMK). Both W-7 and TFP block CaM actions by occupying the hydrophobic site to 
prevent binding of CaMK (Hidaka et al., 1981; Osawa et al., 1998). Figure 3A shows that 
both drugs at 15 µM eliminated the fast inactivation of α1C/HCN2 channels within 15–20 
min, consistent with the time course of inhibiting CaM activity by both drugs. The effect 
of the drug was observed in the same cell. The similar results were obtained in an 
additional five to seven cells.  
We then employed a dominant negative calmodulin mutant, CaM(1,2,3,4) (Xia et al., 1998). 
Compared with the current expression of α1C/HCN2 coexpressed with a wild-type 
calmodulin, CaM(WT), overexpression of CaM(1,2,3,4) eliminated the fast inactivation of 
α1C/HCN2 (Fig. 3B, shaded line). These pharmacological and mutant CaM data strongly 







Role of α2δ in α1C/HCN2 channel inactivation  
Nearly all studies of CaM-mediated α1C inactivation, carried out in either Xenopus 
oocytes or mammalian cells (HEK-293, Chinese hamster ovary, COS), have been 
performed with coexpression of β1- and α2δ-subunits. This is due to the important roles 
of β1- and α2δ-subunits in expression of α1C on plasma membrane and Ca2+ channel 
function (Arikkath et al., 2003). Previous studies also have demonstrated a significant 
role of α2δ in initiating the inactivation of α1C expressed in HEK-293 cells (Felix et al., 
1997; Yasuda et al., 2004). Wondering whether CaM would have the similar impact on 
the α1C/HCN2 channel inactivation in the presence of the α2δ subunit, we tested the 
effects of W-7 and TFP on the current expression of α1C/HCN2/α2δ channels. 
Surprisingly, neither W-7 (left) nor TFP (right) affected the inactivation of 
α1C/HCN2/α2δ channels (Fig. 3C, shaded lines). To further confirm this observation, we 
overexpressed either CaM(WT) or CaM(1,2,3,4) with α1C/HCN2/α2δ channels (Fig. 3D, 
shaded lines). Neither of them affected the inactivation of α1C/HCN2/α2δ channels. 
Compared with its dominant effect in α1C/HCN2 channel inactivation (Fig. 3, A and B), 
CaM plays a minor role in α1C/HCN2/α2δ channel inactivation (Figs. 3, C and D), 
indicating a potential role of α2δ-subunit in the α1C/HCN2 channel inactivation.  
α1C/HCN2 channel interaction requires NH2 terminus of HCN2 and IQ motif of 
α1C 
The fact that the fast inactivation of α1C/HCN2 is Ca2+ independent (since we used Ba2+ 
as a charge carrier) suggested that CaM may not be the only mechanism for α1C/HCN2 




α1C, we studied the current expression of 1) the wild-type α1C with a HCN2 mutant 
lacking the NH2 terminus [HCN2(-N)] and 2) the wild-type HCN2 with an α1C mutant 
lacking the IQ motif in the COOH terminus [α1C∆(1623-1666)] (Gao et al., 2000). Figure 
4A shows that the inactivation of α1C/HCN2 (solid line) was eliminated by either HCN2(-
N) or α1C∆(1623-1666) (shaded lines). 
We next examined how α1C and HCN2 channel mutants interact in the presence of the 
α2δ subunit. Figure 4B shows that compared with the α1C/HCN2/α2δ channel 
inactivation (solid line), both α1C/HCN2(-N)/α2δ and α1C∆(1623-1666)/HCN2/ 2  
channels dramatically slowed the inactivation process (shaded lines). We also observed 
biphasic inactivation of α1C/HCN2(-N)/α2δ (Fig. 4B, shaded line) with its first fast 
inactivation phase close to the wild type but with a second phase almost linear that cannot 
be fitted by an exponential function.  
We finally studied the effects of HCN2 and α1C mutants on α1C/HCN2 inactivation in 
the presence of both α2δ- and β1-subunits. Compared with the wild-type 
α1C/α2δ/β1/HCN2 channel (solid line), the significant slowing of α1C/HCN2 channel 
inactivation by either HCN2(-N) or α1C∆(1623-1666) (shaded lines) still persisted in the 
presence of α2δ- and β1-subunits (Fig. 4C). At +10 mV, the time constants of IBa 
inactivation were 72.5 ± 5.6 ms for α1C/α2δ/β1/HCN2, 108 ± 13 ms for 
α1C/α2δ/β1/HCN2(-N), and 498 ± 43 ms for α1C∆(1623-1666)/α2δ/β1/HCN2, 
respectively (n = 5–7) (Fig. 4D). Together, these results suggest that the NH2 terminus of 
HCN2 and the IQ motif of α1C are the structural elements required for the inactivation of 




Relative roles of CaM, α2δ, and β1 in the inactivation of α1C/HCN2 channels  
To examine the relative contribution of α2δ and CaM to the inactivation of α1C/HCN2 
channels, we compared the inactivation time constants for different combinations of α1C, 
HCN2, α2δ, and CaM, including their respective mutants, except for α1C 1905x/HCN2. 
α1C 1905x is a distal COOH-terminal truncated form of α1C, which is used as a control 
for α1C∆(1623-1666) function (Gao et al., 2000). We found that α1C∆(1623-1666) and 
HCN2(-N) are the two most significant structural motifs that contribute to the inactivation 
of α1C/HCN2 channels independently of α2δ (Fig. 4D). We also found, surprisingly, that 
overexpression of CaM(WT) did not accelerate (as one would expect), but slowed, the 
inactivation of α1C/HCN2/α2δ or α1C 1905x/HCN2/α2δ channels (Fig. 4D).  
In the absence of α2δ, there was a distinct difference between CDI and VDI for 
α1C/HCN2 channels (Fig. 2B). In the presence of α2δ, however, the difference between 
CDI and VDI disappeared (Fig. 4E). Combined with the diminished difference between 
CDI and VDI for α1C/α2δ/β1/HCN2 (Fig. 1B), the results provide additional evidence for 
a major role of α2δ in the inactivation of α1C/HCN2 channels. In comparing Fig. 4, C 
and E, β1 helped complete the IBa inactivation of α1C/HCN2/α2δ channels, which are 








Slowing Ca2+ inactivation by disrupting α1C/HCN2 association in hippocampus 
neurons 
NH2 terminus of HCN2 was reported to be essential in the formation of the homo- and 
heteromeric channels at the plasma membrane (Proenza et al., 2002). Shown in Fig. 5A, 
formation of the rat hippocampal neuron network was visualized after 5–6 days in 
culture. After 24- to 48-h transfection of HCN2(-N) with GFP, the expression of HCN2(-
N) was indicated by the fluorescent image (Fig. 5B) compared with the brightfield image 
of the same region (Fig. 5A). The fluorescent neurons were subject to the patch-clamp 
recordings. Shown in Fig. 5C, overexpression of HCN2(-N) induced a remarkably slow 
inactivation component (light shaded line) that was not present in the control neurons or 
in neurons transfected with the empty vector (solid line, as a transfection control). On the 
other hand, transfection with the full-length HCN2 accelerated the IBa inactivation (dark 
shaded line in Fig. 5C). Currents were verified by verapamil (10 µM) blockade (Fig. 5C). 
At +10 mV, time constants of IBa inactivation were 26.5 ± 2.9 ms (n = 9) for control 
hippocampal neurons (HN), 35.1 ± 3.5 ms (n = 6) for HN + vector, 66.1 ± 3.3 ms (n = 7) 
for HN + HCN2(-N), and 19.0 ± 2.2 ms (n = 10) for HN + HCN2 (Fig. 5D). The altered 
time constants for channel inactivation were marked with statistical significance 








Fig 1. Ca2+-dependent inactivation (CDI) and voltage-dependent inactivation (VDI) 
of α1C/α2δ/β1 and α1C/α2δ/β1/HCN2 in HEK-293. A: Ca2+ current (ICa; solid line) and 
Ba2+ current (IBa; shaded line) of α1C/α2δ/β1 recorded at +10 mV. B: ICa (solid line) and 
IBa (shaded line) of α1C/α2δ/β1/HCN2 recorded at +10 mV. C: time constants (τ) for 
inactivation of ICa and IBa at +10 mV for α1C/α2δ/β1 and α1C/α2δ/β1/HCN2, 
respectively. For simplicity of comparison, we best fit the currents with one exponential 
function. P values shown are the statistical results of comparing ICa and IBa inactivation. 
D and E: ICa currents recorded in the test pulses ranging from –50 to +50 mV in 10-mV 
increments for α1C/α2δ/β1 (D) and α1C/α2δ/β1/HCN2 (E), respectively. A 400-ms 
depolarizing pulse was used. Holding potential was –90 mV. F: current-voltage 





        
Fig 2. α1C/HCN2 channel inactivation in HEK-293 cells. A, top: current expression of 
α1C and α1C/α2δ, respectively. Bottom, current inactivation of α1C/HCN2/α2δ that was 
blocked by 10 µM verapamil. Pulse duration was 200 ms. B, top: α1C/HCN2 inactivation 
using 2 mM Ba2+ (solid line) or 2 mM Ca2+ (shaded line) as the charge carrier, which was 
blocked by 10 µM verapamil. Pulse duration was 400 ms. Bottom, absence of time-
dependent inward current expressions in HEK-293 cells without plasmid transfection. 




comparison of the inactivation kinetics. C: hyperpolarizing pulse control experiments. In 
cells expressing only HCN2, IHCN2 was elicited by a 3-s hyperpolarizing pulse to –125 
mV from the holding potential of –10 mV in modified Tyrode solution containing 140 
mM Na+ and 30 mM K+; in cells coexpressing α1C/HCN2/α2δ, the same hyperpolarizing 
pulse could not detect IHCN2 in the external and internal solutions used to record IBa. 
Although the leak current varies from cell to cell, we chose a leak current that closely 
aligned with the HCN2 time-dependent inward current for better comparison. The pulse 
protocol is shown in the inset. The dashed line shows the holding current. D: depolarizing 
pulse control experiments. In solutions without Na+ and K+ ions (0 Na+, 0 K+), IBa was 
recorded only in cells coexpressing α1C/HCN2/α2δ, not in cells expressing only HCN2. 












Fig 3. Role of calmodulin (CaM) in α1C/HCN2 channel inactivation. A: α1C/HCN2 
channel inactivation (solid line) and lost inactivation in the presence of the CaM inhibitor 
W-7 or trifluoperazine (TFP) (shaded lines). B: α1C/HCN2/CaM(WT) channel inactivation 
(solid line) and lost inactivation of α1C/HCN2/CaM(1,2,3,4) channels (shaded line). 
CaM(WT), wild-type calmodulin; CaM(1,2,3,4), a dominant negative calmodulin mutant. C: 
α1C/HCN2/α2δ channel inactivation in the absence (solid line) and presence of W-7 
(shaded line; left) or TFP (shaded line; right). D: α1C/HCN2/α2δ channel inactivation in 








Fig 4. α1C/HCN2 interaction requires NH2 terminus of HCN2 and IQ motif of α1C. 
A: α1C/HCN2 channel inactivation for wild-type (solid line), α1C∆(1623-1666)/HCN2 
(shaded line), and α1C/HCN2(-N) channels (shaded line). B: α1C/HCN2/α2δ channel 
inactivation for wild-type (solid line), α1C∆(1623-1666)/HCN2/α2δ (shaded line), and 
α1C/HCN2(-N)/α2δ channels (shaded line). C: inactivation of α1C/α2δ/β1/HCN2 (solid 
line), α1C∆(1623-1666)/α2δ/β1/HCN2 (shaded line), and α1C/α2δ/β1/HCN2(-N) (shaded 
line). D: inactivation time constants measured at +10 mV for showing the significant role 
of HCN2(-N) [α1C/HCN2/α2δ, α1C/HCN2(-N)/α2δ, α1C/HCN2/α2δ/CaM(WT), and 




α1C1905x/HCN2, α1C1905x/HCN2/α2δ, α1C1905x/HCN2/α2δ/CaM(WT), and 
α1C∆(1623-1666)/HCN2/α2δ; shaded bars]. Results are expressed as means ± se. *P < 
0.0001, statistically significant difference compared with α1C/HCN2/α2δ; P = 0.07 for 
α1C/HCN2/α2δ/CaM(WT) and P = 0.08 for α1C/HCN2/α2δ/CaM(1,2,3,4) (n = 6–12). &P < 
0.0001, statistically significant difference compared with α1C/HCN2/α2δ or 
α1C1905x/HCN2/α2δ; P = 0.006 for α1C1905x/HCN2/α2δ/CaM(WT) and P = 0.0003 for 
α1C∆(1623-1666)/HCN2/α2δ (n = 5–12). E: inactivation of α1C/HCN2/α2δ channel in 






Fig 5. Altered L-type Ca2+ channel (LTCC) inactivation in rat hippocampal neurons 
(HN) overexpressing HCN2(-N) and the full-length HCN2. A brightfield image (A) 
and fluorescence image (B) of the region is shown 48 h posttransfection of HCN2(-N) or 
HCN2 with GFP. C: Ca2+ current inactivation using Ba2+ as a charge carrier in a control 
neuron and in neurons transfected with the empty vector (HN + vector), in a neuron 
transfected with HCN2(-N) [HN + HCN2(-N)], and in a neuron transfected with HCN2 
(HN + HCN2). IBa currents were recorded at +10 mV. The holding potential was at –90 




moved up by 60 pA for clear illustration of currents under different conditions. D: 
inactivation time constants in HN, HN transfected with HCN2, HN transfected with the 
vector, and HN transfected with HCN2(-N). Results are expressed as means ± se. P 

















Fig 6. A schematic model depicting the potential roles of HCN2 and δ-subunit in the 
inactivation of LTCC. Mechanism 1 summarizes the mechanisms for CDI and VDI of 
LTCC. Mechanism 2 proposes a potential CaM-mediated interaction between the NH2 
terminus of HCN2 and the IQ motif of α1C. Mechanism 3 proposes a potential interaction 
between the COOH tail of the δ-subunit and the NH2 terminus of HCN2 within the 










Both α1C- and δ-subunits are transmembrane proteins with NH2 and COOH tails of α1C 
and COOH tail of δ located intracellularly. CaM and β1-subunit are intracellular proteins 
attached to the α1C near the inner surface of the membrane. These four proteins constitute 
the inactivation machinery for the fine control of Ca2+ influx through LTCC in both VDI 
and CDI (Erickson et al., 2003; Kim et al., 2004; Peterson et al., 1999; Xia et al., 1998).  
Our previous studies showed possible involvement of HCN in the modulation of myocyte 
action potential duration (Yu et al., 2007). In the present work, we evaluated the 
hypothesis that inactivation of LTCC can be modulated via interaction with HCN 
channels under the experimental conditions that prevent HCN2 channel opening. We 
showed here that HCN2 can act as a nonchannel regulatory protein to induce a fast 
inactivation of α1C. To further investigate the possible associated mechanisms involved 
in the interaction between α1C and HCN2 channel proteins, we proposed a model shown 
in Fig 6. Mechanism 1 represents our current understanding of interactions among β-
subunits, which are bound to the α1-interaction domain (AID), apoCaM, and inactivation 
motifs in the COOH-terminal region of α1C. The majority of this conceptual 
understanding was provided from studies in either Xenopus oocytes or HEK-293 cells 
coexpressing α1C with β1- and α2δ-subunits (Erickson et al., 2003; Peterson et al., 1999, 
Pitt et al., 2001; Wang et al., 2007; Zuhlke et al., 1998; 1999). Our present study revealed 
several new concepts. 
First, in the absence of β1- and α2δ-subunits, HCN2 can induce a faster inactivation of 




α1C requires CaM (mechanism 2 in Fig 6), since two CaM inhibitors (W-7 and TFP) and 
the dominant negative CaM(1,2,3,4) all eliminated the inactivation of α1C/HCN2 channel 
(Fig 3, A and B).  
Second, in the presence of the α2δ-subunit, HCN2 can still induce fast inactivation of 
α1C. However, the impact of CaM in affecting the inactivation of α1C/HCN2/α2δ 
channel is diminished compared with that for α1C/HCN2 channel, suggesting a prevalent 
role of the α2δ-subunit in α1C and HCN2 interaction (mechanism 3 in Fig 6).  
Third, mutants of HCN2 (with the NH2 terminus deleted) and α1C (without IQ motif) 
revealed a critical role of these two structural elements in mediating the fast inactivation 
of α1C/HCN2 channels (Fig 4). It is worth noting that the short COOH terminus of the δ-
subunit is located in the intracellular space. Analysis of amino acids in the NH2 terminus 
of HCN2 showed an overall positive charge, which can potentially interact with the 
negatively charged COOH terminus of δ-subunit. Although previous studies have 
suggested a vital role for the δ-subunit in accelerating α1C inactivation (Felix et al., 1997; 
Yasuda et al., 2004), there is limited mechanistic insight into how this process occurs. 
Our data suggested that a key contributor to this accelerated inactivation may be a 
dynamic, coordinated interaction among the COOH terminus of the δ-subunit, the IQ 
motif of α1C, and the NH2 terminus of HCN2. Alternatively, it is also possible that β1-
subunit can interfere with the inactivation of α1C∆(1623-1666)/HCN2/α2δ and 
α1C/α2δ/HCN2(-N), as well (Fig 4C). This may be a logical possibility, since the β1-
subunit is attached to the linker of I-II domains and has been reported to interact with the 




Finally, we have demonstrated that an interaction of α1C and HCN2 is present in native 
tissues, as evidenced by association of the two channel proteins in the hippocampus and 
dramatic slowing of IBa in hippocampal neurons overexpressing HCN2(-N) (Fig 5). It 
should be noted that the currents we recorded in hippocampal neurons are not pure 
LTCCs, since N- and P/Q-calcium channels are present in hippocampal neurons, and 
verapamil can also inhibit N- and P/Q-type calcium currents (Dobrev et al., 1999). 
Nevertheless, the fact that overexpression of HCN2(-N) mutant in HNs induced a 
significant slowing of inactivation supports the hypothesis that dynamic interaction 
between α1C and HCN2 exists in the native tissue.  
Unusual features of α1C/HCN2 and α1C/HCN2/α2δ channel inactivation 
Dissecting VDI and CDI often has been carried out by using Ba2+ and Ca2+, respectively 
(Kim et al., 2004; Peterson et al., 1999; Xia et al., 1998; Zuhlke et al., 1998), yielding 
intriguing results. Not only is CDI about 6–10 times faster than VDI (Kim et al., 2004; 
Liang et al., 2003), but CDI also can come back to the closed state whereas VDI cannot. 
The CDI index, measured by the residual fraction of the currents that remains at the end 
of the test pulse, is much smaller for Ca2+ than for Ba2+ (Erickson et al., 2003; Kim et al., 
2004; Peterson et al., 1999; Zuhlke et al., 1998). Interestingly, the speed of VDI can be 
increased to that of CDI if the IQ motif is deleted (Zuhlke et al., 1998). Furthermore, a 
single mutation of I to A or E in the IQ motif could eliminate the difference in CDI index 
for Ca2+ and Ba2+ (Zuhlke et al., 1999). Recently, using a fluorescence resonance energy 
transfer (FRET) two-hybrid mapping technique, preassociation of apoCaM and a 73-




(Erickson et al., 2003). Disruption of this preassociation significantly accelerated the VDI 
and removed the difference between CDI and VDI (Erickson et al., 2003).  
Both α1C/HCN2 and α1C/HCN2/α2δ channels have exhibited VDI rates that are faster 
than that reported following the disruption of preassociation of IQ motif and apoCaM 
(Erickson et al., 2003). Our data suggest that HCN2, via its NH2 terminus, can interrupt 
the preassociation of apoCaM with the IQ motif of α1C and that this may contribute to the 
accelerated VDI inactivation. The requirement of CaM for α1C/HCN2 inactivation in the 
absence of α2δ subunit is supported by the facts that inhibiting CaM activity using either 
pharmacological inhibitors or overexpression of CaM(1,2,3,4) all eliminated the inactivation 
of α1C/HCN2 (Fig 3, A and B). On the other hand, α1C/HCN2/α2δ channel inactivation 
is largely independent of CaM (Fig 3, C and D). One possible scenario for this difference 
may be that the conformational change of CaM resulted from the interaction between the 
IQ motif and HCN2 is different from that resulted from the interaction between the IQ 
motif and HCN2/α2δ. The interaction between the IQ motif and HCN2 may lead CaM to 
undergo a conformational change that exposes its hydrophobic activation site to the CaM 
blockers, whereas the interaction between the IQ motif and HCN2/α2δ may induce a 
different CaM conformational change that does not make its blockers accessible to the 
activation site. This possibility would explain the fast VDI of α1C/HCN2/α2δ channel 
(solid lines in Fig 3, C and D), the insensitivity of W-7 and TFP to the α1C/HCN2/α2δ 
currents (Fig 3C), and the lack of a difference between CDI and VDI for the 





Potential implications of α1C and HCN2 interaction 
In this study, although we have presented evidence demonstrating the interaction of α1C-
subunit (Cav1.2) with HCN2, interactions of this type might also occur in other types of 
Ca2+ channels that undergo CDI, such as Cav2 channels, as a common mechanism. Use of 
CaM as the key element for Ca2+ channel inactivation has been reported for Cav1 and 
Cav2 channels (Liang et al., 2003).  
Increased Ca2+ influx is associated with a number of neuronal disorders, including 
neuropathic pain (Altier et al., 2004). Gabapentin, a GABA analog, is an antiepileptic 
drug that has been used recently to relieve neuropathic pain and is believed to bind the 
α2δ1-subunit, leading to decreased Ca2+ influx (Altier et al., 2004; Hendrich et al., 2008). 
The mechanism of how gabapentin binding of α2δ1-subunit decreased Ca2+ influx 
remains elusive, since the gabapentin action is acute (Altier et al., 2004). The α2δ-
subunits have been known to enhance the surface expression of α1C and Ca2+ current 
amplitude (Felix et al., 1997; Yasuda et al., 2004). A recent study demonstrated that 
chronic treatment with gabapentin was associated with a reduction in the surface 
expression of α2δ2 and Cav2.1 subunits (Hendrich et al., 2008). On the other hand, the 
α2δ-subunits also promote inactivation of Cav1.2 (α1C) or Cav2.2 (N-type) (Yasuda et 
al., 2004), and inhibition of the α2δ subunit should, in principle, slow the α1C 
inactivation, resulting in an increased Ca2+ influx. The interaction of α1C with HCN2 may 
provide an alternative mechanism to prevent an increase in Ca2+ influx under the 






Although we report for the first time a novel and potentially important mechanism for 
modulation of Ca2+ current inactivation by HCN2 channel, there are many unanswered 
questions. For instance, we noticed that the activation of ICaL also seems to be altered by 
HCN2 (e.g., Fig. 1F). In addition, whether HCN2 may also modulate other Ca2+ channels 
that share similar inactivation machinery to α1C is unknown. More importantly, under 
various physiological and especially pathological conditions, the importance of 
interaction between HCN2 and LTCC requires further investigation, since the expression 















Chapter 4  
Trafficking mechanism of HCN4 and its mutant and the novel 
role of HCN2 in modulation of Ca2+ influx 
This chapter contains two parts showing unpublished work. Part 1 aims to understand the 
trafficking mechanisms of HCN4 as well as how tyrosine phosphorylation may help 
rescue the defective membrane trafficking of HCN4 mutants identified in patients. Part II 


















Part I: Trafficking mechanisms of HCN4 and its mutants 





D553N is a missense mutation in the C-linker of HCN4 channel protein. It was found in a 
patient with severe cardiac arrhythmias including long QT syndrome, ventricular 
tachycardia polymorphisms, and bradycardia induced by sinus node dysfunction. 
Although it has been implicated that the cardiac arrhythmia caused by this mutant was 
due to its trafficking defect, no analysis reveals the underlying mechanism in the 
subcellular level. Here, we demonstrated that the trafficking defective mutant HCN4 
D553N is restricted in the endoplasmic reticulum (ER) and perinuclear region. Two days 
after transfection D553N with the ER maker KKXX in the HEK293 cells, colocalization 
of these two proteins could be observed. Further, we employed the membrane surface dye 
FMI34 to show that D553N cannot colocalize with the membrane dye FMI34. On the 
contrary, wild type HCN4 channels colocalized with the dye FMI34 on the cell 
membrane which serves as the control for the comparison. In conclusion, our data further 
demonstrate the subcellular mechanism that the D553N mutant is retained in the ER, 











HCN4 channels play an important role in the regulation of pacemaker activity of 
sinoatrial nodes. They are responsible for making the “U” turn of maximal diastolic 
potential (phase 4) for the next cycle of the action potential in sinoatrial nodes. Previous 
studies have revealed that the abnormality of HCN4 channels in patients is the cause for 
cardiac arrhythmias such as long QT syndromes, cardiac tachycardia, and sinoatrial 
nodes dysfunction. So far, several HCN4 mutants have been found in patients that are 
correlated with cardiac arrhythmias (Milanesi et al., 2006; Schulze et al., 2003; Ueda et 
al., 2004). Recently, a patient with the severe cardiac arrhythmias was indicated as HCN4 
D553N mutant. The electrocardiogram (ECG) also revealed the relative flat “P” wave 
accompany with long QT interval (0.64s versus 0.44s for the normal people) followed by 
ventricular tachycardia polymorphisms (Ueda et al., 2004). When the cellular 
mechanisms were further analyzed, they found that this mutant was the dominant 
negative mutant, which will dominate the phenotype when coexisting with the wild type 
HCN4 channels.  
 
By using the electrophysiology and imaging, their results indicated that the membrane 
expression or current expression can nearly be eliminated or significantly reduced after 
transfection of D553N alone or cotransfection of D553N with wild type HCN4 in COS7 
cells (Ueda et al., 2004).  The results strongly indicated that the underlying mechanism 
contributing to loss-of function of D553N mutant is due to defective membrane 
trafficking. However, what is the subcellular level that this mutant could be trapped 




to investigate the possible colocalization between D553N mutant and this marker using 
the live-cell confocal imaging. Interestingly, we found that the D553N mutant can 
colocalize with KKXX whereas it cannot colocalize with a membrane dye FM1-34 which 
is exclusively expressed on the cell membrane. The control experiment also revealed the 
colocalization between FM1-34 and wild type HCN4 channels. Overall, our data 
uncovered the subcellular localization of HCN4 mutant D553N, which may provide the 
































In Fig 1, we co-transfect the D553N mutant carried with DsRed with ER marker KKXX 
carried with GFP into HEK293 cells. Two days after, the result showed that D553N 
mutant with DsRed clustered in the centric region of HEK293 cells in which the 
colocalization with the ER marker KKXX carried with GFP can be observed under the 
confocal microscope. As ER is distributed around the nucleus, the localization of D553N 
represented as red can also be observed to surround the region nearby the nucleus and is 
matched to the KKXX represented as green.  
 
However, the D553N cannot colocalize with the membrane dye FM1-43 (Audrey et al., 
2004) which distributes well on the cell membrane as indicated in Fig 2.  
 
Fig 3 is the positive control showing that the wild type HCN4 distributes on the cell 
membrane in which the colocalization can be detected under the microscope. This result 
indicated that the D553N mutant is trapped in the ER and fails to localize in the cell 












Fig 1. Colocalization between D553N mutant and the ER marker KKXX. 
Left up panel shows the D553N carried with DsRed as indicated in the red color. Right 
up panel represents the expression of the fusion protein KKXX carried with GFP as 
indicated in green color. Right down panel reveals the colocalization between D553N and 
KKXX after merge the previous two panels, which indicates as yellow color. Left down 















Fig 2. Non-colocalization of wild type HCN4 channels and the ER marker KKXX. 
Left up panel shows the subcellular distribution of wild type HCN4 channels, which 
express throughout the plasma membrane of HEK 293 cells as indicated in red color. 
Right up panel reveals the expression of KKXX as indicated in green color. Right down 
panel represents the merged result of the previous two panels. There is no colocalization 
between the wild type HCN4 channels and the KKXX. Left down panel shows the bright 













Fig 3. Colocalization between wild type HCN4 channels and the membrane dye 
FM1-43. Left up panel shows the membrane dye FM1-43 as indicated in the green color. 
Left down panel represents the distribution of wild type HCN4 channels carried with 
DsRed as indicated in red color. Right down panel indicates the merged result of the 
previous two panels and shows the colocalization between the wild type HCN4 channels 
and FM1-43 as indicated in yellow color. Right up panel shows the whole HEK293 cell 














Our results indicated that the impairment of the membrane expression of single mutation 
D553N is resulted from trapping in the ER in the process of the trafficking (Fig1-3). 
These results are consistent with previous reports and may explain why this mutant 
expresses little current when studied with whole-cell patch clamp.  
 
This membrane trafficking defective D553N mutant has been proposed to cause cardiac 
arrhythmias such as long QT syndromes accompany with the dysfunction of sinoatrial 
node (Ueda et al., 2004). As D553N is a single amino acid mutation of HCN4 channels 
from Asp to Asn, which removes the negative charge, it may thus cause the abnormal 
folding of the channel protein in the protein synthesis. The disruption of the negative 
charge may alter the interaction among amino acid residues and results in conformation 
change of this mutant. Interestingly, ER is a key subcellular organelle for quality control 
of the channel proteins (Ibba et al., 1999; Wickner et al., 1999). The abnormal folding of 
D553N mutant may retain the channel in ER, which is subsequently through endosomal-
lysosomal pathway for degradation (Cole et al., 1992; Koh et al., 2005). This may 
provide us the possible explanation for our results showing the subcellular localization of 
D553N mutant in ER.  
 
KKXX is the double mutant fusion protein that retains in the ER and serves as an ER 
marker. We take this advantage and transfect D553N mutant with this marker fusion 
protein KKXX to study whether they colocalize in the ER in order to elucidate the 




D553N mutant is attributed to the trapping in the ER and this may make us understand 


































Part II: Association between HCN2 and L-type calcium 





Calcium influx via L-type calcium channels (LTCCs) plays the critical role in the 
regulation of intracellular calcium homeostasis. Inactivation of LTCCs is one of the most 
important mechanisms to modulate calcium influx and prevents the calcium overload 
induced diseases such as cardiac arrhythmias. Thus, how to delicately regulate the 
inactivation of LTCCs is directly linked to the intracellular calcium amount and the 
calcium-based diseases prevention. In the previous studies, using electrophysiology and 
immunoprecipitation, we have demonstrated that the association between the pore 
forming subunit α1C of L-type calcium channels (LTCCs) and HCN2 channels can 
induce the fast inactivation of LTCCs to restrict the calcium influx.  
 
Here, we employed another technique (FRAP) to investigate the dynamic association 
between α1C and HCN2 channels in HEK293 cells. Consistently, the results indicated 
that the half life (t1/2) of fluorescent recovery was significantly slower in the HEK293 
cells co-transfected with α1C-GFP and HCN2 (t1/2=14.04±3.51(s)) than those of N-
terminal deletion of HCN2 with α1C-GFP (t1/2=7.83±2.15(s)) or wild type HCN2-GFP 
with IQ motif deletion of α1C (t1/2=1.12±0.09(s)). The cells co-transfected with α1C and 
HCN2-GFP also reveals the relatively slower half life (t1/2 =10±1.23(s)). Our studies 
strongly demonstrate that HCN2 channels are capable of cross-talking with LTCCs at the 




of α1C in a dynamic manner. These results may provide us supporting evidence of how 



























Inactivation of L-type calcium channels (LTCCs) plays a pivotal role to delicately 
regulate calcium influx in cardiomyocytes, which is closely linked to cardiac 
contractility, and if abnormal, leads to calcium-based diseases such as cardiac 
arrhythmias. The underlying cellular mechanism of inactivation of LTCCs has been 
wildly studied. It is generally believed that the interaction among the IQ motif on the C-
terminal of α1C (the pore region of LTCCs), calmodulin (CaM), and I-II loop near the 
pore region is involved in the regulation of inactivation of LTCCs. Based on the different 
mechanisms, the inactivation of LTCCs can be divided into calcium-dependent fast 
inactivation (CDI) (using Ca2+ as the charge carrier) as well as the voltage-dependent 
slow inactivation (VDI) (using Ba2+ as the charge carrier). The CDI is dependent on the 
influx of calcium ions which can interact with CaM, IQ motif, and I-II loop and induce 
the fast inactivation by closing the pore region of LTCCs. On the other hand, VDI is not 
calcium dependent (Cens et al., 2006; Kim et al., 2004; Pitt et al., 2001); it is only 
responsible for the voltage change on the cell membrane in which the slow inactivation 
will be induced by the conformation change of the CaM, IQ motif, and I-II loop.  
 
Our previous studies have indicated that the inactivation of LTCCs can be fast induced by 
another ion channel, HCN2, on the cell membrane approached by electrophysiology in 
the HEK293 cells co-transfected HCN2 channels with the pore subunit α1C and the 
different recombinant accessory β subunits of LTCCs (Lin et al., 2010). 
Electrophysiology and immunoprecipitation results further indicated that the underlying 




subunit of LTCCs. In this study, using FRAP to examine the mobility of the wild type 
HCN2 or α1C subunit and its mutants tagged with GFP in HEK293 cells, we further 


























In order to investigate whether α1C and HCN2 channels associate with each other, we 
use the FRAP technique to examine the half-time (t1/2) in the HEK293 cells expressing 
the different recombinant proteins such as α1C-GFP and HCN2, α1C and HCN2-GFP, N-
terminal deletion of HCN2 and α1C-GFP, as well as wild type HCN2-GFP and IQ motif 
deletion of α1C.  
 
During the FRAP experiment, photobleaching with high energy light creates a dark and 
bleached region within the sample, named region of interest (ROI), which is indicated by 
the arrow in Fig 1. The neighboring molecules, in this case the GFP-labeled proteins, 
subsequently diffuse into the ROI and replace the bleached molecules to reach a steady 
state. How fast this steady state is achieved is measured by the half-time (t1/2), which is 
correlated with how heavy the GFP-labeled proteins are. For example, if the protein is 
associated with another protein as a complex, the molecular weight is heavier than the 
protein by itself; therefore the diffusion rate is slower, resulting in a longer t1/2. The 
calculation of t1/2 is shown in Fig 1.  
 
Fig 2 indicated that the half-time (t1/2) of α1C-GFP and HCN2 reveals as 14.04±3.51(s) 
(n=3) after subtracting the background and analyzing by the software Igor. When 
comparing with N-terminal deletion of HCN2 with α1C-GFP (indicated as Fig 3) or wild 
type HCN2-GFP with IQ motif deletion of α1C (indicated as Fig 4), the half-time is 
significantly slower in cells co-transfected α1C-GFP with HCN2 (t1/2=7.83±2.15(s) < 




half-time of the cells co-transfected α1C with HCN2-GFP indicated in Fig5 is equal to 
10±1.23(s) (n=3), which is still slower than those of mutants. 
 
These results indicated the dynamic association of HCN2 between α1C possibly through 



















Fi F(t) = (F∞ - Fo) (1 – e-kx)
t1/2 = ln2/k
Mf = (F∞ - Fo)/(Fi – Fo)
Recovery half-time (t1/2) is calculated based on:
 
Fig 1. Fluorescence recovery after photobleaching (FRAP).  
Red arrows indicate region of interest (ROI) generated by photobleaching. The bleached 
molecules in ROI are gradually replaced by adjacent molecules (GFP-labeled proteins) 
and reach the steady state. The half-time t1/2 represents the time required for the bleach 





Fig 2. Half-time (t1/2) of HEK293 cells co-transfected α1C-GFP with HCN2.  
The recovery half-time (t1/2) of α1C-GFP and HCN2 reveals as 14.04±3.51(s) after 
subtracting the background and analyzing by the software LM510 and Igor (n=3). Figure 
2 indicated the representative figure in HEK293 cells co-transfected HCN2 with α1C 













Fig 3. Half-time (t1/2) of HEK293 cells co-transfected N-terminal deletion HCN2 
with α1C-GFP. The recovery half-time is revealed as 7.83±2.15(s) after analysis by the 
software LSM510 and Igor (n=3). Figure 3 indicated the representative figure in HEK293 














Fig 4. Half-time (t1/2) of HEK293 cells co-transfected wild type HCN2-GFP with IQ 
motif deletion of α1C. The recovery half-time is revealed as 1.12±0.09(s) after analysis 
by the software LSM510 and Igor (n=3). Figure 4 indicated the representative figure in 













Fig 5. Half-time (t1/2) of HEK293 cells co-transfected α1C with HCN2-GFP. The 
recovery half-time is revealed as 10±1.23(s) after analysis by the software LSM510 and 
Igor (n=3). Figure 5 indicated the representative figure in HEK293 cells co-transfected 


















FRAP is an optical technique that can be used to quantify two dimensionally molecular 
diffusion. The photobleaching of ROI allows adjacent molecules diffuse toward ROI in 
which the dynamic protein-protein interaction can be quantified by this approach. In the 
previous study, we have demonstrated that association between N-terminus of HCN2 and 
C-terminus of LTCC (Lin et al., 2010). In order to further confirm this association in a 
dynamic manner, we employed FRAP here to test the half-time of fluorescence recovery 
in HEK293 cells transfected with different recombinant proteins. If one protein is 
associated with another protein as a complex, the diffusion rate of the protein complex is 
slower than the protein by itself due to increase of the molecular weight. Our results 
revealed that the half-time in HEK293 cells co-expressed with the mutant (either N-
terminal mutant of HCN2 or C-terminal mutant of LTCC) is significantly faster than that 
of the wild type, indicating N-terminus of HCN2 and C-terminus of LTCC are key 
contributors for the association between LTCC and HCN2.      
 
It is worth to notice here that although the half-time of cells cotransfected α1C with 
HCN2-GFP indicated in Fig 5 revealed faster a little bit when compared with α1C-GFP 
and HCN2 (Fig 2) (t1/2=10±1.23(s) < t1/2=14.04±3.51(s), n=3), the value is significantly 
slower than those of the mutants. This may be due to the larger molecular weight of α1C 
(~150KD) than HCN2 (~100KD) (Huang et al., 2008; Lin et al., 2010). Our results 
strongly demonstrated that HCN2 associate with α1C via the N-terminus of HCN2 and 
IQ motif of α1C, indicating the crosstalk between these two channels on the cell 






Up till now, several approaches have been developed to establish animal models for the 
study of arrhythmias. These include: (1) Aorta bandage to induce ischemic condition 
(Billman et al., 2005), (2) Installation of pacemakers to induce heart failure (Timek et al., 
2003), and (3) Genetic ablation (Benkusky et al., 2007). Although widely used in many 
different studies, these model systems are all associated with structural remodeling, 
which results in ectopic automaticity or reentrant excitation and therefore induces cardiac 
arrhythmias.     
 
However, structural remodeling is not the only mechanism for arrhythmias. It is known 
that SCD can also occur acutely (in several seconds) without structural remodeling 
(MacAlpin, 1993; Zipes et al., 1998), indicating that short-term dysregulation can also be 
an important arrhythmogenic mechanism. Therefore, it is of great value to establish an 
animal arrhythmic model for in the absence of structural remodeling. In Chapter 1, we 
successfully established a new rat arrhythmia model without structural remodeling, 
enabling research on mechanisms leading to short-term cardiac dysfunction.    
 
Alteration of cardiac rhythm by tyrosine phosphorylation  
 
In this study, we found that increasing tyrosine phosphorylation by applying tyrosine 
phosphatase inhibitor, sodium orthovanadate, led to different types of ventricular 
arrhythmias. Furthermore, reducing tyrosine phosphorylation by Src kinase inhibitor, 
PP2, significantly decreased heart rate as well as HRV. These results let us conclude that 




system delicately modulate the rhythm of the heart via balancing with each other in the 
physiological condition: Src-mediated tyrosine phosphorylation is dominant in atria 
whereas phosphatase-mediated tyrosine dephosphorylation is dominant in ventricles. 
That may explain why PP2 can reduce heart rate at a low dose (0.2 mg/kg) and induce 
AV block at a higher dose administration (0.3 mg/kg); whereas sodium orthovanadate 
can induce different types of ventricular arrhythmias at different doses (3.8 mg/kg and 
5.5 mg/kg). 
 
Although our main purpose of using PP2 is to decrease tyrosine phosphorylation (we 
have PP3 as the negative control), we cannot exclude the possibility that PP2 may 
directly affect other signal pathways, such as the pathways mediated by phosphatidyl 
inositol 3′-kinase (PI3K) and p38 mitogen-activated protein kinase (MAPK), the 
downstream of epidermal growth factor (EGF) receptor-mediated pathways (Kumar et 
al., 2003). Whether these kinases may also involve in the regulation of cardiac rhythm 
need further investigated.   
 
The observed changes of cardiac rhythm and HRV by reducing tyrosine phosphorylation 
after administration of PP2 could be a result of 1) altered activity of autonomic nervous 
system (ANS), and/or 2) altered sensitivity of sinus node responding to ANS. Previous 
studies have demonstrated that Src family tyrosine kinases are associated with β 
adrenergic receptors and regulate the internalization of these receptors (Huang et al., 
2004). It is possible that Src kinases mediate G protein activation and alter the 
intracellular cAMP level leading to downstream signaling events. Therefore, inhibition of 




reducing ANS activity may not be the only explanation. The other possibility could be 
due to a reduced sensitivity of SA node to the ANS involving the alteration of ion 
channel activities. Previous studies showed that EGF increases heart rate and channel 
currents through tyrosine phosphorylation in the isolated heart system (Nair et al., 1993). 
Since HCN4 channels express dominantly in the sinus node contributing to the “U” turn 
in the phase 4 of sinus node action potential, one possible scenario is that HCN channel 
activities can be altered by tyrosine phosphorylation, thus mediating the change observed 
in the heart rate and HRV.  
 
Modulation of HCN channel activities by tyrosine phosphorylation 
 
To elucidate the possibility that the change of cardiac rhythm by tyrosine phosphorylation 
is due to the alteration of HCN channel activities, in chapter 2, we employed HEK293 
cells co-expressing HCN channel proteins and other regulators. The advantage of using 
HEK293 cells is because this is a well-established expressing system without endogenous 
channel proteins, providing a clean platform to study channel proteins of our interest. 
Using this in vitro system combined with techniques of electrophysiology and confocal 
imaging, we were able to dissect the mechanism of phosphorylation-dependent regulation 
of heart rate and HRV.  
 
Our results indicated that the increase of Src-mediated tyrosine phosphorylation 
dramatically enhanced surface expression and gating properties of HCN channels; 
conversely, RPTPα, a tyrosine phosphatase, led to the decrease of surface expression and 
gating properties of channels by reducing tyrosine phosphorylation. In accordance with 




myocytes also revealed that increased tyrosine phosphorylation by sodium orthovanadate 
(a tyrosine phosphatase inhibitor) could enhance the current amplitude and gating 
properties of HCN channels (decrease the activation threshold from -135 mv to -90 mv) 
in comparison with that in the absence of sodium orthovanadate (Huang et al., 2008). 
These data suggest that changed sensitivity of SA node to the ANS could indeed be a key 
contributor to the changed heart rate/ HRV when the phosphorylation level is altered. 
 
Since HCN4 channels are dominantly expressed on atria whereas HCN2 channels on 
ventricles, altered activities of HCN channels increase the risk of ectopic automaticity by 
changing the slope in the phase 4 of atrial or ventricular action potential. If the 
automaticity of sinus node (primary pacemaker) is replaced by other regions of atriums or 
ventricles, atrial or ventricular arrhythmias could occur. This may explain why different 
types of ventricular arrhythmias can be induced as a response to the increased tyrosine 
phosphorylation by sodium orthovanadate.  
 
On the other hand, reduced tyrosine phosphorylation state by PP2 may associate 
reduction of HCN4 channel activities and thus decrease the cardiac rhythm. However, 
there are still some questions that are not entirely understood, such as: 1) why Src kinases 
differentially modulate atrial activities whereas phosphatases dominantly regulate 
ventricular activities; 2) whether HCN4 channels can be downregulated on atrium by 
reduced tyrosine phosphorylation after administration of PP2; 3) whether HCN2 channels 
can be upregulated by increased tyrosine phosphorylation followed by application of 





Under pathological conditions, we also demonstrated that enhancement of tyrosine 
phosphorylation by three Src kinases, Src, Fyn, and Yes, can rescue the membrane 
trafficking defect mutant HCN4 D553N that has been found in a patient with long QT 
symptom followed by polymorphic ventricular tachycardia. By employing 
electrophysiology and confocal imaging, we found that not only membrane surface 
expression but gating properties and kinetics of this mutant can also be rescued after 
cotransfection of these three Src kinases. One possible explanation is that this single 
amino acid mutant (from D to N) causes the loss of negative charges at the residue 553, 
which leads to conformation change (misfolding) and therefore interfering with 
trafficking and/or localizing to the surface membrane. These three Src kinases can 
provide phosphate, which is negatively charged, to tyrosine residues of this mutant and 
possibly prevent misfolding. Furthermore, our results also demonstrated that the 
subcellular location of HCN4 D553N mutant was at endoplasmic reticulum (ER), 
confirming that this mutant has membrane trafficking defect (Ueda et al., 2004).  
 
Our biochemical results also showed that these three Src kinases have different tyrosine 
phosphorylation effects on the D553N mutant: Fyn has the highest whereas Yes has the 
lowest (Lin et al., 2009). It may explain why these three Src kinases have differential 
results: Yes and Src can rescue the surface expression whereas Fyn can accelerate the 
kinetics of this mutant. Nevertheless, the exact relationships among tyrosine 
phosphorylation, surface expression, and kinetics of the channel protein are not 
understood completely.  Therefore, further studies are also needed in cardiac myocytes.            





Calcium influx limitation of LTCC by HCN2   
 
We have also found a novel role of HCN2 in the regulation of LTCC inactivation. LTCCs 
contribute to the plateau phase of action potentials and delicately regulate the calcium 
influx. Since calcium homeostasis is pivotal for the maintenance of normal cardiac 
function, abnormal calcium handling can be directly linked to cardiac arrhythmias. 
Excessive calcium influx is known to lead to long QT interval and induce DAD-related 
tachyarrhythmias ((Burashnikov et al., 2003; Nattel et al., 1988; Satoh et al., 1998). 
EADs can also be induced if plateau potentials become abnormally prolonged (Chen et 
al., 2001; Coutu et al., 2006; Stambler et al., 2003). 
 
 In chapter 3, we found a new mechanism to restrict calcium influx via facilitation of 
inactivation of LTCCs. By electrophysiology after the cotransfection of α1C (core 
subunit of LTCC) with HCN2 in HEK 293 cells, we concluded that HCN2 can induce 
faster inactivation of LTCCs when compared with the control. In order to investigate 
whether CaM is involved in this regulation, we used two structurally different CaM 
inhibitors, W-7 and TFP. Surprisingly, either W-7 or TFP can totally eliminate this fast 
inactivation of LTCCs triggered by HCN2. Similar results were also observed when we 
employed a CaM dominant negative mutant, CaM(1,2,3,4). These data demonstrated that 
CaM is necessary in this HCN2-triggered fast inactivation, which is consistent with 
previous studies where CaM played the critical roles in the regulation of both VDI and 
CDI of LTCCs (Cens et al., 2006; Erickson et al., 2003; Kim et al., 2004; Pitt et al., 
2001). The inhibitory time period of these two drugs is also comparable to that of 




α2δ subunit, the role of CaM is compromised since neither W-7 nor TFP affected this fast 
inactivation regulated by HCN2 any more, indicating the potential role of α2δ in this 
regulation. One possibility is that the negative charges in the N-terminus of HCN2 may 
associate with the positive charges in the C-terminus of α2δ and interfere with its 
interaction with CaM. Besides, previous studies also revealed that α2δ is pivotal to 
regulate the surface expression and gating properties of LTCCs (Arikkath et al., 2003; 
Felix et al., 1997; Yasuda et al., 2004), which is consistent with the reported finding here.  
In order to test the hypothesis that the fast inactivation of LTCCs initiated by HCN2 may 
depend on the interaction between N-terminus of HCN2 and IQ motif of α1C, we 
employed two mutants: N-terminal deleted HCN2 and IQ motif deleted α1C. Our results 
indicate that either of these two mutants could abolish or slow down this fast inactivation 
regulated by HCN2, suggesting that N-terminus of HCN2 and IQ motif of α1C are two 
key domains responsible for this regulation. Consistently, our results in FRAP further 
demonstrated the dynamic association between these two key domains, confirming the 




In chapter 1 and chapter 2, the in vivo and in vitro results from my thesis work strongly 
indicated that tyrosine phosphorylation played a crucial role in the regulation of heart rate 
and cardiac arrhythmogenesis possibly through modulation of HCN channels. In chapter 
3, we have demonstrated that the inactivation of LTCC, facilitated by HCN2 through the 




scientific basis for potential therapeutic strategy for the treatment of cardiac arrhythmias 
(such as long QT syndrome) caused by excessive calcium homeostasis.     
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ROLES OF Src, Fyn, AND Yes TYROSINE KINASES*□S
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Therapeutic strategies such as using channel blockers and
reducing culture temperature have been used to rescue some long
QT-associated voltage-gated potassium Kv trafficking defective
mutant channels. Ahyperpolarization-activated cyclic nucleotide-
gated HCN4 pacemaker channel mutant (D553N) has been
recently found in a patient associated with cardiac arrhythmias
including long QT. D553N showed the defective trafficking to the
cell surface, leading to little ionic current expression (loss-of-func-
tion).We show in this report that enhanced tyrosine phosphoryla-
tion mediated by Src, Fyn, and Yes kinases was able to restore the
surface expression ofD553N for normal current expression. Src or
Yes, but not Fyn, significantly increased the current density and
surface expression ofD553N. Fyn accelerated the activation kinet-
ics of the rescuedD553N.Co-expressionofD553NwithYes exhib-
ited the slowest activation kinetics of D553N. Src, Fyn, and Yes
significantly enhanced the tyrosine phosphorylation of D553N. A
combination of Src, Fyn, and Yes rescued the current expression
and the gating of D553N comparable with those of wild-type
HCN4. In conclusion, we demonstrate a novel mechanism using
three endogenous Src kinases to rescue a trafficking defective
HCN4 mutant channel (D553N) by enhancing the tyrosine phos-
phorylation of themutant channel protein.
Defective trafficking leading to the reduced surface expres-
sion of ion channels is one of the mechanisms responsible for a
loss-of-function of the ion channel on the plasma membrane
(1). Severalmethods have been developed to rescue the voltage-
gated potassiumKv trafficking defective channels: reducing the
culture temperature, applying the channel blockers, altering
the molar ratio of glycerol, and using the sarcoplasmic/endo-
plasmic reticulum Ca2-ATPase inhibitor thapsigargin (2–6).
Hyperpolarizing-activated cyclic nucleotide-gated (HCN)3
pacemaker channels generate time- and voltage-dependent
inward currents, named Ih in neurons or If in the heart (7). They
are important in various cell functions including excitability,
synapse transmission, and rhythmic activity (7). The most well
studied regulation of If is its response to autonomic stimulation.
-Adrenergic receptor activation increases and acetylcholine
receptor activation decreases the intracellular cAMP levels,
which in turn increases/decreases If by binding to the cyclic
nucleotide-binding domain of the HCN channels, respectively
(7). Other important mechanisms for the modulation of
If/HCN channels have recently been found including-subunit
(8), lipids (9, 10), and p38 mitogen-activated protein kinase
(11).
Accumulating evidence has revealed tyrosine phosphoryla-
tion as an important mechanism for modulation of HCN chan-
nel properties (12–16). An acute increase in tyrosine phospho-
rylation of If or HCN channels increases the channel activity,
including an increase in the current amplitude, a positive shift
of the voltage-dependent activation, an acceleration of activa-
tion kinetics, and an increase in whole cell conductance (12–
15). Recently, we discovered that the cell surface expression of
HCN2 channels can be remarkably inhibited by tyrosine
dephosphorylation mediated by receptor-like protein tyrosine
phosphatase  (RPTP) and increased by tyrosine phosphoryl-
ation via Src kinase after long term treatment (17).
D553N, a missense HCN4mutant, was recently identified in
a patient with cardiac arrhythmia associated with depressed
HCN gating properties (18). Functional and structural assays
revealed that D553N expresses little ionic currents, which is
possibly due to the defective channel trafficking so that the
channels cannot reach the plasma membrane for normal func-
tions (18).
The Src kinase family has nine members (19). They are
closely related and share the same regulatory function. Three of
them, Src, Fyn, and Yes, are ubiquitously expressed in a variety
of tissues including neurons and myocytes (19, 20). Without
stimulation, they are inactive. However, mutation of key tyro-
sine residue results in the constitutively active form of the
kinase, SrcY529F, FynY531F, and YesY537F, respectively (15,
21, 22). Using these Src kinases, we show in this report a novel
approach that can restore the surface expression of D553N for
normal current expression via tyrosine phosphorylation.
EXPERIMENTAL PROCEDURES
cDNA Plasmids—The human version of HCN4-pcDNA1.1
was kindly provided by Dr. U. B. Kaupp and subcloned into
pcDNA3.1 vector. HCN4-D553N-pcDNA3 was made by sub-
* This work was supported, in whole or in part, by National Institutes of Health
Grant HL075023. This work was also supported by the Office of Research
and Graduate Programs/Health Sciences Center at West Virginia University
(to H.-G. Y.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1 and S2.
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3 The abbreviations used are: HCN, hyperpolarizing-activated cyclic nucleoti-
de-gated; RPTP, receptor-like protein tyrosine phosphatase; PBS, phos-
phate-buffered saline.
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stituting aspartic acid with asparagine using PCR. HCN4-
D553N-DsRedwasmade by subcloningHCN4-D553N into the
DsRed vector. RPTP was a generous gift from Dr. Jan Sap
(University of Copenhagen, Copenhagen, Denmark). The con-
stitutively active form of Fyn, FynY531F, in pcDNA3.1 vector,
was kindly provided by Dr. Shigeru Kanda (Nagasaki Univer-
sity, Nagasaki, Japan). The constitutively active form of Yes
(YesY537F) was kindly provided by Dr. Arkadiusz Welman
(Edinburgh Cancer Research Center), and we subcloned it into
the pcDNA3.1 vector. Src529 (SrcY529F) was purchased from
Upstate Biotechnology (Millipore). For simplicity, we also use
Src, Fyn, andYes and Src529, Fyn531, andYes537 in the text for
interchangeable use with the constitutively active form of each
kinase: SrcY529F, FynY531F, and YesY537F.
Cell Culture and Plasmids Transfection—HEK293 cells were
grown in Dulbecco’s modified Eagle’s medium (Invitrogen),
supplemented with 10% fetal bovine serum, 100 IU/ml penicil-
lin, and 100 g/liter streptomycin. Cells with 50–70% confluence
in 6-well plates were used for plasmid transfection using Lipo-
fectamine2000 (Invitrogen).
Cell Lysis, Immunoprecipitation, and Western Blot Analysis—
Total protein extracts were prepared from cells transfected for
24–48 h usingCelLytic cell lysis reagent (Sigma) supplemented
with protease inhibitors. For membrane fraction preparations,
we used a membrane protein extraction kit (Pierce). The pro-
tein concentration of the lysate was determined using the Brad-
ford or BCA assay. Equal amounts of total protein (0.5–1 mg)
were incubated with a specific antibody for 1 h at 4 °C, and
protein A/G Plus-agarose (Santa Cruz) was then added and
incubated overnight with gentle rocking. The beads were
washed three times with cold PBS buffer and resuspended in
2 sample buffer. The immune complexes were separated by
SDS-PAGE and analyzed by Western blot using the specific
antibody of interest. Total protein of 5–20 g/sample was sub-
jected to SDS-PAGE using 4–12% gradient gels (Invitrogen)
and then transferred to nitrocellulose membranes (Amersham
Biosciences) and incubatedwith proper antibodies. After wash-
ing and incubating with horseradish peroxidase-conjugated
secondary antibody, immunoreactive proteins were visualized
with the SuperSignal West Pico kit (Pierce).
Cell Surface Biotinylation—Cell surface biotinylation ex-
periments were performed by following the manufacturer’s
instruction (Pierce). Briefly, HEK293 cells transfected with
desired plasmidswere first treatedwith EZ-link Sulfo-NHS-SS-
Biotin to label cell surface proteins. The cells were subsequently
lysed with lysis buffer containing protease inhibitor mixture
(Sigma). The labeled proteins were then isolated with immobi-
lized NeutrAvidin-agarose. After washing three times, the
bound proteins were released by incubating with SDS-PAGE
sample buffer containing 50 mM dithiothreitol and then ana-
lyzed byWestern blotting. All of the protein experiments were
repeated at least three times.
Whole Cell Patch Clamp Recordings—For recording IHCN4,
day 1 (24–30 h) up to day 4 (90–98 h) post-transfection
HEK293 cells with green fluorescence were selected for patch
clamp studies. TheHEK293 cells were placed in a Lucite bath in
which the temperature was maintained at 25  1 °C by a tem-
perature controller (Cell MicroControls). IHCN4 currents were
recorded using the whole cell patch clamp technique with an
Axopatch-200B amplifier. The current amplitude of HCN4 or
D553N current is defined as the amplitude of the onset time-
dependent inward current elicited by the hyperpolarizing pulse,
excluding the instant jump at the beginning of the pulse. The
current density is the current amplitude divided by the cell
capacitance measured in each cell studied. The pipettes had a
resistance of 2–4 M when filled with internal solution: 6 mM
NaCl, 130 mM potassium aspartate, 2 mM MgCl2, 5 mM CaCl2,
11 mM EGTA, and 10 mM HEPES; pH was adjusted to 7.2 by
KOH. The external solution contained 120 mM NaCl, 1 mM
MgCl2, 5 mM HEPES, 30 mM KCl, 1.8 mM CaCl2; pH was
adjusted to 7.4 by NaOH. The Ito blocker, 4-aminopyridine (2
mM), was added to the external solution to inhibit the endoge-
nous transient potassium current, which can overlap with and
obscure IHCN4 tail currents recorded at20mV. The data were
acquired by CLAMPEX and analyzed by CLAMPFIT (pClamp
8; Axon).
The data are shown as the means  S.E. The threshold acti-
vation of IHCN4 is defined as the first hyperpolarizing voltage
at which the first time-dependent inward current can be
observed. Student’s t test was used for statistical analysis with
p  0.05 being considered statistically significant. Time con-
stantswere obtained by usingBoltzmannbest fit with one expo-
nential function on current traces that reach steady state.
HCN4 activates slowly, and the cells would not tolerate pulses
sufficiently long to reach the steady state.We therefore used the
following approach to obtain an accurate estimate of the steady
state activation (15). The onset current traces were fitted with a
single exponential function to 30–40 s to allow estimates of
steady state current levels. The fitted current amplitudes were
then divided by the driving force (the difference between test
pulses and the reversal potential that wasmeasured in each cell)
to obtain the conductance at each test pulse. The activation
curves were constructed by normalizing the conductance to its
maximal value in response to the most negative test pulse.
Confocal Fluorescent Imaging of HEK293 Cells—HEK293
cells transfected with HCN4-DsRed or HCN4-DsRed-D553N
were incubated on coverslips and fixed in 4% paraformalde-
hyde/PBS for 15 min and then washed with PBS (10 mM phos-
phate buffer, 150 mM NaCl, pH 7.4) for 5 min for three times,
followed by blocking in 1% bovine serum albumin/PBS, pH 7.4,
for 60 min. After washing six times in PBS, the coverslips were
mounted on slide glasses using Fluoromount G (Southern Bio-
technology). The cells were imaged by a LSM510 confocal
microscopy using a Plan-Neofluar 40/0.75 objective or a
Plan-Apochromat 63/1.4 Oil differential interference con-
trastM27objective. ForDsRed imaging, a 1.2-milliwatt 543-nm
HeNe laser was used for excitation, and a 560–615-nm BP
emission filter was used for emission.
RESULTS
Inhibition of HCN4 Current Expression by RPTP—We have
recently demonstrated that RPTP can inhibit the surface
expression of HCN2 channels via tyrosine dephosphorylation
(17). Given the high structural homology between HCN2 and
HCN4 (80%) (7), it was expected that RPTPmay also inhibit
the surface expression of HCN4. Fig. 1 shows a typical current
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expression of HCN4 expressed in HEK293 cells (Fig. 1A). The
expression was dramatically suppressed across the test voltages
(65 to 135mV) whenHCN4was co-expressed with RPTP
after 1 day of transfection (Fig. 1B). The reduction in current
expression was associated with a negative shift in threshold
activation (Figs. 1,A andB, arrows). After 2 days of transfection,
RPTP almost eliminated the current expression ofHCN4 (Fig.
1C). The effect of RPTP on HCN4 current expression is sim-
ilar to that on HCN2 current expression (17). As a control, the
empty vector, pRK5 (used to subclone RPTP), did not affect
the current expression of HCN4 (Fig. 1D). Each of these results
was confirmed in an additional 5–7 cells.
Inhibited Surface Expression and Reduced Tyrosine Phospho-
rylation of HCN4 by RPTP—Wondering whether HCN4 cur-
rent inhibition of RPTP is due to the suppressed membrane
expression of the channel proteins, we examined the HCN4
channel membrane preparation (Fig. 2A). The left triplet shows
HCN4 expression. The split bands indicate unglycosylated and
glycosylated forms, similar to HCN2 membrane expression
(17). The glycosylated formofHCN4was significantly inhibited
by RPTP (middle triplet) and enhanced by Src529 (a constitu-
tively active form of Src) (right triplet).
Using the phosphotyrosine-specific antibody 4G10, Fig. 2B
shows that the tyrosine phosphorylation of HCN4 channel pro-
tein (middle lane) was significantly enhanced by Src529 (second
lane from the right) but inhibited by RPTP (left lane). These
results suggested that the altered membrane expression of
HCN4 is possibly caused by the increased or decreased tyrosine
phosphorylation of the channel protein by Src tyrosine kinase
and RPTP tyrosine phosphatase, respectively.
To further seek supporting evidence that reduced ionic cur-
rent expression of HCN4 is caused by the suppressed surface
expression of HCN4 channels, we tagged HCN4 with a fluores-
cent protein, DsRed, and examined the distribution of HCN4
using fluorescent confocal microscopy. Fig. 3A shows a typical
fluorescent image of HCN4 expressed alone in a HEK293 cell
FIGURE 1. RPTP on HCN4 current expression in HEK293 cells. A, HCN4
current expression in response to 15-s hyperpolarizing pulses from 65 to
135 mV in 10-mV increments. Tail currents were recorded at 20 mV. B, in a
cell co-transfected with RPTP after 1 day of incubation, HCN4 current
expression in response to 10-s hyperpolarizing pulses from 65 to 135 mV
in 10-mV increments. C, in a cell co-transfected with RPTP after 2 days of
incubation, HCN4 current expression in response to 10-s hyperpolarizing
pulses from 65 to 135 mV in 10-mV increments. D, HCN4 current expres-
sion in HEK293 cells co-expressed with the empty vector, pRK5.
FIGURE 2. Src/RPTP on HCN4 membrane protein expression and tyro-
sine phosphorylation in HEK293 cells. A, immunoblots (IB) on membrane
fraction for HCN4, HCN4 RPTP, and HCN4Src529. -Actin was used as a
loading control. B, tyrosine phosphorylation of HCN4 by Src529 and RPTP.
The total protein samples were first immunoprecipitated (IP) using 4G10 anti-
body and then immunoblotted using an HCN4 antibody. Weak phosphoryl-
ation signals of HCN4 and HCN4RPTP can be seen in long exposed film (1
min). The immunoblot of HCN4 (right lane) was used as a size marker.
FIGURE 3. Src/RPTP on HCN4 cell surface expression in HEK293 cells.
A, fluorescence imaging of HCN4-DsRed, HCN4-DsRedRPTP, and HCN4-
DsRedSrc529. B, fluorescence (left panel) and bright field (right panel)
images of cells transfected with DsRed alone.
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(left panel). An approximately equal amount of HCN4 is dis-
tributed on the plasmamembrane and in the cytosol, consistent
with the membrane protein expression results (Fig. 2A). When
co-expressedwithRPTP,mostHCN4channels are retained in
the cytosol (middle panel of Fig. 3A). On the other hand, Src529
significantly enhanced the cell surface expression of HCN4
(Fig. 3A, right panel). As a control, Fig. 3B shows the fluores-
cence (left panel) and bright field (right panel) images of the
empty DsRed vector expressed in HEK293 cells.
Rescuing D553N Current Expression by Src, Fyn, and Yes—
D553N has been recently identified in a patient suffering from
sinus node dysfunction, long QT, ventricular tachycardia, and
torsade de pointes (18). In vitro studies of the mutant channel
revealed defective surface expression on plasma membrane,
leading to the loss of current expression (18). Given the facts
that the HCN4 channel activity including the channel surface
expression can be significantly enhanced by Src-mediated tyro-
sine phosphorylation and the ubiquitous expression of three
Src kinase family members (Src, Fyn, and Yes), we set forth to
test the hypothesis that the current expression of the defective
trafficking D553N can be restored by constitutively active
forms of Src kinases (Src529, Fyn531, and Yes537).
Fig. 4 provides a typical set of current recordings under dif-
ferent conditions. The current expression of wild-typeHCN4 is
shown in Fig. 4A, as compared with the loss of current expres-
sion for D553N (Fig. 4B). Fig. 4
(C–E) shows the effects of individ-
ual Src, Fyn, and Yes on D553N
current expression, respectively.
Fig. 4 (F–H) also shows the effects
of SrcFyn, SrcYes, and FynYes
on D553N current expression, re-
spectively. Fig. 4I shows the overall
effects of combined SrcFynYes
on D553N current expression.
For effective comparison of the
actions of Src kinases on D553N to
HCN4, we calculated the current
density and the activation kinetics
at 125 mV, which is near the fully
activated voltage. Current density at
the voltage in which all channels are
open is directly related to our cen-
tral interest of evaluating whether
Src kinases can rescue the surface
expression of D553N. The current
densities under different conditions
are shown in Fig. 5A.
Src and Yes, but not Fyn, can sig-
nificantly rescue D553N current
expression. Different combinations
of three kinases all enhanced the
current expression of D553N (Fig.
5A, asterisk). All three Src kinases
expressed together (Fig. 4I) can
restore 68% current expression of
D553N as compared with the wild-
type HCN4 expression (Fig. 5A,
dark bars, HCN4: 37.15 3.21 pA/pF, n	 7; D553NSrc/Fyn/
Yes: 25.25  2.17 pA/pF, n 	 10) (Fig. 5A).
The effects of Src/Fyn/Yes kinases on the current activation
kinetics are also different (Fig. 5B). The time constants for acti-
vation kinetics were obtained by fitting the onset current with
one-exponential function at 125 mV under different condi-
tions. Fyn accelerated but Yes slowed the activation kinetics of
D553N, whereas Src had no effects (p* values). The combina-
tions of SrcFyn and FynYes can accelerate D553N activa-
tion kinetics, whereas the combination of SrcYes cannot. A
combination of all three Src kinases can speed D553N activa-
tion kinetics at 125 mV (Fig. 5, B and D); the time constants
are 4.07 0.59 s (n	 3) for D553N and 1.24 0.05 s (n	 9) for
D553N/Src/Fyn/Yes, respectively (p 	 0.01). It is worth point-
ing out that in 16D553N transfected cells we studied only three
cells that expressed time-dependent inward currents at 125
mV and that were used for calculating current density and acti-
vation kinetics shown in Fig. 5 (A and B). The other 13 cells
expressed no currents at the test potentials ranging from
75mV to 135mV. As a comparison, we also showed the
statistical analysis of comparing Src kinases on D553N to
HCN4 indicated by p values in Fig. 5B.
To assess the overall functional rescuing effects of Src/Fyn/
Yes on D553N gating, we examined the biophysical properties
of D553N co-expressed with Src/Fyn/Yes (Fig. 4I) in compari-
FIGURE 4. Src/Fyn/Yes kinases on current expression of D553N at 125 mV. Currents elicited by
hyperpolarizing pulses in 10-mV increments are presented for HCN4 (A), D553N (B), D553NSrc529 (C),
D553NFyn531 (D), D553NYes537 (E), D553NSrc529Fyn531 (F), D553NSrc529Yes537 (G),
D553NFyn531Yes537 (H), and D553NSrc529Fyn531Yes537 (I). The test potentials are labeled in
the figures. The pulse durations were 15 s for A–C, E, and G; 12 s for F, H, and I; and 6 s for D. The holding
potential was 10 mV.
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son with the wild-type HCN4 (Fig. 4A). The Boltzmann equa-
tion best fit from the averaged activation curves obtained from
tail currents (see “Experimental Procedures” for details in the
construction of the activation curve) showed a small depolariz-
ing shift ofD553NSrc/Fyn/Yes comparedwithHCN4with no
altered slope factors(s). However, sta-
tistical analysis fromthemeansof two
groups yielded no significant differ-
ence (V0.5_HCN4: 86.1  1.5 mV,
n 	 7; V0.5_D553NSrc/Fyn/Yes:
81.6  1.4 mV, n 	 9; p 	 0.0724,
s_HCN4: 8.2  0.2 mV, n 	 7;
s_D553NSrc/Fyn/Yes: 8.4  0.2
mV, n 	 9, p 	 0.577) (Fig. 5C). On
the other hand, the effects of Src
kinases on D553N activation
kinetics are complex. Compared
with the wild-type HCN4, the
averaged activation kinetics for
D553NSrc/Fyn/Yes were slowed
at the beginning of the activation
curve, accelerated near the middle
of the activation curve, but statis-
tically indistinguishable at the
potentials after the half-activation
point (Fig. 5D) (n 	 7 for HCN4,
n 	 9 for D553NSrc/Fyn/Yes).
Enhanced Tyrosine Phosphoryla-
tion andMembrane Surface Expres-
sion of D553N by Src, Fyn, and Yes
Tyrosine Kinases—We have previ-
ously shown that Src-mediated
tyrosine phosphorylation increases
theHCN2 andHCN4 channel activ-
ity via shifting the activation curve
to depolarizing potentials (short term effect) and enhancing the
cell surface expression (long term effect) (12, 14, 15, 17). We
have now demonstrated that reduced tyrosine phosphorylation
by RPTP (Fig. 2B) can lead to the suppressed surface expres-
sion of HCN4 (Fig. 2A). To investigate whether tyrosine phos-
phorylation is involved in rescuing actions of Src, Fyn, and Yes
on D553N current expression, we studied the tyrosine phos-
phorylation state of D553N by Src, Fyn, and Yes kinase, respec-
tively. Fig. 6 shows the tyrosine phosphorylation of HCN4 (Fig.
6A) and D553N (Fig. 6B) by three Src kinases in HEK293 cells.
HCN4 background phosphorylationwasweak and significantly
increased by Src529 and Fyn531, but not by Yes537. D553N
background phosphorylation was barely detectable but dra-
matically increased by Src529, Fyn531, and Yes537. It was
noticed that Src529 increased most significantly the phospho-
rylation of thewild-typeHCN4, but Fyn531 induced the highest
phosphorylation of D553N channel proteins.
We next examined the effects of Src kinases on D553N sur-
face expression using biotinylation approach (see “Experimen-
tal Procedures” for details). Fig. 6C shows that the surface
expression of D553N was barely detected. Src, Fyn, and Yes
each significantly enhanced the surface expression to various
degrees. Yes had a larger effect than Src and Fyn in promoting
the surface expression of D553N. The HCN4 wild-type surface
expression (Fig. 6C, second lane from the left) was used as a
positive control.
To seek further supporting evidence for rescuing surface
expression of D553N by three Src kinases, we constructed the
FIGURE 5. Src/Fyn/Yes kinases on current density and gating of D553N compared with HCN4. A, current
density measured at 125 mV under different conditions. An asterisk indicates a statistically significant differ-
ence in comparison with D553N current density. B, time constants of activation kinetics at 125 mV under
different conditions. p values indicated statistical significance in comparing the effects of the kinases on D553N
to HCN4 (white bar). p* values indicated statistical significance in comparing the effects of the kinases on
D553N to D553N alone (gray bar). C, activation curves of HCN4 (WT) and D553NSrc/Fyn/Yes. D, activation
kinetics of HCN4 (WT) and D553NSrc/Fyn/Yes. All of the statistical results were from seven to nine cells for
each group except for D553N (only three cells expressed little currents of 16 cells tested).
FIGURE 6. Src/Fyn/Yes kinases on tyrosine phosphorylation and surface
expression of D553N. A, tyrosine phosphorylation of HCN4, HCN4Src529,
HCN4Fyn531, and HCN4Yes537, respectively. B, tyrosine phosphoryla-
tion of D553N, D553NSrc529, D553NFyn531, and D553NYes537,
respectively. Samples for A and B were immunoprecipitated (IP) with 4G10
antibody prior to the detection by HCN4 antibody. C, Src/Fyn/Yes effects on
surface expression of D553N using a biotinylation method. IB, immunoblot.
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D553N-DsRed fusion protein and performed the confocal
imaging experiments. Fig. 7 shows thatmostwild-typeHCN4 is
expressed on the cell surface (Fig. 7A). By contrast,mostD553N
cannot reach the cell surface (Fig. 7B). Co-expression with
either Src (Fig. 7D) or Yes (Fig. 7F) can significantly enhance the
surface expression of D553N.However, Fyn has beenmuch less
significant on D553N surface expression, as evidenced by a sig-
nificant amount of D553N remaining in the cytosol (Fig. 7E).
DsRed vector itself was uniformly expressed across the cell (Fig.
7C) and served as a negative control. These results, combined
with the protein biochemistry analysis, collectively provide the
cellular evidence for the functional rescue of D553N current
expression at the plasma membrane by Src/Fyn/Yes kinases.
DISCUSSION
Defective trafficking of mutant channels represents an
important mechanism for Kv channels causing long QT2 (1).
Studying longQT related Kv channel modulation has led to the
findings that lower temperature and channel blockers can
restore the surface and ionic current expression of the defective
traffickingmutant channels (1). In this work, we showed for the
first time that by modulating the Src/Fyn/Yes kinase activity, a
human HCN4 trafficking defective mutant D553N (also linked
to long QT (18)) can be rescued for normal surface and current
expression. The corrected D553N exhibited the gating proper-
ties comparable with those of the wild-type HCN4 channels.
Enhanced tyrosine phosphorylation increased the activity of
the cardiac pacemaker current, If, in the sinoatrial node cells
(13). Using genistein, a nonspecific tyrosine kinase inhibitor, we
found a differential modulation of tyrosine phosphorylation for
HCN1,HCN2, andHCN4 expressed inXenopus oocytes; genis-
tein had no effects on HCN1 but reduced HCN2 or HCN4 cur-
rent expression (12). In the case of HCN2, there was also a
negative shift in the voltage dependence of activation that
accompanied the current reduction. These studies represent
the acute effects of altered tyrosine phosphorylation of HCN
channel proteins on the gating properties of If.
To investigate the long term effects of specific tyrosine
kinases on HCN channels in a mammalian background, we
studied the effects of Src kinase on HCN4 channel (the main
isoform in the heart) expressed inHEK293 cells.We focused on
the Src kinases for two reasons: it mediates epidermal growth
factor receptor signaling (19) and Src homology 3 domain was
initially used to clone the first HCN channels (23). We found
that Src associatedwith and phosphorylated theHCN4 channel
proteins, leading to the enhanced HCN4 current density near
diastolic potentials (15). This was the first direct evidence
showing that 1) HCN4 channels can be phosphorylated by Src-
mediated tyrosine kinases and 2) long term effects of tyrosine
phosphorylation of HCN4 channels can induce the changes in
the current density, which directly correlates with the number
of functional channels expressed at the plasma membrane.
Accompanying the increased current density were the acceler-
ated activation kinetics and a positive shift in the voltage-de-
pendent activation, which has been typically observed in the
short term modulation of HCN4 channels. These conclusions
were confirmed by the subsequent investigation on the major
tyrosine residues that mediate Src actions (14). Using PP2, a
selective inhibitor of Src kinase family, we found that the
reduced Src kinase activity can indeed shift the voltage-depend-
ent activation to hyperpolarizing potentials, an effect mediated
by HCN4 Tyr531 (14). Another tyrosine residue, HCN4 Tyr554
previously reported by others (16), also contributed to the slow-
ing of activation kinetics by PP2 (14).Work on the action of PP2
onHCN4 also resulted in two surprising observations. First, the
PP2-induced negative shift of HCN4 voltage-dependent activa-
tion is not in agreement with our previous results with genis-
tein. At least two factors can contribute to this discrepancy:
mammalian cell (HEK293) versus amphibian (Xenopus oocytes)
background and general (genistein) versus selective (PP2) inhi-
bition of tyrosine kinases. Second, we found that PP2 also
reduced thewhole cell channel conductance (supplemental Fig.
3 in Ref. 14). These results implied that even the short term
effect of altered tyrosine phosphorylation may affect the num-
ber of functional channels at the plasma membrane.
More recently in the investigation of the potential role the
tyrosine phosphatase might play in the modulation of HCN
channel function, we found the dramatic inhibition of HCN2
current expression by RPTP (17). The inhibited HCN2 cur-
rent expression was due to the reduced surface expression of
HCN2 channels via association between RPTP and the HCN2
channel proteins, resulting in the channel dephosphorylation
(17). The work demonstrated a previously unrecognized fea-
ture of HCN channel modulation by tyrosine phosphorylation:
the tyrosine phosphorylation state of HCN channel proteins
represents one important regulatory mechanism for the cell
surface expression of the functional channels, which directly
determines the current expression of functionalHCNchannels.
This feature may be utilized to enhance the surface and ionic
current expression of HCN mutant channel that cannot reach
the plasma membrane for normal function.
FIGURE 7. Src/Fyn/Yes kinases on D553N fluorescence imaging. Fluores-
cence images of cells transfected with HCN4 (A), D553N (B), DsRed vector (C),
D553NSrc529 (D), D553NFyn531 (E), and D553NYes537 (F). All of the
results were repeated in an additional eight to ten cells.
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Indeed, the evidence presented in this work showed that the
enhanced tyrosine phosphorylation mediated by Src kinases
can rescue the surface expression of D553N for normal channel
function. What was unexpected, however, is the finding that
three Src kinases that were ubiquitously expressed in the heart
have different functional effects on D553N channel activity.
Subsequent phosphorylation studies showed that all three
kinases significantly enhanced phosphorylation of D553N with
the order of potency: Fyn531  Src529  Yes537 (Fig. 6B). In
comparison, the wild-type channel background phosphoryla-
tion was increased mostly by Src529, to moderate degree by
Fyn531, and nearly unaffected by Yes537. In agreement with
the previous studies, the Src kinase-mediated tyrosine phos-
phorylation is associated with the acceleration of channel acti-
vation kinetics (14–16). These differential effects by Src/Fyn/
Yes on enhancing D553N expression and function are
summarized in Table 1.
The differential phosphorylation of both wild-type HCN4
and D553N channels by three Src kinases suggested that dif-
ferent tyrosine residues are involved in mediating each of the
kinases. These results also suggested a possibility that
D553N may undergo a protein misfolding that prevents the
nearby tyrosine residues from being phosphorylated. Asso-
ciation of Src tyrosine kinases appears to partially correct the
protein folding that leads to the exposure of key tyrosine
residues for phosphorylation.
To understand the mechanism by which tyrosine phospho-
rylation used to restore the surface expression of D553N, we
proposed amodel utilizing the three-dimensional crystal struc-
ture of the C-linker region of HCN2 for the following three
reasons. First, D553N mutation occurred in the C-linker. Sec-
ond, there is a high homology (91.6%) between HCN2 and
HCN4 in the C-linker (supplemental Fig. S1). Third, HCN2 is
the only protein in the HCN family whose crystal structure of
the C-linker has been solved (24). HCN4Asp553 corresponds to
HCN2Asp475. Amongmany potentialmechanisms responsible
for the defective trafficking of HCN4-D553N, protein misfold-
ing is an attractive one.We hypothesized that there may exist a
potential electrostatic interaction betweenAsp475 and Lys472 of
the B
 helix. The negatively charged Asp475 is spatially close to
the positively charged Lys472, similar to the relative spatial loca-
tions of Lys472 and Glu502 of the D
 helix, which have been
demonstrated to form a salt bridge critical in maintaining the
local folding of C-linker (24) (supplemental Fig. S2). The puta-
tive D475N (equivalent to D553N in HCN4) mutation can
cause the loss of a negative charge, whichmay change the inter-
subunit interaction between Lys472 and Glu502 to alter local
folding of the C-linker structure. We noted that Lys472 is
changed to Arg550 in HCN4. With a guanyl group, Arg550 is
more capable than Lys472 in forming multiple electrostatic
interactions with nearby residues having negative side chains.
Therefore, inHCN4-D553Nmutant, the potential salt bridge of
Asp553withArg550 could be disrupted, which affected the inter-
action between Arg550 and Glu580 (Glu502 in HCN2) that is
critical in intersubunit contacts (24). Furthermore, the Src
kinase-mediated tyrosine phosphorylation at Tyr554 residue
near Asp553 (supplemental Fig. S1) could introduce a negatively
charged phosphate group, which could mimic the effect of
Asp553 to rebuild the salt bridge interaction betweenArg550 and
Glu580, consistent with the previous studies demonstrating the
importance of Tyr554 (14, 16). For wild-typeHCN4, the existing
negative charge on Asp553 might repel the entry of a phosphate
group and limit the phosphorylation on certain nearby tyrosine
residues. It can explain why the differential modulation by Src,
Fyn, and Yes is different between the wild-type HCN4 and the
D533N mutant channels (Fig. 6, A and B).
While presenting a novel mechanism to correct the surface
expression of a trafficking defective HCN4 mutant channel,
we left at least three questions unanswered. First, what are the
tyrosine residue(s) in HCN4 channel proteins that mediate the
actions of Fyn and Yes? The same tyrosine residues (such as
Tyr531 and Tyr554) are unlikely to be used by all three kinases.
Fyn, not Src, accelerated D553N activation kinetics (Fig. 5B).
Fynmay target the tyrosine residues in or near A
 and B
 helices
of the C-linker. On the other hand, Yes may phosphorylate
different tyrosine residues that are located outside of the
C-linker, which can explain its lack of acceleration in the acti-
vation kinetics. Second, what is the correlation, if any, among
the surface expression and activation kinetics and the tyrosine
phosphorylation state of HCN4 channels? Fyn showed signifi-
cant tyrosine phosphorylation and acceleration of the channel
activation kinetics but little effect on promoting the channel
surface expression. Yes did not exert the highest phosphoryla-
tion in comparison with Src and Fyn (Fig. 6B), slowed the chan-
nel activation kinetics, but exhibited the most potency of pro-
moting the cell surface expression of D553N (Figs. 6C and 7F
and Table 1). It might involve other unknown proteins yet to be
identified. Third, will an increase in the endogenous Src/Fyn/
Yes kinase activity in myocytes help promote the surface
expression of D553N in vivo? Addressing these questions rep-
resents our future research endeavors, leading to the discovery
of an effective endogenous regulatory mechanism to correct
cardiac arrhythmias caused by HCN channel mutants.
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Lin Y, Huang J, Zhang Q, Hollander JM, Frisbee JC, Martin
KH, Nestor C, Goodman R, Yu H. Inactivation of L-type calcium
channel modulated by HCN2 channel. Am J Physiol Cell Physiol
298: C1029–C1037, 2010. First published February 17, 2010;
doi:10.1152/ajpcell.00355.2009.—Ca2 entry is delicately con-
trolled by inactivation of L-type calcium channel (LTCC) composed
of the pore-forming subunit 1C and the auxiliary subunits 1 and
2. Calmodulin is the key protein that interacts with the COOH-
terminal motifs of 1C, leading to the fine control of LTCC inacti-
vation. In this study we show evidence that a hyperpolarization-
activated cyclic nucleotide-gated channel, HCN2, can act as a non-
channel regulatory protein to narrow the L-type Ca2 channel current-
voltage curve. In the absence of LTCC auxiliary subunits, HCN2 can
induce 1C inactivation. Without 2, HCN2-induced fast inactiva-
tion of 1C requires calmodulin. With 2, the 1C/HCN2/2
channel inactivation does not require calmodulin. In contrast, 1-
subunit plays a relatively minor role in the interaction of 1C with
HCN2. The NH2 terminus of HCN2 and the IQ motif of 1C subunit
are required for 1C/HCN2 channel interaction. Ca2 channel inac-
tivation is significantly slowed in hippocampus neurons (HNs) over-
expressing HCN2 mutant lacking NH2 terminus and accelerated in
HNs overexpressing the wild-type HCN2 compared with HN controls.
Collectively, these results revealed a potentially novel protection
mechanism for achieving the LTCC inactivation via interaction with
HCN2.
L-type calcium channel inactivation; hyperpolarization-activated cy-
clic nucleotide-gated channels; calmodulin; hippocampal neuron
L-TYPE CALCIUM CHANNEL (LTCC) current inactivation is depen-
dent on both Ca2 ions and voltage (3, 13). The - and
2-subunits regulate the membrane expression and the volt-
age-dependent inactivation of the 1C-subunit (2). Calmodulin
(CaM) plays a central role in both Ca2-dependent inactivation
(CDI) and voltage-dependent inactivation (VDI) using Ba2 as
the charge carrier (12, 13). CaM is proposed to tether with the
IQ motif in the COOH terminus of 1C (15, 16). Ca2 influx
through LTCC activates apoCaM (Ca2-free CaM)/IQ com-
plex. The activated CaM/IQ triggers a conformational change
of the inactivation machinery consisting of 1C COOH-termi-
nal domains such as peptide A, peptide C (or CB), IQ motif,
and CaM. As a result, the inactivation machinery rapidly
blocks the inner surface of the pore, leading to fast CDI (6, 16).
CaM also has been proposed to interact with the linker of the
transmembrane I and II segments associated with the 1-
subunit to modulate VDI (3, 12).
Hyperpolarization-activated, cyclic nucleotide-gated (HCN)
channels are activated by membrane hyperpolarization, gener-
ating a voltage- and time-dependent inward current called Ih or
If, which has been traditionally thought to permeate both Na
and K ions (4). Recently, we discovered that Ca2 ions also
can permeate HCN channels, even in a small percentage of the
total current (24, 25). Furthermore, activation of Ih and If can
increase the synapse transmission in dorsal root ganglion
neurons (25) and shorten the action potential duration in
ventricular myocytes (24), respectively. However, the under-
lying mechanisms are not well understood. In the present work,
we focus on a hypothesis that a closed HCN channel can
interact with LTCC at the plasma membrane, leading to the fast
inactivation of L-type Ca2 current (ICaL).
MATERIALS AND METHODS
cDNA constructs. Various full-length cDNA plasmids were gener-
ous gifts from other investigators as detailed in the Supplemental
Material. (Supplemental data for this article is available online at the
American Journal of Physiology-Cell Physiology website.)
Cell culture and plasmids transfection. Human embryonic kidney
(HEK)-293 cells were grown on poly-D-lysine-coated coverslips in
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with
10% fetal bovine serum, 100 IU/ml penicillin, and 100 g/l streptomy-
cin. Cells with 50–70% confluence in a six-well plate were used for
plasmid transfection (2–5 g for each plasmid) using Lipo-
fectamine2000 (Invitrogen).
An HEK-293 cell line stably expressing 2/1 was kindly pro-
vided by Dr. Richard Tsien (Stanford University). Culture of these
cells was similar to that described above except for addition of
antibiotics, G418 (0.5 mM/ml) and 5 mM L-glutamine, to the DMEM.
Preparation of hippocampus tissue. Adult rats (300–350 g) were
euthanized by intraperitoneal injection of pentobarbital sodium (1.2
g/kg). After euthanasia, the adult rats were decapitated. The protocol
was approved by the Institutional Animal Care and Use Committee of
the Health Sciences Center at West Virginia University. Hippocampal
tissues were cut out and quickly frozen in liquid nitrogen.
Cell lysis, immunoprecipitation, and Western blot analysis. Coim-
munoprecipitation and Western blot experiments were the same as
previously reported (11). Details are provided in the Supplemental
Material.
Hippocampus neuron culture, transfection, and imaging. Primary
embryonic day 18 rat hippocampus neurons were used for studying
the interaction between 1C and HCN2. Neuron culture and plasmid
transfection were completed following the instruction manual (In-
vitrogen). Live-cell images of hippocampal neurons were visualized
using an inverted Nikon TE2000S epifluorescent microscope with
Prior filter wheels and a Photometrics Coolsnap HQ charge-coupled
device camera. More details are provided in the Supplemental Mate-
rial.
Whole cell patch-clamp recordings. Patch-clamp recordings are the
same as previously reported (11). The pipettes had a resistance of 2–5
M when filled (in mM): 108 CsCl, 4 MgCl2, 9 EGTA, and 9
Address for reprint requests and other correspondence: H.-G. Yu, Center for
Cardiovascular and Respiratory Sciences, West Virginia Univ. School of
Medicine, One Medical Center Drive, Morgantown, WV 26506 (e-mail:
hyu@hsc.wvu.edu).
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HEPES. The bath solution contained (in mM) 2 BaCl2, 1 MgCl2, 10
HEPES, 40 tetraethylammonium, 10 glucoses, and 65 CsCl. Both
solutions were adjusted with CsOH to pH 7.2. Unless specifically
mentioned in the text, the Ba2 currents (IBa) were recorded at 10
mV from a holding potential of 90 mV. IBa current inactivation was
sometimes normalized for better comparison of kinetics in different
combinations of plasmids coexpressed in different HEK-293 cells
(e.g., Figs. 2, A and D, and 3, A–C). Normalization is indicated
without vertical scales; where vertical scales are present, P/4 protocols
were used to remove the leak currents. The capacitive currents were
minimized with 75–85% series resistance compensation. More details
are provided in the Supplemental Material.
RESULTS
CDI and VDI of 1C/2/1 and 1C/2/1/HCN2 chan-
nels in HEK-293 cells. Figure 1A exemplified a well-estab-
lished difference between CDI and VDI: faster inactivation
for ICa (solid line) than for IBa (shaded line), recorded
at 10 mV. This difference, however, is largely diminished in
the presence of HCN2 (Fig. 1B): like ICa, the IBa of 1C/2/
1/HCN2 can inactivate almost completely to the closed state.
Figure 1C summarizes the time constants of inactivation of ICa
and IBa for 1C/2/1 and 1C/2/1/HCN2. They are
25.0	 3.2 ms for ICa and 228.5	 24.2 ms for IBa of 1C/2/1,
and 58.3 	 3.3 ms for ICa and 72.5 	 5.6 ms for IBa of
1C/2/1/HCN2. The difference between ICa and IBa of
1C/2/1/HCN2 inactivation kinetics was diminished com-
pared with that between ICa and IBa of 1C/2/1 inactivation
kinetics, indicating that HCN2 can help complete the IBa
inactivation.
We also examined whether the current-voltage relationship
curves of 1C/2/1 are altered by HCN2. Representative ICa
are shown for 1C/2/1 (Fig. 1D) and 1C/2/1/HCN2
(Fig. 1E). In the presence of HCN2, there was a positive shift
in the threshold activation of ICaL and more reduced current
amplitude at the depolarized end of the bell shape near 50
mV (Fig. 1F, shaded line). All results were repeated in an
additional five to eight cells.
Fast inactivation of 1C/HCN2 channels in HEK-293. To
examine a possible hidden interaction between 1C and
HCN2, we studied 1C inactivation by coexpressing 1C and
HCN2 in the absence of auxiliary subunits. With the use of
Ba2 as the charge carrier, 1C exhibited little current inacti-
vation when expressed alone (Fig. 2A, top). The auxiliary
subunit 2 could limit the Ca2 influx by inducing a slow
inactivation of 1C (Fig. 2A, top). Figure 2B, bottom, shows
the absence of endogenous time-dependent inward currents in
HEK-293 cells without cDNA transfection under our experi-
mental conditions. These results are in agreement with the
previous reports (7, 23). However, when HCN2 was coex-
pressed with 1C, a fast inactivation of 1C/HCN2 was
observed (Fig. 2B, top). This new inactivation has a differential
sensitivity for Ba2 and Ca2 ions, capable of coming back to
the closed state in the presence of Ca2 (shaded line) but not
Ba2 (solid line), the typical characteristics of the conventional
LTCC inactivation (12, 28). Adding 2 did not significantly
affect the 1C/HCN2 inactivation (Fig. 2A, bottom). With
Ba2 as the charge carrier, time constants for inactivation of
1C/2,1C/HCN2, and1C/HCN2/2were 156	 19, 26	 4,
and 22 	 2 ms, respectively (n 
 8). The inactivation for
1C/2 channels was significantly slower than that for 1C/
HCN2 or 1C/HCN2/2 (P 
 0.002, n 
 8). There was no
statistical difference between 1C/HCN2 and 1C/HCN2/2
Fig. 1. Ca2-dependent inactivation (CDI)- and voltage-dependent inactivation (VDI) of 1C/2/1 and 1C/2/1/HCN2 in HEK-293. A: Ca2 current (ICa;
solid line) and Ba2 current (IBa; shaded line) of 1C/2/1 recorded at 10 mV. B: ICa (solid line) and IBa (shaded line) of 1C/2/1/HCN2 recorded
at 10 mV. C: time constants () for inactivation of ICa and IBa at 10 mV for 1C/2/1 and 1C/2/1/HCN2, respectively. For simplicity of comparison,
we best fit the currents with one exponential function. P values shown are the statistical results of comparing ICa and IBa inactivation. D and E: ICa currents
recorded in the test pulses ranging from 50 to 50 mV in 10-mV increments for 1C/2/1 (D) and 1C/2/1/HCN2 (E), respectively. A 400-ms
depolarizing pulse was used. Holding potential was 90 mV. F: current-voltage relationship curves for 1C/2/1 and 1C/2/1/HCN2.
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channel inactivation (P 
 0.5, n 
 8). To verify that the
current is via the conventional 1C channel, verapamil (10
M) was applied to block the current activation (Fig. 2, A,
bottom, and B, top).
To address the concern that the fast inactivation of 1C/
HCN2 or 1C/HCN2/2 channel was probably due to the
contamination from the deactivation of HCN2 channels, we
studied current expression of HCN2 in the external solution
normally used for characterization of HCN2 and in the external
solution used to record IBa inactivation (e.g., Fig. 2, A and B).
The hyperpolarization-activated HCN2 channels permeate
both Na and K ions (4). The channel cannot be activated in
the absence of external Na and K ions (4). In the external
solution containing 140 mM Na and 30 mM K, a typical
HCN2 current (the time-dependent inward current) was re-
corded in response to a 3-s hyperpolarizing pulse to 125 mV
(Fig. 2C), consistent with the previous reports (e.g., Ref. 24). When
the Na and K ions were removed from the external solution, no
time-dependent inward current was recorded (Fig. 2C).
HCN2 channels are closed at membrane depolarization that
is used to activate LTCC (4). In response to a depolarization to
10 mV from the holding potential of 90 mV, there was no
HCN2 activation current in the solution containing 140 mM
Na and 30 mM K (Fig. 2D). The inactivation of 1C/
HCN2/2 channel in the Na- and K-free solution was used
as a comparison (Fig. 2D). These data strongly indicate that the
closed HCN2 channels can act as the nonfunction channel to
induce a fast inactivation of 1C.
Role of Ca2-free CaM in 1C/HCN2 channel inactivation.
Given the pivotal role CaM plays in the Ca2 channel inacti-
vation, we tested the idea that CaM may be involved in the fast
inactivation of 1C/HCN2 channel for two reasons: CaM is
endogenously present in HEK-293 cells, and apoCaM (no
Ca2-bound CaM) is tethered to structural domains in the
COOH terminus of 1C subunit (6, 16).
We first used two structurally different calmodulin inhibi-
tors, W-7 [N-(6-aminohexyl)-5-chloro-1-naphthalenesulfon-
amide] (10) and trifluoperazine (TFP) (18), to study their
potential effects on 1C/HCN2 channel inactivation. After
binding Ca2 ions, CaM undergoes a conformational change
leading to the exposure of its hydrophobic activation site for
binding to its substrate, CaM-dependent kinase (CaMK). Both
W-7 and TFP block CaM actions by occupying the hydropho-
bic site to prevent binding of CaMK (10, 14). Figure 3A shows
that both drugs at 15 M eliminated the fast inactivation of
1C/HCN2 channels within 15–20 min, consistent with the
time course of inhibiting CaM activity by both drugs. The
effect of the drug was observed in the same cell. The similar
results were obtained in an additional five to seven cells.
We then employed a dominant negative calmodulin mutant,
CaM(1,2,3,4) (22). Compared with the current expression of
1C/HCN2 coexpressed with a wild-type calmodulin, CaM(WT),
overexpression of CaM(1,2,3,4) eliminated the fast inactivation of
1C/HCN2 (Fig. 3B, shaded line). These pharmacological and
mutant CaM data strongly suggested that the interaction of 1C
and HCN2 is partially mediated by CaM.
Role of 2 in 1C/HCN2 channel inactivation. Nearly all
studies of CaM-mediated 1C inactivation, carried out in
either Xenopus oocytes or mammalian cells (HEK-293, Chi-
nese hamster ovary, COS), have been performed with coex-
pression of 1- and 2-subunits. This is due to the important
roles of 1- and 2-subunits in expression of 1C on plasma
membrane and Ca2 channel function (2). Previous studies
also have demonstrated a significant role of 2 in initiating
the inactivation of 1C expressed in HEK-293 cells (7, 23).
Wondering whether CaM would have the similar impact on the
1C/HCN2 channel inactivation in the presence of the 2
subunit, we tested the effects of W-7 and TFP on the current
expression of 1C/HCN2/2 channels. Surprisingly, neither
W-7 (left) nor TFP (right) affected the inactivation of 1C/
HCN2/2 channels (Fig. 3C, shaded lines). To further con-
firm this observation, we overexpressed either CaM(WT) or
CaM(1,2,3,4) with 1C/HCN2/2 channels (Fig. 3D, shaded
lines). Neither of them affected the inactivation of 1C/HCN2/
2 channels. Compared with its dominant effect in 1C/
Fig. 2. 1C/HCN2 channel inactivation in HEK-293 cells. A, top: current
expression of 1C and 1C/2, respectively. Bottom, current inactivation of
1C/HCN2/2 that was blocked by 10 M verapamil. Pulse duration was
200 ms. B, top: 1C/HCN2 inactivation using 2 mM Ba2 (solid line) or 2 mM
Ca2 (shaded line) as the charge carrier, which was blocked by 10 M
verapamil. Pulse duration was 400 ms. Bottom, absence of time-dependent
inward current expressions in HEK-293 cells without plasmid transfection.
Pulse duration was 300 ms. In A, the current inactivation was normalized for
better comparison of the inactivation kinetics. C: hyperpolarizing pulse control
experiments. In cells expressing only HCN2, IHCN2 was elicited by a 3-s
hyperpolarizing pulse to 125 mV from the holding potential of 10 mV in
modified Tyrode solution containing 140 mM Na and 30 mM K; in cells
coexpressing 1C/HCN2/2, the same hyperpolarizing pulse could not detect
IHCN2 in the external and internal solutions used to record IBa. Although the
leak current varies from cell to cell, we chose a leak current that closely aligned
with the HCN2 time-dependent inward current for better comparison. The
pulse protocol is shown in the inset. The dashed line shows the holding current.
D: depolarizing pulse control experiments. In solutions without Na and K
ions (0 Na, 0 K), IBa was recorded only in cells coexpressing 1C/HCN2/
2, not in cells expressing only HCN2. The pulse protocol is shown in the
inset.
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HCN2 channel inactivation (Fig. 3, A and B), CaM plays a
minor role in 1C/HCN2/2 channel inactivation (Figs. 3, C
and D), indicating a potential role of 2-subunit in the
1C/HCN2 channel inactivation.
1C/HCN2 channel interaction requires NH2 terminus of
HCN2 and IQ motif of 1C. The fact that the fast inactivation
of 1C/HCN2 is Ca2 independent (since we used Ba2 as a
charge carrier) suggested that CaM may not be the only
mechanism for 1C/HCN2 channel interaction. To explore an
unconventional idea that HCN2 may also interact with 1C,
we studied the current expression of 1) the wild-type 1C with
a HCN2 mutant lacking the NH2 terminus [HCN2(-N)] and 2)
the wild-type HCN2 with an 1C mutant lacking the IQ motif
in the COOH terminus [1C(1623-1666)] (8). Figure 4A
shows that the inactivation of 1C/HCN2 (solid line) was
eliminated by either HCN2(-N) or 1C(1623-1666) (shaded
lines).
We next examined how 1C and HCN2 channel mutants
interact in the presence of the 2 subunit. Figure 4B shows
that compared with the 1C/HCN2/2 channel inactivation
(solid line), both 1C/HCN2(-N)/2 and 1C(1623-1666)/
HCN2/2 channels dramatically slowed the inactivation pro-
Fig. 3. Role of calmodulin (CaM) in 1C/
HCN2 channel inactivation. A: 1C/HCN2
channel inactivation (solid line) and lost inac-
tivation in the presence of the CaM inhibitor
W-7 or trifluoperazine (TFP) (shaded lines).
B: 1C/HCN2/CaM(WT) channel inactivation
(solid line) and lost inactivation of 1C/HCN2/
CaM(1,2,3,4) channels (shaded line). CaM(WT),
wild-type calmodulin; CaM(1,2,3,4), a dominant
negative calmodulin mutant. C: 1C/HCN2/
2 channel inactivation in the absence (solid
line) and presence of W-7 (shaded line; left) or
TFP (shaded line; right). D: 1C/HCN2/2
channel inactivation in the absence (solid line)
and presence of CaM(1,2,3,4) (shaded line).
Fig. 4. 1C/HCN2 interaction requires NH2 ter-
minus of HCN2 and IQ motif of 1C. A: 1C/
HCN2 channel inactivation for wild-type (solid line),
1C(1623-1666)/HCN2 (shaded line), and 1C/
HCN2(-N) channels (shaded line). B: 1C/HCN2/
2 channel inactivation for wild-type (solid line),
1C(1623-1666)/HCN2/2 (shaded line), and
1C/HCN2(-N)/2 channels (shaded line). C: in-
activation of 1C/2/1/HCN2 (solid line),
1C(1623-1666)/2/1/HCN2 (shaded line), and
1C/2/1/HCN2(-N) (shaded line). D: inactiva-
tion time constants measured at 10 mV for
showing the significant role of HCN2(-N) [1C/
HCN2/2, 1C/HCN2(-N)/2, 1C/HCN2/2/
CaM(WT), and 1C/HCN2/2/CaM(1,2,3,4); solid
bars] and the significant role of 1C(1623-
1666) [1C1905x/HCN2, 1C1905x/HCN2/2,
1C1905x/HCN2/2/CaM(WT), and 1C(1623-
1666)/HCN2 /2; shaded bars]. Results are ex-
pressed as means 	 SE. *P  0.0001, statistically
significant difference compared with 1C/HCN2/
2; P 
 0.07 for 1C/HCN2/2/CaM(WT) and
P 
 0.08 for 1C/HCN2/2/CaM(1,2,3,4) (n 

6–12). &P  0.0001, statistically significant differ-
ence compared with 1C/HCN2/2 or 1C1905x/
HCN2/2; P 
 0.006 for 1C1905x/HCN2/2/
CaM(WT) and P 
 0.0003 for 1C(1623-1666)/
HCN2/2 (n 
 5–12). E: inactivation of 1C/
HCN2/2 channel in the presence of Ba2 (solid
line) and Ca2 (shaded line), respectively.
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cess (shaded lines). We also observed biphasic inactivation of
1C/HCN2(-N)/2 (Fig. 4B, shaded line) with its first fast
inactivation phase close to the wild type but with a second
phase almost linear that cannot be fitted by an exponential
function.
We finally studied the effects of HCN2 and 1C mutants on
1C/HCN2 inactivation in the presence of both 2- and
1-subunits. Compared with the wild-type 1C/2/1/HCN2
channel (solid line), the significant slowing of 1C/HCN2
channel inactivation by either HCN2(-N) or 1C(1623-1666)
(shaded lines) still persisted in the presence of 2- and
1-subunits (Fig. 4C). At 10 mV, the time constants of IBa
inactivation were 72.5	 5.6 ms for 1C/2/1/HCN2, 108	 13
ms for 1C/2/1/HCN2(-N), and 498 	 43 ms for
1C(1623-1666)/2/1/HCN2, respectively (n 
 5–7)
(Fig. 4D). Together, these results suggest that the NH2 termi-
nus of HCN2 and the IQ motif of 1C are the structural elements
required for the inactivation of the 1C/HCN2 channel.
Relative roles of CaM, 2, and 1 in the inactivation of
1C/HCN2 channels. To examine the relative contribution of
2 and CaM to the inactivation of 1C/HCN2 channels, we
compared the inactivation time constants for different combi-
nations of 1C, HCN2, 2, and CaM, including their respec-
tive mutants, except for 1C1905x/HCN2. 1C1905x is a
distal COOH-terminal truncated form of 1C, which is used as
a control for 1C(1623-1666) function (8). We found that
1C(1623-1666) and HCN2(-N) are the two most significant
structural motifs that contribute to the inactivation of 1C/
HCN2 channels independently of 2 (Fig. 4D). We also
found, surprisingly, that overexpression of CaM(WT) did not ac-
celerate (as one would expect), but slowed, the inactivation of
1C/HCN2/2 or 1C1905x/HCN2/2 channels (Fig. 4D).
In the absence of 2, there was a distinct difference
between CDI and VDI for 1C/HCN2 channels (Fig. 2B). In
the presence of 2, however, the difference between CDI and
VDI disappeared (Fig. 4E). Combined with the diminished
difference between CDI and VDI for 1C/2/1/HCN2 (Fig.
1B), the results provide additional evidence for a major role of
2 in the inactivation of 1C/HCN2 channels. In comparing
Fig. 4, C and E, 1 helped complete the IBa inactivation of
1C/HCN2/2 channels, which are consistent with the results
shown in Fig. 1B.
Association of 1C and HCN2 channel proteins in HEK-293
and hippocampus. Whether the interaction of 1C and HCN2
is mediated by CaM (for 1C/HCN2 channels) or by -subunit
(for 1C/HCN2/2 channels), 1C and HCN2 channel pro-
teins should be physically close. Fig 5A shows that in HEK-
293 cells expressing 1C and HCN2, 1C signal could indeed
be detected with an 1C antibody after the samples were
immunoprecipitated by an HCN2 antibody (left lane). Immu-
noblots using an 1C antibody for cells expressing 1C/2
and cells with no cDNA transfection (NT) served as positive
and negative controls, respectively. Figure 5B shows that
HCN2 signal could also be detected with its antibody after the
samples were immunoprecipitated by an 1C antibody. Figure
5C shows that in HEK-293 cells expressing 1C and a hem-
agglutinin (HA)-tagged HCN2 cDNA plasmid, the 1C signal
was detected using an anti-1C antibody after the sample was
immunoprecipitated with an anti-HA antibody (Fig. 5C, top).
The signal was, however, undetected in cells expressing
1C(1623-1666)/HCN2 or HCN2(-N)/1C (Fig. 5C, top).
On the other hand, HCN2 bands were seen with an HA
antibody in the sample immunoprecipitated using an antibody
specific to 1C (Fig. 5C, bottom). However, the signals were
very weak in cells expressing 1C(1623-1666)/HCN2 and
undetectable in cells expressing HCN2(-N)/1C (Fig. 5C,
bottom).
To investigate the relative contribution of 2 and CaM to
the association of 1C and HCN2, Fig. 5D shows the coim-
munoprecipitation results in HEK-293 cells overexpressing the
respective combinations of cDNAs. In the presence of 2, the
association of 1C and HCN2 was not significantly enhanced
by CaM compared with CaM(1,2,3,4). In the absence of 2,
however, the association of 1C and HCN2 was more signif-
icantly enhanced by CaM than by CaM(1,2,3,4), as evidenced by
much stronger signals detected by either 1C antibody (top) or
HCN2 antibody (bottom). Although one should not expect a
linear correlation between the protein chemistry result and
whole cell patch-clamp data due to the technical difference,
these results are consistent with the functional roles of 2 and
CaM in the interaction of 1C and HCN2 (Fig. 3).
To demonstrate the existence of such an association in native
tissues, we chose rat hippocampus as a test model due to the
technical feasibility and rich expression of LTCC (21) and
HCN2 (19) in the hippocampus. We used fresh rat hippocam-
pus tissues for the abundant amount of proteins to facilitate the
coimmunoprecipitation experiments. In Fig. 5E, the 1C sig-
nals were readily detectable when the sample was first immu-
noprecipitated by an HCN2 antibody (left). On the other hand,
the HCN2 band was also evident in the sample immunopre-
cipitated first by 1C antibody (right). For negative control of
coimmunoprecipitation in hippocampal neurons, the samples
were immunoprecipitated with a GFP antibody and then blot-
ted by either an HCN2 antibody or an 1C antibody. No
expected signals were detected (Fig. 5F).
Slowing Ca2 inactivation by disrupting 1C/HCN2 asso-
ciation in hippocampus neurons. NH2 terminus of HCN2 was
reported to be essential in the formation of the homo- and
heteromeric channels at the plasma membrane (17). Overex-
pression of HCN2 lacking NH2 terminus in the hippocampal
neurons, in which the endogenous expression levels of both
1C and HCN2 channel proteins are comparable and the two
proteins are associated (Fig. 5E), may disrupt the association.
Shown in Fig. 6A, formation of the rat hippocampal neuron
network was visualized after 5–6 days in culture. After 24- to
48-h transfection of HCN2(-N) with GFP, the expression of
HCN2(-N) was indicated by the fluorescent image (Fig. 6B)
compared with the brightfield image of the same region (Fig.
6A). The fluorescent neurons were subject to the patch-clamp
recordings. Shown in Fig. 6C, overexpression of HCN2(-N)
induced a remarkably slow inactivation component (light
shaded line) that was not present in the control neurons or in
neurons transfected with the empty vector (solid line, as a
transfection control). On the other hand, transfection with the
full-length HCN2 accelerated the IBa inactivation (dark shaded
line in Fig. 6C). Currents were verified by verapamil (10 M)
blockade (Fig. 6C). At 10 mV, time constants of IBa inacti-
vation were 26.5 	 2.9 ms (n 
 9) for control hippocampal
neurons (HN), 35.1	 3.5 ms (n 
 6) for HN vector, 66.1	 3.3
ms (n 
 7) for HN HCN2(-N), and 19.0	 2.2 ms (n 
 10) for
HN  HCN2 (Fig. 6D). The altered time constants for channel
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inactivation were marked with statistical significance compared
with the control HN or HN transfected with vector (Fig. 6D).
DISCUSSION
Both 1C- and -subunits are transmembrane proteins with
NH2 and COOH tails of 1C and COOH tail of  located
intracellularly. CaM and 1-subunit are intracellular proteins
attached to the 1C near the inner surface of the membrane.
These four proteins constitute the inactivation machinery for
the fine control of Ca2 influx through LTCC in both VDI and
CDI (6, 12, 15, 22).
Our previous studies showed possible involvement of HCN
in the modulation of myocyte action potential duration (24). In
the present work, we evaluated the hypothesis that inactivation
of LTCC can be modulated via interaction with HCN channels
under the experimental conditions that prevent HCN2 channel
opening. We showed here that HCN2 can act as a nonchannel
regulatory protein to induce a fast inactivation of 1C. To
further investigate the possible associated mechanisms in-
volved in the interaction between 1C and HCN2 channel
proteins, we proposed a model shown in Fig. 7. Mechanism 1
represents our current understanding of interactions among
-subunits, which are bound to the 1-interaction domain
(AID), apoCaM, and inactivation motifs in the COOH-terminal
region of 1C. The majority of this conceptual understanding
was provided from studies in either Xenopus oocytes or HEK-
Fig. 5. Association of 1C and HCN2 proteins in HEK-293 cells and in the hippocampus. A: cells expressing 1C and HCN2 were immunoprecipitated (IP) using
an HCN2 antibody, followed by signal detection (IB) using an 1C antibody (left lane). Cells expressing 1C and 2 were blotted by an 1C antibody (middle
lane), serving as a positive control. Cells without cDNA transfection (NT) were blotted using an 1C antibody (right lane), serving as a negative control. B: cells
expressing 1C and HCN2 were immunoprecipitated using an 1C antibody, followed by signal detection using an HCN2 antibody. Cells without cDNA
transfection served as a negative control. C, top: in cells coexpressing 1C and HA-HCN2, 1C signal was detected using an anti-1C antibody after the sample
was immunoprecipitated by a specific anti-hemagglutinin (HA) antibody. Signals were not detected in cells expressing HCN2(-N)/1C or HCN2/1C(1623-
1666). Bottom, in cells coexpressing 1C and HCN2, HCN2 signals were detected by an HA antibody in the sample immunoprecipitated with an 1C antibody.
Very weak signal was seen in cells expressing HCN2/1C(1623-1666) but not in cells expressing HCN2(-N)/1C. D: effect of CaM and 2 on association
of 1C and HCN2. Top, samples were immunoprecipitated using an HCN2 antibody, followed by signal detection with an 1C antibody. Bottom, samples were
immunoprecipitated using an 1C antibody, followed by signal detection with an HCN2 antibody. IgG bands were included as controls. E: coimmunoprecipi-
tation of 1C and HCN2 in the hippocampus. Left, sample was immunoprecipitated with an HCN2 antibody and blotted by an 1C antibody. Right, sample was
immunoprecipitated with an 1C antibody and blotted by an HCN2 antibody. F: negative control for coimmunoprecipitation in the rat hippocampus. Samples
were immunoprecipitated using a green fluorescent protein (GFP) antibody, followed by immunoblots using an HCN2 antibody (left lane) and an 1C antibody
(right lane), respectively.
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293 cells coexpressing 1C with 1- and 2-subunits (6, 15,
16, 20, 27, 28). Our present study revealed several new
concepts.
First, in the absence of 1- and 2-subunits, HCN2 can
induce a faster inactivation of 1C than 2 as measured by
IBa (compare Fig. 2, A and B). This interaction of HCN2 and
1C requires CaM (mechanism 2 in Fig. 7), since two CaM
inhibitors (W-7 and TFP) and the dominant negative
CaM(1,2,3,4) all eliminated the inactivation of 1C/HCN2 chan-
nel (Fig. 3, A and B).
Second, in the presence of the 2-subunit, HCN2 can still
induce fast inactivation of 1C. However, the impact of CaM
in affecting the inactivation of 1C/HCN2/2 channel is
diminished compared with that for 1C/HCN2 channel, sug-
gesting a prevalent role of the 2-subunit in 1C and HCN2
interaction (mechanism 3 in Fig. 7).
Third, mutants of HCN2 (with the NH2 terminus deleted)
and 1C (without IQ motif) revealed a critical role of these two
structural elements in mediating the fast inactivation of 1C/
HCN2 channels (Fig. 4). It is worth noting that the short
Fig. 6. Altered L-type Ca2 channel (LTCC) inactivation in rat
hippocampal neurons (HN) overexpressing HCN2(-N) and the
full-length HCN2. A brightfield image (A) and fluorescence
image (B) of the region is shown 48 h posttransfection of
HCN2(-N) or HCN2 with GFP. C: Ca2 current inactivation
using Ba2 as a charge carrier in a control neuron and in
neurons transfected with the empty vector (HN  vector), in a
neuron transfected with HCN2(-N) [HN  HCN2(-N)], and in
a neuron transfected with HCN2 (HN  HCN2). IBa currents
were recorded at 10 mV. The holding potential was at 90
mV. Pulse duration was 400 ms. P4 protocol was used. The HN 
vector trace was moved up by 60 pA for clear illustration of currents
under different conditions. D: inactivation time constants in HN, HN
transfected with HCN2, HN transfected with the vector, and HN
transfected with HCN2(-N). Results are expressed as means 	 SE.
P values indicate statistical significance compared with either HN or
HN  vector group.
Fig. 7. A schematic model depicting the
potential roles of HCN2 and -subunit in the
inactivation of LTCC.Mechanism 1 summa-
rizes the mechanisms for CDI and VDI of
LTCC. Mechanism 2 proposes a potential
CaM-mediated interaction between the NH2
terminus of HCN2 and the IQ motif of 1C.
Mechanism 3 proposes a potential interac-
tion between the COOH tail of the -subunit
and the NH2 terminus of HCN2 within the
COOH-terminal inactivation machinery of
1C-subunit. AID, 1-interaction domain.
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COOH terminus of the -subunit is located in the intracellular
space. Analysis of amino acids in the NH2 terminus of HCN2
showed an overall positive charge, which can potentially in-
teract with the negatively charged COOH terminus of -sub-
unit. Although previous studies have suggested a vital role for
the -subunit in accelerating 1C inactivation (7, 23), there is
limited mechanistic insight into how this process occurs. Our
data suggested that a key contributor to this accelerated inac-
tivation may be a dynamic, coordinated interaction among the
COOH terminus of the -subunit, the IQ motif of 1C, and the
NH2 terminus of HCN2. Alternatively, it is also possible that
1-subunit can interfere with the inactivation of 1C(1623-
1666)/HCN2/2 and 1C/2/HCN2(-N), as well (Fig. 4C).
This may be a logical possibility, since the 1-subunit is
attached to the linker of I-II domains and has been reported to
interact with the IQ motif either directly or possibly through
the actions of CaM (26). Our results for HCN2(-N) and
1C(1623-1666) (Fig. 5C) also are consistent with previous
reports that the NH2 terminus of HCN2 and IQ motif of 1C
are important structural elements for the respective channel
surface expression (8, 17). Thus it is possible that the altered
channel trafficking leading to the reduced surface expression of
either HCN2 or 1C provides a potential mechanism for the
roles of NH2 terminus of HCN2 and IQ motif of 1C in the
interaction of the two channels.
Finally, we have demonstrated that an interaction of 1C
and HCN2 is present in native tissues, as evidenced by asso-
ciation of the two channel proteins in the hippocampus and
dramatic slowing of IBa in hippocampal neurons overexpress-
ing HCN2(-N) (Fig. 6). It should be noted that the currents we
recorded in hippocampal neurons are not pure LTCCs, since N-
and P/Q-calcium channels are present in hippocampal neurons,
and verapamil can also inhibit N- and P/Q-type calcium cur-
rents (5). Nevertheless, the fact that overexpression of
HCN2(-N) mutant in HNs induced a significant slowing of
inactivation supports the hypothesis that dynamic interaction
between 1C and HCN2 exists in the native tissue.
Unusual features of 1C/HCN2 and 1C/HCN2/2 chan-
nel inactivation. Dissecting VDI and CDI often has been
carried out by using Ba2 and Ca2, respectively (12, 15, 22,
28), yielding intriguing results. Not only is CDI about 6–10
times faster than VDI (12, 13), but CDI also can come back to
the closed state whereas VDI cannot. The CDI index, measured
by the residual fraction of the currents that remains at the end
of the test pulse, is much smaller for Ca2 than for Ba2 (6, 12,
15, 28). Interestingly, the speed of VDI can be increased to that
of CDI if the IQ motif is deleted (28). Furthermore, a single
mutation of I to A or E in the IQ motif could eliminate the
difference in CDI index for Ca2 and Ba2 (27). Recently,
using a fluorescence resonance energy transfer (FRET) two-
hybrid mapping technique, preassociation of apoCaM and a
73-amino acid segment containing IQ motif was found to be
critical for the slow VDI (6). Disruption of this preassociation
significantly accelerated the VDI and removed the difference
between CDI and VDI (6).
Both 1C/HCN2 and 1C/HCN2/2 channels have exhib-
ited VDI rates that are faster than that reported following the
disruption of preassociation of IQ motif and apoCaM (6). Our
data suggest that HCN2, via its NH2 terminus, can interrupt the
preassociation of apoCaM with the IQ motif of 1C and that
this may contribute to the accelerated VDI inactivation. The
requirement of CaM for 1C/HCN2 inactivation in the absence
of 2 subunit is supported by the facts that inhibiting CaM
activity using either pharmacological inhibitors or overexpres-
sion of CaM(1,2,3,4) all eliminated the inactivation of 1C/
HCN2 (Fig. 3, A and B). On the other hand, 1C/HCN2/2
channel inactivation is largely independent of CaM (Fig. 3, C
and D). One possible scenario for this difference may be that
the conformational change of CaM resulted from the interac-
tion between the IQ motif and HCN2 is different from that
resulted from the interaction between the IQ motif and HCN2/
2. The interaction between the IQ motif and HCN2 may lead
CaM to undergo a conformational change that exposes its
hydrophobic activation site to the CaM blockers, whereas the
interaction between the IQ motif and HCN2/2 may induce a
different CaM conformational change that does not make its
blockers accessible to the activation site. This possibility
would explain the fast VDI of 1C/HCN2/2 channel (solid
lines in Fig. 3, C and D), the insensitivity of W-7 and TFP to
the 1C/HCN2/2 currents (Fig. 3C), and the lack of a
difference between CDI and VDI for the 1C/HCN2/2
channel (Fig. 4E).
Potential implications of 1C and HCN2 interaction. In this
study, although we have presented evidence demonstrating the
interaction of 1C-subunit (Cav1.2) with HCN2, interactions
of this type might also occur in other types of Ca2 channels that
undergo CDI, such as Cav2 channels, as a common mechanism.
Use of CaM as the key element for Ca2 channel inactivation has
been reported for Cav1 and Cav2 channels (13).
Increased Ca2 influx is associated with a number of neu-
ronal disorders, including neuropathic pain (1). Gabapentin, a
GABA analog, is an antiepileptic drug that has been used
recently to relieve neuropathic pain and is believed to bind the
21-subunit, leading to decreased Ca2 influx (1, 9). The
mechanism of how gabapentin binding of 21-subunit de-
creased Ca2 influx remains elusive, since the gabapentin
action is acute (1). The 2-subunits have been known to
enhance the surface expression of 1C and Ca2 current
amplitude (7, 23). A recent study demonstrated that chronic
treatment with gabapentin was associated with a reduction in
the surface expression of 22 and Cav2.1 subunits (9). On the
other hand, the 2-subunits also promote inactivation of
Cav1.2 (1C) or Cav2.2 (N-type) (23), and inhibition of the
2 subunit should, in principle, slow the 1C inactivation,
resulting in an increased Ca2 influx. The interaction of 1C
with HCN2 may provide an alternative mechanism to prevent
an increase in Ca2 influx under the conditions in which the
2-subunit expression is reduced.
Study limitations. Although we report for the first time a
novel and potentially important mechanism for modulation of
Ca2 current inactivation by HCN2 channel, there are many
unanswered questions. For instance, we noticed that the acti-
vation of ICaL also seems to be altered by HCN2 (e.g., Fig. 1F).
In addition, whether HCN2 may also modulate other Ca2
channels that share similar inactivation machinery to 1C is
unknown. More importantly, under various physiological and
especially pathological conditions, the importance of interac-
tion between HCN2 and LTCC requires further investigation,
since the expression levels of HCN2, 1C, and 21 are
altered.
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